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ABSTRACT 
Resistin is an adipokine which is found elevated in patients suffering from 
metabolic syndrome, affecting a large proportion of the population. It is 
characterised by obesity, insulin resistance (IR), type 2 diabetes mellitus 
(T2DM) and cardiovascular disease (CVD), which are the biggest contributors to 
morbidity and mortality in the modern world. Platelets play a major role in CVD, 
where their activation leads to formation of thrombi, which when uncontrolled, 
leads to the pathophysiological effects of CVD. The role of resistin in CVD 
progression and its mechanism of action on its target cells still remains 
debatable and surrounded by controversies. In a bid to assess this, the present 
study aims at illustrating the effect of resistin on platelet activation by deriving 
conclusions from platelet functional assays. This thesis makes novel 
observations that resistin blunts thrombin-mediated platelet aggregation and 
secretion and seemingly affects the platelet actin cytoskeleton. It also finds that 
resistin activates downstream effectors of phosphoinositide 3 kinase (PI3K) and 
mitogen activated protein kinase (MAPK) pathways in platelets. 
Adenylyl cyclase associated protein 1 (CAP1), a cytoskeletal protein, was 
recently identified as a receptor for resistin. When CAP1 was investigated in 
platelets, interesting observations were made, where CAP1 temporally 
translocated from the membrane fraction in response to thrombin mediated 
activation. Furthermore, in an attempt to improve our knowledge of platelet 
biology and to delineate future avenues for exploration, an observational 
proteomics investigation of cytoskeletal proteins and the change in abundance 
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upon thrombin activation was carried out, further highlighting their importance in 
platelet regulation. Additionally the subcellular localisation of specific 
cytoskeletal proteins (IQGAP1, Arp2/3, coronin1a, profilin, cofilin, villin, l-plastin, 
myosin IIa, and tropomyosin) that are either known or hypothesised to interact 
with CAP1 was also conducted. Further investigations with proteins IQGAP1 
and Arp2/3 revealed that these proteins did not interact with CAP1.  
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CHAPTER 1 
INTRODUCTION 
1.1 Platelets in metabolic syndrome: role of adipokines 
The World Health Organisation (WHO) estimates that more than 1 billion adults, 
worldwide are overweight and of these, over 300 million are clinically obese 
(Body Mass Index [BMI] ≤ 30kg/m2) suffering from the characteristic pathology 
of metabolic syndrome (MetS) (Miranda et al., 2005; Santilli et al., 2012).  MetS 
as defined by the British Heart Foundation (BHF), is a combination of central 
obesity, impaired glucose metabolism, dyslipidemia, IR and arterial 
hypertension, making it a powerful and prevalent predictor of cardiovascular 
events and a leading cause of mortality in developed countries (Less, 2014). 
Obesity is an increasing public health problem constituting an independent 
cardiovascular risk factor. Abdominal obesity is directly related to IR, leading to 
increased blood pressure and alterations in the lipid profile and blood glucose 
levels (Anfossi, Russo and Trovati, 2009; Assumpção et al., 2010). Clinical 
evidence supports the fact that IR plays a central role in metabolic syndrome, 
which is associated with around three times higher CVD mortality and 
approximately two times higher all-cause mortality in adults compared to healthy 
individuals (Assumpção et al., 2010).  
IR is a pathological condition whereby the target cells are unable to respond to 
normal levels of insulin. The outcome is the disruption of insulin-mediated 
glucose and lipid homeostasis, leading to increased requirement of insulin to 
26 
 
maintain normoglycaemia. The main characteristics of IR are disinhibited 
lipolysis in adipose tissue, impaired uptake of glucose by muscle and 
disinhibited gluconeogenesis, where compensatory obligate hyperinsulinemia is 
observed (Mlinar et al., 2007).  
Patients with MetS and T2DM have high risk of microcirculation complications 
and microangiopathies. An increase in thrombogenic risk is associated with 
platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis (Alesso and 
Juhan-Vague, 2008). 
 
Blood platelets are anucleate, discoid cells which are central to haemostasis. 
Haemostasis is a critical physiological process which prevents blood loss after 
vascular injury by formation of haemostatic plugs and helps regain blood fluidity 
thereby maintaining the integrity of the circulatory system. Blood components 
and vascular endothelium together form a regulatory system which aids in the 
process of haemostasis – the vascular endothelium which lines the circulatory 
system separates thrombogenic factors present in the vessel wall from the 
circulating blood (Versteeg et al., 2013). Arterial blood flow generates shear 
stress pushing platelets into close proximity with the endothelial cell layer. 
Platelets remain quiescent during normal circulation under the influence of 
endothelial prostacyclin (PGI2) and nitric oxide (NO) (Smolenski, 2012). Injury to 
the vascular endothelium breaks the physical barrier exposing subendothelial 
agonists to platelets which initiates their adhesion, activation and aggregation 
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and triggers the coagulation cascade. The coagulation cascade enables stable 
thrombus formation, thus regaining haemostasis (Heemskerk, Bevers and 
Lindhout, 2002). 
Thrombus size is tightly regulated by neighbouring endothelial cells producing 
platelet inhibitors (PGI2 and NO) which prevent occlusion of the artery by the 
growing thrombus in healthy individuals (Schwarz, Walter and Eigenthaler, 
2001).  
In addition to the most widely studied role of platelets in haemostasis, platelets 
also act as inflammatory effector cells and perform a broad spectrum of 
functions from acute inflammation to adaptive immunity (Rondina, Weyrich and 
Zimmerman, 2013). Thrombin and fibrinogen, which are generated during the 
formation of haemostatic plug function not only in the amplification of the platelet 
response in the coagulation cascade but also as key proinflammatory factors 
(Leger et al. 2006). Platelet surface immunoreceptors and platelet releasates 
containing proinflammatory chemokines enhance the inflammation at the site of 
injury. Platelets are therefore described as guardians of vascular integrity 
patrolling the circulation for vessel leakage in their quiescent, discoid shape and 
upon encountering molecular cues for vascular damage they change shape, 
undergoing dramatic cytoskeletal reorganisation (Aslan and Mccarty, 2013). 
In pathological conditions like T2DM, obesity, CVD, and MetS, cumulative 
effects of dyslipidemia, hypertension and IR lead to increased risks of vascular 
harm. A key mechanism is involved, namely the progression of atherogenesis 
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(Alesso and Juhan-Vague, 2008). In atherosclerosis, blood flow within arteries is 
occluded due to platelet dysregulation leading to uncontrolled thrombosis and 
chronic inflammation increasing in severity over time. Endothelial barrier 
destabilisation, lipid deposition and plaque formation, angiogenesis and 
subsequent rupture cause thrombotic obstruction of blood circulation causing 
ischemia and infarctions in multitude of organs, often fatal (Badimon and 
Vilahur, 2014). Further aggravation of the MetS and T2DM disease occurs due 
to factors leading to platelet activation comprising IR, hyperglycaemia, non-
enzymatic glycosylation, oxidative stress, and inflammation (Suslova et al., 
2014).  
A number of platelet regulation mechanisms are affected in patients presenting 
MetS. Table 1.1 lists some of the effects of MetS on patients’ platelets that have 
been correlated in clinical studies.  
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Table 1.1 Effects of metabolic syndrome (MetS) on patients’ platelets 
Effects of MetS on platelets References 
cGMP inhibitory pathway dysregulation (Santilli et al., 2012) 
High platelet turnover (Vaduganathan et al., 2008; 
Santilli et al., 2012) 
Abnormal platelet morphology 
(high % of reticulated platelets) 
(Vaduganathan et al., 2008; 
Santilli et al., 2012) 
Increased ADP-induced P-selectin expression (Vaduganathan et al., 
2008) 
Increased platelet microparticles in circulation 
(increased CD40L, IL-1β, CRP, IL-6 and other 
inflammatory cytokines) 
(Serebruany et al., 2008; 
Santilli et al., 2012; 
Gyulkhandanyan et al., 
2013) 
 
It is discussed that platelets are sites of IR- thus causing the lack of the 
physiological action exerted by insulin on platelet function, such as reduction of 
the prothrombotic properties of agonists, including adenosine diphosphate 
(ADP), collagen, thrombin, epinephrine; activation of endothelial NO synthase, 
with increased NO formation and intra-platelet concentrations of cyclic 
adenosine monophosphate (cAMP); sensitization of platelets to the inhibitory 
actions of PGI2 and NO on aggregation (Trovati et al., 1997; Anfossi, Russo and 
Trovati, 2009; Gerrits et al., 2012). 
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An understanding of the mechanisms and factors affecting platelet function are 
critical to assessing and improving treatments provided to patients suffering 
from MetS owing to the collateral complications that arise due to myriad of 
pathologies.  
In a bid to isolate MetS effects on platelets further; in our study we investigate 
the role of an adipokine, resistin, and its effect on platelet activation.  
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1.2 Adipokines 
Obesity and specifically the presence of excessive visceral adipose tissue has 
been correlated to IR and MetS in clinical investigations  (Fantuzzi et al., 2005; 
Rabe et al., 2008; Assumpção et al., 2010; Ayeser et al., 2016). Adipose tissue 
as an endocrine organ in addition to energy storage organ has been extensively 
described. Adipose tissue secretes cytokines, termed adipokines, and 
components of the complement system (Table 1.2). It is therefore implicated in 
complex roles in vascular haemostasis, inflammation and metabolism 
(Bełtowski, 2003; Kershaw and Flier, 2004). Adipokines are primarily involved in 
the regulation of insulin sensitivity of target cells. Shearer et al. (2005) describe 
leptin, adiponectin, resistin, adipsin and visfatin as true adipokines, whereas 
additional chemokines secreted by the adipocytes are classified separately as 
they are secreted more abundantly by other cell types compared to adipocytes 
(Frühbeck and Salvador, 2004; Rabe et al., 2008; Piya, McTernan and Kumar, 
2013). 
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Table 1.2: List of adipokines: Compilation of list of adipokines is derived from 
the following reviews - (Frühbeck and Salvador, 2004; Rabe et al., 2008; Piya, 
McTernan and Kumar, 2013) 
True adipokines Other adipokines 
Adiponectin Tumor necrosis factor α (TNF-α) 
Leptin Interleukin 6 (IL-6) 
Resistin IL-10 
Adispsin Omentin 
Visfatin Retinol binding protein-4 (RBP-4) 
Apelin Monocyte-chemoattractant protein-1 
(MCP-1) 
 Transforming growth factor β (TGF-β) 
Ghrelin 
Chemerin 
RANTES (Regulated on activation 
normal T cell expressed and secreted) 
Plasminogen activator inhibitor 1 (PAI-
1) 
C-reactive protein (CRP) 
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A differential role of adipokines in lean and obese individuals has been identified 
– white adipose tissue of lean individuals preferentially secreting anti-
inflammatory cytokines like adiponectin, TGFβ, IL-10, apelin, whereas white 
adipose tissue in obese individuals have increased secretion of pro-
inflammatory cytokines like resistin, leptin, TNF-α, IL-6, PAI-1, that subsequently 
affect the modulation of IR, and insulin signalling pathways (Piya, McTernan and 
Kumar, 2013). 
In the following sections, true adipokines like leptin and adiponectin are further 
described. A more detailed account of resistin is presented in section 1.3, as it is 
the main protein of interest in this thesis. Other true adipokines like apelin, 
adipsin and visfatin are relatively newly identified and there is limited information 
available about their effects on platelet function and hence they are only 
described along with other adipokines. 
 
1.2.1 Leptin 
Leptin, which is a 16 kDa protein comprising of 167 amino acids, was one of the 
first adipokines described in literature and widely studied in the obese mouse 
model ob/ob (leptin deficient) and diabetic model db/db mice (leptin-receptor 
deficient) (Wang, Chandrasekera and Pippin, 2014). Leptin has been 
predominantly known for its role in regulation of food intake and body weight 
labelled as the hunger hormone. It elicits its function by activation of JAK-STAT 
signalling pathway in response to the leptin receptor activation. A dual 
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mechanism of action has been observed, as db/db mice, where leptin receptor 
activation and JAK-STAT is inhibited, glucose haemostasis was regulated by 
phosphatidylinositol-3 kinase (PI3K), suggesting that leptin activated PI3K and 
was required for maintaining normoglycemia in the wild-type and knockout mice 
(Stavros Konstantinides et al., 2001). Additionally, leptin was found to inhibit 
insulin production in lean mice in response to induction of suppressor of 
cytokine signalling proteins 3 (SOCS-3) (Kershaw and Flier, 2004; Dellas et al., 
2008). Elevated levels of leptin in the plasma of patients suffering from T2DM 
has been described in HUVECs, where induction of tissue factor (TF) 
expression and upregulation of PAI and t-PA thus led to hypercoagulability in 
diabetic patients (Bobbert et al., 2011). Platelets are thought to be the main 
target of leptin action owing to the presence of the leptin receptor on their 
surface. The long form of the receptor regulates platelet activity of downstream 
pathways involving JAK activation, PI3K, phospholipase Cγ2 (PLCγ2) and 
phospholipase A2 (PLA2) activation, which therefore alters cAMP hydrolysis, 
GPIIa/IIb expression and thromboxane A2 (TXA2) synthesis (Nakata et al., 1999; 
Zhang and Colman, 2007; Santilli et al., 2012). Clinical studies have shown 
platelets from obese donors are not resistant to the enhancing effects of leptin 
on ADP-induced platelet aggregation further corroborating leptin as an 
independent indicator of cardiovascular events due to platelet hyperactivity 
(Dellas et al., 2008; Lukasik et al., 2012). 
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1.2.2 Adiponectin 
Adiponectin is a 244 amino acid protein that has two active forms – full-length 
and globular adiponectin with contrasting physiological functions. It is 
synthesised by adipocytes in response to increase in circulating pro-
inflammatory factors (Kwon and Pessin, 2013). Full-length adiponectin (fAd) has 
anti-thrombotic properties and exerts its vasculoprotective effects through its 
direct actions in the vascular system, such as increasing endothelial NO 
production, inhibiting endothelial cell activation and endothelium-leucocyte 
interaction, enhancing phagocytosis, and suppressing macrophage activation, 
macrophage-to-foam cell transformation and platelet aggregation (Zhu et al., 
2008; Restituto et al., 2010). fAD increases insulin sensitivity by regulating 
glucose metabolism via specific receptors on platelet surface, AdipoR1 and 
AdipoR2 that trigger p38 MAPK and PPARα (Kadowaki et al., 2006; Santilli et 
al., 2012)– PPARγ antagonists stimulate expression of adiponectin by 
adipocytes (Bełtowski, 2003; Kwon and Pessin, 2013). Enhanced platelet 
response to ADP and collagen was observed in adiponectin deficient mice, 
whereas preincubation with adiponectin in the platelet-rich plasma of patients 
suffering from MetS, prevented platelet aggregation when stimulated with ADP 
and epinephrine (Santilli et al., 2012). Hypoadiponectinaemia is suggested to be 
involved IR and accelerated atherogenesis associated with obesity (Bełtowski, 
2003; Lihn, Pedersen and Richelsen, 2005). Exogenous administration of 
adiponectin or overexpression in transgenic mice results in improved insulin 
sensitivity whereas adiponectin deficient mice develop high fat diet-induced 
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inflammation and IR suggesting that adiponectin plays a major role in prevention 
of atherosclerosis (Kato et al., 2006).  
The proteolytic cleavage of fAd by leukocyte elastase gives rise to a biologically 
active globular adiponectin (gAd) in vitro, but the in vivo production of gAd has 
yet to be characterised (Waki et al., 2005). Most recent studies that explore the 
role of gAd in immune functions, reveals that gAd serves as a potent mobilizer 
of haematopoietic progenitors and leukocytes into the peripheral blood (Sung et 
al., 2015). In cardiac fibroblasts and vascular endothelial cells, gAd plays a role 
in activation of inflammatory pathway mediated by NF-ƙB and proliferation by 
increased expression of angiotensin II (Goldstein et al., 2007), although this has 
been challenged by Adya et al. (2012) and they propose that a synergistic, 
potentially protective mechanism of gAd occurs at the initiation site of the 
atherosclerotic plaque. gAd has been shown to trigger the GPVI-FcγR complex 
mediated activation pathway in platelets, where it triggers Src-family kinase, Syk 
and PLCγ2 (Riba et al., 2008).  
  
1.2.3 Other true adipokines 
No data is available illustrating effects of adipokines like apelin, visfatin and 
adipsin on platelet function (Santilli et al., 2012), but their mechanism of action 
in adipose tissue is documented. Apelin has been shown to be regulated by 
insulin overexpression and has been correlated with PI3K and MAPK 
stimulation (Boucher et al., 2005). Visfatin is an adipokine which is responsible 
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for destabilisation of atherosclerotic plaques and enhanced expression of 
visfatin by macrophages was reported at the site of atherogenesis, thereby 
implicating it in the progression of acute cardiovascular outcomes (Romacho et 
al. 2013). Adipsin is an adipokine which is implicated in T2DM owing to its role 
in insulin regulation. Adipsin deficient mice lack glucose tolerance due to 
decreased levels of insulin whereas diabetic mice, when given exogenous 
adipsin have improved glucose metabolism and increased insulin expression in 
the β islets (Lo et al., 2014). 
 
1.2.4 Other adipokines 
Several cytokines released from adipocytes are also secreted by other cell 
types. These affect insulin sensitivity and inflammatory responses in obese, 
MetS, T2DM patients. Ghrelin, which is mainly produced by the cells in 
gastrointestinal tract, is also secreted by adipose tissue where it regulates the 
adiposity of the tissue and Santilli et al. (2012) present it to have no effect on 
platelet aggregation (Tsubone et al., 2005).  
TNF-α, which is an inflammatory cytokine, modulates platelet function by 
activation of NF-ƙB pathway, MAPK pathway via ERK and p38, thus contributing 
towards the inflammatory role of platelets (Piya, McTernan and Kumar, 2013). 
Platelets express functional TNF receptors and engagement of TNF-α with its 
receptors elicits platelet activation, with enhanced TXA2 biosynthesis and 
CD40L shedding (Santilli et al., 2012).  
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A number of other cytokines like IL-6, IL-10, MCP-1, PAI-1, RBP-4, have 
activatory effects on platelets (Fantuzzi et al., 2005; Santilli et al., 2012), but 
they are not detailed as a part of this introduction as we restrict it to the products 
mainly contributed by adipocytes compared to other cell types. 
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1.3 Resistin 
Resistin, also known as FIZZ3 (found in inflammatory zone 3) and ADSF 
(adipocyte-secreted factor), was initially identified in a screen for adipocyte-
specific transcripts downregulated by treatment with antidiabetic 
thiazolidinedione (TZD) drugs (insulin sensitizers) (Schwartz and Lazar, 2011). 
It was first correlated to obesity in diabetic mice as the protein that conferred IR 
( Steppan et al., 2001). In mice it is exclusively produced by white adipose 
tissue, while in humans high levels of resistin are expressed by macrophages, 
monocytes, leukocytes, spleen and bone marrow cells, followed by lung tissue, 
resting endothelial cells and placenta in addition to pre-adipocytes that are 
differentiating to adipocytes (Tarkowski et al., 2010). High levels of circulating 
resistin are characteristic of obese mice and gender-based variations have been 
noted in mice and in humans, where plasma obtained from females has been 
shown to have higher levels of resistin (Steppan and Lazar, 2004). In rodents, 
resistin immunoneutralisation is reported to promote normoglycemia and 
improve IR in high-fat diet fed mice (Steppan et al., 2001; Rajala et al., 2004). 
The attempts at correlating resistin with obesity, MetS, T2DM and IR have been 
controversial owing to the differences in the techniques used to assess resistin 
expression -researchers correlated disease states to mRNA levels, circulating 
resistin in plasma or resistin concentrations detected using immunoblotting 
(Ukkola, 2002). An important difference which complicates extending resistin 
observations from mice to men is the fact that in humans, resistin is secreted by 
monocytes and macrophages, and negligible amounts produced by the adipose 
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tissue leading to physiological differences in its mechanism and target of action 
(Ukkola, 2002; Jamaluddin et al., 2012).  
 
 
1.3.1 Resistin structure 
Human resistin is a 12.5kDa molecule that belongs to a cysteine-rich family of 
resistin-like molecule (RELMs) proteins - RELMα, RELMβ and resistin (FIZZ1, 
FIZZ2 and FIZZ3 respectively), where each member of the family has a unique 
tissue distribution pattern ( Steppan et al., 2001). Human and mouse resistin 
share 59% identity at the amino acid level. Its structural elements contain a 
variable N-terminal and a similar repeat sequence of cysteine residues found in 
both mouse and human isoforms (Al Hannan and Culligan, 2015). The two 
structurally distinct domains, N-terminal and C-terminal, are linked via a flexible 
neck domain. The C-terminal is a disulfide-rich beta-sandwich "head" domain 
and N-terminal alpha-helical "tail" segment. The alpha-helical segments 
associate to form three-stranded coiled coils, and surface-exposed interchain 
disulfide linkages (Cys6) mediate the formation of tail-to-tail hexamers, where 
the intertrimer formation is the key step in forming a functional resistin molecule. 
(Patel et al., 2004). Figure 1.1 shows a homotrimer of resistin, where each 
colour represents a distinct molecule. However, the recombinant human resistin 
(PeproTech, USA) that was later used during experimentation was a 19.5kDa, 
disulfide-linked, homodimeric protein composed of two identical 92 amino acid 
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chains linked by a single disulfide bond. In order to address if the difference in 
oligomerisation caused any functional difference, control experiments were 
performed and can be found in sections 3.2.1.5 (Figure 3.6), and 3.2.3 (Figure 
3.12).  
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Figure 1.1 Resistin protein structure: Resistin exists as a homotrimer 
assembly of molecules. The N-terminal domains are found central to the 
assembly, while the C-terminal, cysteine-rich domains form the disulphide 
linkages that hold the trimer assembly together. (A) A broadly classified domain 
structure of the human resistin molecule of 108 a.a. is shown. (B) The α-helical 
domains at the N-terminal region and the β-strand sandwich at the C-terminal 
are clearly viewed in the front view of the protein trimer, where each colour 
represents one molecule of resistin (C) while the top view of the resistin protein 
trimer shows the central N-terminal domains towards the top and the C-terminal, 
disulphide linked domains towards the bottom. (Further details can be accessed 
at: http://www.ebi.ac.uk/pdbe/entry/pdb/1rgx)(Patel et al., 2004). 
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1.3.2 Resistin gene expression 
 The human resistin gene, RETN, is located on chromosome 19p13.2 and was 
first identified as 10-cysteine containing protein (XCP) (Nagaev et al., 2006). 
Resistin mRNA expresses 120 a.a. which contains a 20 a.a. signal peptide, and 
in its mature form it has 108 a.a. in humans and 94 a.a. in mice (Ukkola, 2002; 
Yang et al., 2003). The expression of RETN is exclusively in myeloid cells and 
highest expression being in the bone marrow. Furthermore, expression of RETN 
is dependent on the myeloid-specific nuclear transcription factor, the 
CCAAT/enhancer binding protein epsilon (CEBPE). This transcription factor was 
found to be essential for and co-expressed with RETN. The disruption of 
CEBPE leads to silencing of RETN and its overexpression leads to expression 
of RETN even in non-myeloid cells (Chumakov et al., 2004; Nagaev et al., 
2006). Chumakov et al. (2004) also showed that RETN played an important role 
in chemotaxis of bone-derived myeloid cells and specifically interacts with 
neutrophil α-defensins. Nagaev et al. (2006) observed that human and mouse 
resistin genes present with complications in understanding resistin’s function as 
resistin gene lineages underwent various modifications during the evolution of 
different mammalian species. They also claim that resistin genes are not true 
homologues but the resulting proteins are functional analogues of each other, 
whereas Al Hannan & Culligan (2015) give the opposite view that resistin in 
mice and humans have distinct functional properties and expressed as a result 
of different signalling molecules.  
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In the studies related to resistin genetics, a polymorphism in the resistin gene 
(420 C>G) was reported in relation to the BMI of women, where women carrying 
the G-allele had lower BMI compared to C/C homozygote women (Feng and 
Zhang, 2011).  
Resistin expression has been shown to be affected by insulin in adipocytes, 
where insulin-desensitiser (TZDs), PPARγ receptor agonists, caused an 
increase in resistin expression (Steppan et al., 2001; Bełtowski, 2003). In a 
contradicting study stimulation of resistin expression in response to PPARγ 
agonists in obese rodent models was observed (Way et al., 2001). Steppan & 
Lazar (2004) suggest that secretory profiles of resistin change, depending on 
which rodent model and/or study technique further contributing to the resistin 
conundrum. 
 
1.3.3 Mechanism of action of resistin in endothelial and immune cell lines 
Resistin exerts its influence over a number of cell types in a pleiotropic manner 
– via endocrine, paracrine and autocrine mechanisms. Implication of resistin in 
inflammation, MetS, T2DM, obesity, atherosclerosis and development of 
atherosclerosis, and cancer metastasis and the mechanisms involved therein 
are yet unclear owing to limited knowledge regarding resistin receptors 
(Codoner-Franch and Alonso-Iglesias, 2015). In addition to this, the role of 
resistin under healthy patients is as yet unclear. It is therefore, important to 
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identify a receptor for resistin and delineate both receptor-dependent and 
independent effects induced by this multifaceted hormone. 
A number of putative resistin receptors have been described in the literature. An 
isoform of decorin (that lacks the glycation site) is reported as a resistin receptor 
in adipose progenitor cells, where it is reported to affect adipocyte 
differentiation, migration and proliferation (Daquinag et al., 2011). Mouse 
resistin is also described to interact with tyrosine-kinase-like orphan receptor 
(ROR1) to mediate a decrease in glucose uptake and negatively affect 
adipogenesis in mouse adipocyte cell line (Sánchez-Solana, Laborda and 
Baladrón, 2012).  
Toll-like receptor-4 (TLR-4), which is mainly known for its role in triggering 
inflammation responses in immune cells is also proposed as a receptor for 
resistin. Tarkowski et al. (2010) show that resistin binds to TLR-4 and induces 
cytokine production by initiation of NF-ƙB and MAPK signalling pathways, where 
it competes with a known TLR-4 ligand, LPS (lipopolysaccharide – present on 
the bacterial cell wall). Myeloid differentiation marker 88 (MyD88), which is 
essential for downstream signalling by TLRs also participates in the signalling 
cascade (Rondina, Weyrich and Zimmerman, 2013). Resistin-TLR-4 complex is 
also demonstrated to reduce insulin mediated phosphorylation of insulin 
receptor, upregulation of SOCS-3 and phosphotyrosine phosphatase-1B (PTP-
1B), which are indicative of its role in IR (Benomar et al., 2013). Most recently, 
resistin was shown to play a role in IR and hypertension in TLR-4 deficient mice 
by activation of the renin-angiotensin system (Jiang et al., 2016) supporting the 
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view that resistin performs its inflammatory role by activating downstream 
signalling molecules of the TLR-4 pathway. A brief summary of resistin 
mediated signalling activated downstream of TLR4 are shown in Figure 1.2. 
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Figure 1.2 Resistin mediated activation of TLR4 signalling pathways and 
its influence on insulin signalling. Resistin mediated signalling occurs by 
binding TLR4 followed by MyD88 on the intracellular face triggering NF-ƙB and 
MAPK pathways. Phosphorylation of JNK and p38 downstream of MAPK 
activation and NF-ƙB phosphorylation leads to suppressor of cytokine signalling 
proteins 3 (SOCS-3), interleukin 6 (IL-6) and phosphotyrosine phosphatase-1B 
(PTP-1B) generation, which in turn inhibits insulin signalling in the cell, thus 
contributing to IR. 
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Another elaborate study claimed that adenylyl cyclase protein 1 (CAP1) was a 
bonafide receptor for resistin in a monocytic cell line. They presented evidence 
that interaction of resistin with CAP1 initiated adenylyl cyclase [or protein kinase 
A (PKA)] -mediated activation of NF-ƙB and the release of cytokines by the 
monocytes (Lee et al., 2014). Lee et al. (2014) performed a detailed analysis of 
resistin mediated responses in cells where they silenced each of the four 
putative resistin receptors – CAP1, TLR-4, decorin and ROR1. They present 
evidence that cell migration, and cytokine expression upon resistin treatment 
was significantly reduced in cells lacking CAP1 compared to cell populations 
lacking TLR-4, decorin and ROR1, therefore claiming it as a confirmed receptor 
for resistin. As described in detail in section 1.6 of this chapter, CAP1 is mainly 
a cytosolic protein, that is associated with the membrane (Noegel et al., 2004) 
but it has no transmembrane domains. It is therefore difficult to conceptualise 
the circumstances under which extracellularly released resistin might encounter 
cytosolic CAP1, as there is no evidence of resistin internalisation in the literature 
(Al Hannan and Culligan, 2015) and therefore, the resistin receptor conundrum 
remains unresolved. 
Since we investigate the effects of resistin on platelets, a description of platelets 
and their cytoskeleton and regulation is given in the following sections and we 
investigate CAP1 in platelets subsequently. 
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1.3.4 Resistin function 
The function of resistin in mice and men is controversial at best, as studies have 
not been able to clarify the precise role of resistin or its target cells under 
normal, healthy conditions. It has been difficult to assess whether elevated 
serum resistin is the cause of pathologies or if it is the effect of patients suffering 
from those pathologies like metabolic dysfunction in diabetes, obesity and IR 
that lead to the observed increase in resistin levels. Most recent observation 
regarding resistin function is that resistin may foster in vivo oxidative stress, 
thromboxane-dependent platelet activation and platelet-derived inflammatory 
proteins release in patients suffering from T2DM leading to atherothrombosis 
(Santilli et al., 2016). 
 
1.3.4.1 Resistin in MetS and associated CVD progression 
The first functional attribute of resistin described in the literature is its role in IR 
in obese mice (Steppan et al., 2001).  Similar evidence was found in relation to 
increased expression of human resistin leading to IRin obese patients 
(McTernan et al., 2002; Smith et al., 2003) but simultaneously disputed due to 
inconsistency in the observations in other similar studies (Nagaev and Smith, 
2001; Ukkola, 2002; Lee et al., 2003). Several other studies provide positive 
correlation of elevated serum resistin in obesity and decreased insulin sensitivity 
and its role in progression of T2DM (Rajala et al., 2004; Piya, McTernan and 
Kumar, 2013; Abate et al., 2014; Nieva-Vazquez et al., 2014). (Bobbert et al., 
2011) also provide evidence of resistin-mediated increase in procoagulability in 
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patients suffering from T2DM by causing an increase in expression of TF and 
disturbing the balance of fibrinolytic system by upregulation of PAI and t-PA 
expression, thus contributing towards increased CVD risk in patients suffering 
from T2DM.  Resistin is described as a biomarker of systemic inflammation and 
atherosclerosis (Lehrke et al., 2004; Reilly et al., 2005). In mice, induction of 
hypertension and IR in response to administration of recombinant resistin was 
shown to be triggered via TLR4 pathway (Jiang et al., 2016). 
 A number of controversies regarding the role of resistin in diabetes, obesity and 
IR have arisen over the years after it was first described in 2001 (Smith, 2002; 
Schwartz and Lazar, 2011). A unifying observation is that antidiabetic TZD 
drugs inhibit resistin gene expression in human macrophages as well as in 
mouse adipocytes suggesting that although resistin might be expressed in 
different tissues in humans and mice, it can potentially have similar function 
upon expression (Banerjee, 2004).  
 
1.3.4.2 Resistin in inflammation: Effects on human monocytes and 
endothelial cells 
Resistin is secreted from and affects monocyte behaviour, where it enhances 
monocyte-endothelial adhesion via p38 MAPK pathway, consequently 
increasing ICAM-1 and VCAM-1 expression (Hsu et al., 2011), and enhances 
monocyte transmigration towards endothelial cell layer via TLR4-pathway 
(Pirvulescu et al., 2014). The same research group had previously shown that 
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resistin caused increased expression of adhesion proteins (fractalkine) in 
human endothelial cells by activating p38 MAPK and NF-ƙB pathways, in 
comparable mechanisms to TNF-α (Manduteanu et al., 2009) and that high 
glucose enhanced the effects of resistin mediated increase in fractalkine 
(Manduteanu et al., 2010). These observations along with clinical examinations 
that recorded circulating serum resistin have shown that resistin plays a key role 
in inflammation and potential indicator of the degree of systemic inflammation 
(Fantuzzi et al., 2005; Jamaluddin et al., 2012; Kwon and Pessin, 2013; Piya, 
McTernan and Kumar, 2013; Al Hannan and Culligan, 2015).  
 
1.3.4.3 Function of resistin in adipokine regulation in diabetic mouse 
models 
Adiponectin, leptin and resistin each regulates the expression of others to 
maintain a balance of circulating adipokines. Direct reciprocal effect of 
adiponectin and resistin is seen in vascular endothelial cells where induction of 
ICAM-1 and  VCAM-1 by resistin is inhibited by adiponectin (Kawanami et al., 
2004). In leptin deficient, obese mice, loss of resistin is shown to improve 
glucose homeostasis and thus contribute to its role in IRin diabetic mice (Qi et 
al., 2006). As described earlier, leptin and resistin together contribute to 
increased CVD risk in T2DM patients (Bobbert et al., 2011). 
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1.3.4.4 Function of resistin in glucose metabolism in rodent disease 
models and human endothelial cell lines 
Dysregulation of glucose metabolism or glucose tolerance by resistin has been 
demonstrated in resistin deficient mice, where authors observed that blood 
glucose of fasting resistin deficient mice was lower than that of wild-type mice 
and this was recovered upon administration of recombinant resistin to the 
deficient mice (Banerjee, 2004). In humans also, hyperglycemia is always 
accompanied by high serum concentrations of resistin but with weak links to IR 
(Pagano et al., 2006). Activation of SOCS proteins, that are inhibitors of insulin 
signalling, was observed in hyperresistinemic mice, leading to activation of PI3K 
and Akt phosphorylation, that was prevented in mice expressing dominant 
negative resistin with improvement in glucose tolerance and insulin sensitivity 
(Steppan et al., 2005).  
Glucose transporters, GLUT1 and GLUT4, are translocated to the membrane 
enabling glucose uptake by cells. Resistin reduces the uptake of glucose by rat 
skeletal muscle cells (Fan et al., 2007), Further, resistin causes tyrosine 
phosphorylation of insulin-receptor substrate-like 1 (IRS-1) thus decreasing 
GLUT4 translocation inhibiting glucose permeability of cells (Palanivel et al., 
2006). Additionally, resistin downregulates the expression of GLUT1 in 
endothelial cells, thus impairing glucose permeability (Li et al., 2016). Within the 
scope of disrupting metabolism, resistin disrupts glycogen synthesis under high 
insulin and high glucose levels by downregulating the levels of GSK3β, 
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integrating the observations that it causes SOCS-3 activation and Akt 
phosphorylation (Song et al., 2013). 
 
1.3.4.5 Upregulation of resistin in cancerous cells: Role in cell proliferation 
Resistin promotes smooth muscle cell proliferation by activation of extracellular 
related kinase 1/2 (ERK1/2) and PI3K ( Calabro et al., 2004). Resistin mediated 
upregulation of matrix metalloproteinases, MMP-2 and MMP-9 was reported in 
breast cancer cell lines (Pan et al., 2007). Progression of cancer, upon 
exogenous administration of recombinant resistin, in prostate cancer cell lines 
occurred via stimulation of PI3K/Akt signalling pathway (Housa et al., 2008). In 
gastric cancer cell lines, resistin was shown to stimulate p38 MAPK thereby 
activating NF-ƙB pathway (Codoner-Franch and Alonso-Iglesias, 2015). In their 
review, Feng & Zhang (2011) describe evidence of studies that observe a 
correlation of elevated resistin levels in endometrial cancer, colorectal cancer 
and lung cancer patients.   
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1.4 Platelets  
Platelets are anucleate cells, which are discoid when quiescent in normal 
circulation and undergo dramatic shape change to become flattened upon 
activation at site of injury, playing a major role in regulation of haemostasis and 
inflammation. They are present in the blood along with erythrocytes and 
leukocytes and under shear stresses of circulation they flow close to the 
endothelial cell lining the vessel walls. Platelets are derived from their progenitor 
cells, the megakaryocytes, in the bone marrow in response to the hormone 
thrombopoietin (TPO). Cytoskeletal changes in the mature megakaryocytes 
form protrusions called proplatelets or in state of inflammation undergo 
cytoplasmic fragmentation and microtubule reorganisation (Poulter and Thomas, 
2015) determining their structural and functional attributes finally releasing 
platelets into circulation. The normal platelet count of blood ranges between 150 
and 400 × 109/L and human platelets have a lifespan of 1-10 days, thus forming 
a heterogeneous population that varies in size and responsiveness to agonists 
(Bearer, Prakash and Li, 2002). 
 
1.4.1 Platelet morphology 
Platelets are about 3.0 by 0.5 µm in size in their resting state, containing a mean 
volume of 6-10 fL (Hartwig and Italiano, 2006). Platelets have characteristic 
morphological features including an unusual membrane system which 
comprises of an open canalicular system (OCS), which is a system of tunnelling 
invaginations of the plasma membrane that tracks through the platelet, and a 
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dense tubular system (DTS), which is thought to be derived from the 
endoplasmic reticulum of megakaryocytes and contains intracellular calcium 
stores (White, 1972). In the active platelet the OCS serves as a conduit system 
which enables fusion and release of granules together with accommodating the 
extra surface area of the spreading platelet (Hartwig and Michelson 2012). 
Additionally, platelets contain multiple organelles like mitochondria, lysosomes 
and granules including alpha and dense granules. Further details of the granular 
system are listed in Table 1.3. 
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Table 1.3 Details of the platelet granular system 
Platelet 
granule 
Alpha-granules Dense granules Lysosomes 
# /platelet 50-80 5-6 Variable 
Diameter 0.2-0.4µm 0.15µm Variable 
Contents Adhesive proteins 
(Thrombospondin, 
P-selectin) 
Haemostatic 
factors (factor V, 
vWF, fibrinogen) 
Angiogenic factors 
(angiogenin, 
VEGF) 
Anti-angiogenic 
factors 
(angiostatin, PF4) 
Growth factors 
(PDGF, bFGF, 
SDF1α) 
Proteases (MMP-
2, MMP-9) 
Necrotic factors 
(TNF-α, TNF-β)  
Cytokines 
 
Serotonin 
ATP, ADP  
Polyphosphates 
(Calcium, 
Magnesium and 
Potassium) 
 
Hydrolytic 
enzymes 
 
References (Harrison and 
Cramer, 1993; 
Whiteheart, 2011) 
(McNicol and 
Israels, 1999) 
(White, 2007) 
 
  
57 
 
The contents of granules are released in the process of platelet activation and 
their secretome has paracrine effects on activating neighbouring platelets and 
aiding the coagulation cascade (Fitch-Tewfik and Flaumenhaft, 2013). Platelet 
granules become centralised during activation. Interestingly, this centralisation 
is independent of platelet shape change and it has been proposed that 
depolymerisation of filamentous (F-) actin cytoskeleton is required for normal 
granule secretion (Flaumenhaft, 2003). Secretion of the granulomere initiates 
secondary activation in platelets, thus enhancing the platelet response at the 
haemostatic site. 
The platelet cytoskeleton comprises of a peripheral band of microtubules, which 
gives it the discoid shape, and actin cytoskeleton and its associated proteins, 
which play an important role in cytoskeletal reorganisation of the activated 
platelet by formation of filopodia and lamellipodia finally merging to form a 
completely spread platelet with a centralised granulomere or hyalomere 
(Hartwig, Steffen and Cell, 1992; Blanchoin et al., 2014). 
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Figure 1.3 Ultrastructure of discoid, resting platelet. Platelet seen had been 
sectioned along the equatorial plane (magnification x 22,000). Glycocalyx, 
phospholipid bilayer forms the outermost layers of platelet. Open canalicular 
system (OCS) pits outline the surface of the platelet and the dense tubular 
system (DTS) within the platelet form a network of calcium rich zones. 
Underneath the outer layers lies the platelet cytoskeleton comprising of a 
microtubular coil and actin networks. A number of alpha and dense granules are 
observed along with other organelles like mitochondria. Figure modified from 
(White 2007).  
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1.4.2 Platelet plug formation 
Platelets express a plethora of receptors on their surface that regulates platelet 
activity by responding to the variable microenvironments at the site of 
endothelial damage to enable their holistic role in haemostasis and 
inflammation. Platelet agonists like collagen, that initiate platelet adhesion and 
aggregation are present in the subendothelium (Roberts, McNicol and Bose, 
2004). The subendothelial matrix is exposed upon vascular injury or rupture of 
an atherosclerotic plaque (Figure 1.4). Von Willebrand Factor (vWF), which is a 
plasma protein, interacts with collagen from the subendothelium altering the 
conformation of glycoprotein GP1b receptor complex, thus promoting transient 
tethering and rolling action of platelets on the exposed subendothelium 
(Jackson, 2011). Rolling platelets then adhere in response to binding of collagen 
to GPVI and α2β1 receptors (Watson et al., 2005). Soluble agonists are then 
generated at the site of injury which triggers activation of G-protein coupled 
receptors (GPCRs), followed by activation of integrin αIIbβ3, which results in 
aggregation and stable plug formation (Li et al., 2010). Ligand binding at the 
membrane triggers signalling cascades that enable platelets to amplify their 
presence by secretion of their granulomere and the coagulation cascade ensues 
by formation of thrombin and thrombin-mediated conversion of fibrinogen to 
fibrin (Heemskerk, Bevers and Lindhout, 2002; Palta, Saroa and Palta, 2014). 
Platelet membrane expresses phosphatidylserine (PS) on the surface 
designating platelets with a procoagulant state within the thrombus. Fibrin 
strands ensure compaction and stability of the developing thrombus (Versteeg 
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et al., 2013). Thrombus consolidation occurs when endothelial cells surrounding 
the thrombus start generating platelet inhibitors like PGI2 and NO (Smolenski, 
2012). 
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Figure 1.4 Platelet plug formation. At the site of endothelial interruption, 
platelets begin to roll inducing transient platelet adhesion by binding to plasma 
protein vWF. The GP1b-IX-V complex then mediates binding to collagen in the 
subendothelial matrix completing platelet adhesion. As platelets adhere, they 
begin to change shape from discoid to form more flattened structures. Outside-
in signalling triggers activation of integrins and therefore initiate platelet 
aggregation. Platelet granulomere is released from its cytosol providing 
additional platelet agonists, like ADP, serotonin and coagulating factors. 
Presence of factor V, VIII lead to conversion of prothrombin into active thrombin 
protease. As the coagulation cascade begins, thrombin converts fibrinogen into 
fibrin, enabling the stabilisation of the growing thrombus. Thrombin, ADP and 
TXA2 also activate G-protein coupled receptors amplifying platelet activation 
and recruiting more platelets to the site of injury and enabling platelet 
procoagulant activity. Thrombus consolidation mediated by platelet inhibitory 
pathways triggered by NO and PGI2 production by neighbouring endothelial 
cells prevents the thrombus from occluding the vessel. Figure from Versteeg et 
al. 2013.  
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1.4.2.1 Platelet adhesion: vWF/GP1b complex mediated platelet activation 
At the site of injury, shear rates within the vasculature promote transient binding 
of vWF in the subendothelium to platelet receptor complex GP1b-IX-V. This 
then enables binding collagen and therefore, the initial platelet adhesion, 
leading to integrin activation and integrin-dependent stable platelet adhesion 
and aggregation (Li et al., 2010). Binding of the receptor complex to collagen 
induces an early increase in intracellular calcium (Ca2+) due to interaction with 
Src-family kinases (SFK) and PI3K. An increase in intracellular cGMP (cyclic 
guanosine monophosphate) levels is also observed when GP1b-IX-V complex is 
activated in response to stimulation of protein kinase G (PKG) (Riba et al. 
2006).  
 
1.4.2.2 Platelet adhesion: Collagen/GPVI mediated platelet activation 
At the site of vascular rupture, integrin α2β1 receptors enable platelet adhesion 
to collagen thereby enabling GPVI mediated activation. This binding of 
immunoglobulin receptor GPVI to collagen then causes tyrosine phosphorylation 
of FcγRIIA. This then causes recruitment of Syk at the platelet membrane 
(Janmey and Matsudaira, 1988). Next, phosphorylation of Syk activates PLCγ2, 
which then leads to generation of diacylglycerol (DAG) and inositol triphosphate 
(IP3). IP3 is freely soluble in the cytosol and translocates and binds DTS, 
initiating the release of intracellular stores of Ca2+ in response to IP3 receptor. 
Intracellular calcium levels are further elevated upon opening of the calcium 
channels in the plasma membrane, whereas DAG activates protein kinase C 
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(PKC). Ca2+, as a secondary messenger, together with DAG mediate 
characteristic platelet activation leading to shape change, granule secretion and 
aggregation (Roberts, McNicol and Bose, 2004). Granule secretion enhances 
platelet activation when platelets are presented with low concentrations of 
collagen. 
 
1.4.2.3 GPCR mediated platelet activation 
Platelets adhere at the site of injury initially forming a monolayer which serves 
as a base for platelet aggregation. This process is dependent on binding of 
bivalent fibrinogen to integrin αIIbβ3 (Parise, 1999). Aggregation is mediated by a 
process involving capture of platelets by vWF bound to αIIbβ3 and activation of 
αIIbβ3 by the secondary mediators, ADP and TXA2, and by the product of the 
coagulation cascade, thrombin (Watson et al., 2005). Soluble platelet agonists 
(that are not bound to subendothelium surface) are released from cellular 
damage and produced as a result of coagulation or platelet exocytosis, activate 
platelets via G-protein coupled receptors (GPCR) (Li et al., 2010).  
GPCRs are 7 transmembrane domain containing proteins coupled to G proteins. 
G-proteins consist of α, β, and γ subunits. The extracellular N-terminus of G-
proteins provides a connection to the intracellular C-terminus (Ma et al., 1998). 
The α-subunits bind GDP in inactive state and GTP in their active form. There 
are four categories of the α-subunits – Gq, Gi/Go/Gz, G12/13, and Gs. Gq, Gi/Go/Gz, 
G12/13 are responsible for activation of platelets, whereas Gs plays a role in 
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platelet inhibition. The β- and γ- subunits are regulated by acylation and 
prenylation, respectively, in close association with each other and are 
responsible for G-protein association to the membrane (Offermanns, 2006; Li et 
al., 2010).  
In platelets, there is one Gαs subunit mediating platelet inhibition, four Gαi, 
which inhibit adenylyl cyclases thereby activating platelets, three Gαq subunits, 
which activate PLCβ thereby enabling phosphotidylinositol 4,5 bisphosphate 
(PIP2) to form IP3 (leading to elevation of intracellular Ca
2+) and diacylglycerol 
(DAG) (leading to PKC activation), and Gα12 and Gα12/13 subunits, which 
activate Rho A, and thus regulate actin cytoskeletal reorganisation. The 
inhibition and consolidation of thrombus formation by αs is described in section 
1.4.2.6. 
Gq and G12/13 deficient mice have been reported to be unresponsive to thrombin, 
TXA2 and that Gi stimulation or only the βγ subunits is not efficient in platelet 
stimulation (Simon et al., 1997; Moers et al., 2003). These mice also have 
severely impaired thrombosis and haemostasis, as evidence from these mice 
shows that collagen-induced activation of mouse platelets resulting in platelet 
aggregation and thrombus formation is completely dependent on intact G 
protein-mediated signalling pathways (Moers et al., 2004). These observations 
emphasise the importance of G-protein signalling in comprehensive platelet 
activation under shear rate. 
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GPCR signalling pathways in platelets are represented in Figure 1.5 and details 
of agonist specific responses are given in the following sections. 
 
 
 
Figure 1.5 GPCR signalling pathways in platelet activation. The key events 
that occur downstream of GPCR activation by agonists like thrombin, 
thromboxane and ADP include cytoskeletal reorganisation following Rho 
signalling (ROCK-LIMK mediated regulation of the actomyosin complexes), and 
phospholipase mediated calcium mobilisation via PIP2 and PKC activation. 
From (Brass, 2003; Goggs and Poole, 2012) with modifications. 
  
MLCP 
PLCβ PLCβ 
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1.4.2.3.1 Platelet activation pathways triggered by thrombin 
Thrombin causes activation of Gq, G12/13 via protease activated receptor, 
PAR1/PAR4 activation (Coughlin, 2000). PAR1 and PAR4 differentially regulate 
the actin cytoskeleton and the granule secretion (Flaumenhaft et al., 2005). 
Coupling of PARs to Gq subunits initiates PLC activation, followed by production 
of IP3 and DAG from PIP2 and subsequent release of Ca
2+ from the DTS and 
PKC activation, whereas G12/13 subunits allows interactions with Rho GEFs (Rho 
guanosine exchange factor) such as p115RhoGEF and causes activation of the 
Rho family of small GTPases. Rho GTPases mediate rearrangement of the 
platelet actin cytoskeleton and subsequent generation of filopodia and 
lamellipodia (Brass, 2003; Leger, Covic and Kuliopulos, 2006; Soh et al., 2010).  
 
1.4.2.3.2 Platelet activation pathways triggered by ADP 
ADP binds purinergic receptors like P2Y1 and P2Y12 via Gi and activates the 
PI3K pathway aiding in amplification of platelet activity (Kim, Jin and Kunapuli, 
2003; Damman et al., 2012). The ADP-mediated coupling of P2Y1 to Gq induces 
a transient and reversible aggregation mediated by increase in intracellular Ca2+ 
levels in response to PLCβ and is amplified further by activation of P2Y12. The 
coupling of P2Y1 to Gq additionally induces Rac1 mediated granule secretion 
and formation lamellipodia, and coupling to G12/13 leads to ROCK activation and 
is responsible for platelet shape change (Dorsam and Kunapuli, 2004; Hardy et 
al., 2005). ADP stimulation of platelets also leads to the coupling of P2Y12 to the 
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Gβγ subunits which then associate with Gi, to initiate signalling events involved 
in integrin αIIbβ3 activation (Goggs and Poole, 2012).  
 
1.4.2.3.3 Platelet activation pathways triggered by thromboxane A2, 
serotonin and epinephrine 
 TXA2 coupling with prostaglandin receptor, TXA2 receptor (TP)activates Gq, 
which then initiates PKC activation and stimulation of PLCβ. TP coupling with 
G12/13 causes shape change by activation of ROCK (Goggs et al., 2015). 
Serotonin (5-HT - 5 hydroxytryptamine) couples with Gq leading to platelet 
activation via PLCγ2 activation of PKC (Versteeg et al., 2013). Epinephrine 
couples with Gi and Gz, and blocks PKA by PI3K activation (Goggs and Poole, 
2012).  
 
1.4.2.3.4 GPCR ligand desensitisation 
Interestingly, the ligand binding to receptors mediated by GPCR undergo 
desensitisation after rapid signal transduction. PAR receptors are concentrated 
in OCS pits. Once activated by agonist-mediated cleavage, they become 
internalised and are degraded in the platelet lysosomes or shed in platelet 
derived microparticles, although differences in PAR1 and PAR4 internalisation 
are yet unexplored (Molino et al., 1997; Duvernay et al., 2013). Since platelets 
contain a limited pool of PAR, restricted within the OCS, no other PARs are 
available at the membrane after initial activation, signal transduction, and 
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internalisation (Goggs and Poole, 2012). Therefore, platelets are able to 
respond to thrombin only once. Similarly, P2 receptors undergo desensitisation 
when stimulated by ADP. In case of P2 receptors, they are transiently 
endocytosed and this internalisation is reversible (Hardy et al., 2005). Whether 
the processing of P2 receptors is clathrin-dependent or independent is still 
unclear (Goggs and Poole, 2012).  
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1.4.2.4 Amplification of platelet activation: Granule secretion 
Activation of agonist receptors triggers platelet exocytosis. Once activated, α 
and dense granules release a number of autocrine and paracrine stimulators, 
which activate and recruit platelets to the growing thrombus. Centralisation of 
platelet granules is believed to be required for fusion of granules with each other 
as well as with the OCS and the plasma membrane (Offermanns, 2006). The 
contents of α and dense granules are discussed in section 1.4.1. The key 
characterisation of α granule secretion involves assessment of expression of all 
or a combination of responses of P-selectin, thrombospondin, and epinephrine 
release (Harrison and Cramer, 1993; Furie, Furie and Flaumenhaft, 2001; Blair 
and Flaumenhaft, 2009). Dense granule release is mainly characterised by the 
measurement of the release of ADP and adenosine triphosphate (ATP) 
(McNicol and Israels, 1999; Murugappan et al., 2004). A mutual coordination 
and regulation of platelet secretion exists as ADP-induced TXA2 generation in 
human platelets requires coordinated signalling through integrin activation and 
P2 receptors (Jin et al., 2002). Thus, TXA2 is generated de novo when platelets 
are activated by P2Y12. Phospholipase A2 (PLA2) enables the release of 
arachidonic acid from the plasma membrane, in response to elevated Ca2+ 
levels post-stimulation in a PI3K-dependent manner. Arachidonic acid is then 
converted to TXA2 by serial actions of cyclooxygenases and thromboxane 
synthase. TXA2 augments platelet activation by binding to TP receptor and 
coupling G-proteins at the membrane, therefore initiating a greater platelet 
response by potentiating Ca2+ (Bye, Unsworth and Gibbins, 2016). Influence of 
71 
 
secondary platelet agonists like ADP and TXA2 are analysed by using apyrase, 
which is an ADP degrading enzyme and indomethacin, aspirin that block the 
generation of TXA2 by inhibiting cyclooxygenases. 
Platelet degranulation involves activation of PLC and subsequent cleavage of 
PIP2 into DAG and IP3. DAG directly activates PKC, and IP3 mobilizes 
intracellular Ca2+, which synergistically contributes to release of the platelet 
secretome (Golebiewska and Poole, 2015). This is supported by evidence that 
platelet secretion in Gq- or PLCβ-deficient mice and humans is weakened 
significantly (Gabbeta et al., 1997; Simon et al., 1997; Golebiewska and Poole, 
2015).  
 
1.4.2.5 Integrin αIIbβ3 activation as a central event in platelet activation 
Integrin activation marks a central point in platelet activation signalling 
pathways. Signalling mechanisms that affect the cytoplasmic tail of the αIIbβ3 
initiate ‘inside-out signalling’ response without which platelet fail to adhere or 
aggregate. These interactions at the cytoplasmic tail of αIIbβ3 are responsible for 
changing it from low affinity ‘bent’ conformation to enable ‘open’ conformation 
having a high affinity towards fibrinogen, vWF, thrombospondin-1 and 
fibronectin (Shattil and Newman, 2004). αIIbβ3 binds divalent fibrinogen and 
multivalent vWF facilitating platelet-platelet interaction, forming a thrombus. In 
vivo it is likely that pathways triggered by activation of GP1b-IX-V complex, 
GPVI, by soluble agonists like thrombin, ADP, TXA2, are all activated during the 
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course of platelet responses to vascular injury and act synergistically to 
efficiently activate αIIbβ3 and ensure redundancy for an important signalling 
event (Goggs and Poole, 2012). Key events in the signalling mechanisms 
leading to αIIbβ3 activation include DAG and IP3 formation by PLCβ activation. 
The IP3–related increase in cytosolic Ca
2+ is required for αIIbβ3 activation, but it is 
insufficient for inside-out signalling. DAG-related PKC activation by phorbol 
esters also leads to αIIbβ3 activation (Offermanns, 2006). Mice deficient in Gq, 
G13, and Gi are reported to have aggregation defects (Moers et al., 2003; 
Woulfe et al., 2004a; Offermanns, 2006). 
αIIbβ3 assembles in a complex with actin binding proteins like talins and kindlins 
that support activation of the actin cytoskeleton in response to stimulation 
(Bennett et al., 1999). Additional information about the actin binding proteins is 
described in section 1.5.2.3. The small GTPase Rap1b is an important regulator 
of integrin αIIbβ3 activation (Goggs and Poole, 2012; Goggs et al., 2015). 
Activation of PI3K is another central event in sustained platelet activation, and 
this modulates Rap1b. PI3K is known to act by inhibiting the GTPase-activating 
protein RASA3, which negatively regulates Rap1b activation (Offermanns, 2006; 
Bye, Unsworth and Gibbins, 2016). A role of PI3K in the αIIbβ3 activation is also 
supported by observations in PI3K-deficient mice, which show reduced 
aggregation responses to ADP, as well as by studies using specific inhibitors of 
PI3K, which suggests that this enzyme plays an important role in sustaining 
platelet aggregation in response to low concentrations of platelet activators. 
Consistent with these observations, platelets lacking the downstream effectors 
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of PI3K, Akt1, and/or Akt2 show reduced aggregation (Woulfe et al., 2004a; 
O’Brien et al., 2011). 
Outside-in signalling pathways are triggered by ligand binding to αIIbβ3, and 
therefore induce cytoskeletal rearrangement, platelet aggregate formation, 
granule secretion, procoagulant surface expression, and clot retraction (Goggs 
and Poole, 2012). Integrin clustering is a characteristic of this phase of 
activation (Campbell and Humphries, 2011). Kinase c-Src (cellular-sarcoma) 
and other Src-family kinases (SFK) are bound to the β3-tails and remain in an 
autoinhibited form by phosphorylation of tyrosine residues by kinase, Csk (C-
terminal src kinase), until αIIbβ3 activation. The receptor-like PTP-CD148 
maintains a pool of active SFKs at the plasma membrane, thus contributing 
towards outside-in signalling. αIIbβ3 activation by binding fibrinogen potentiates 
the recruitment of protein phosphatases like PTP-1b to replace Csk. This 
dissociation of Csk, frees c-Src to phosphorylate and activate several 
downstream effector proteins like SHP1 (Src-homology 2 domain containing 
phosphatase-1), Syk, PLCγ2 and PI3K, thus enhancing Ca2+ mobilisation 
(Senis, Mazharian and Mori, 2014). 
 
1.4.2.6 Regulation of platelet activation 
Although thrombus formation at the site of injury is important for haemostasis, 
regulation of the size of thrombus becomes vital to prevent occlusion of blood 
vessel and ensure continuous blood flow. In the absence of inhibitory 
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mechanisms, spontaneous microangiopathies can lead to morbid outcomes 
when thrombi remain unregulated. Under haemostatic conditions, platelet 
activation by vascular ADP is prevented by continuous degradation by CD39, an 
endothelial ectonucleotidase (NTPDase-1), which ensures that platelets 
circulate in their resting state under physiological conditions (Michelson, 2012). 
Adenosine released as a result of cellular damage or degradation of ADP by 
CD39, activates Gs-coupled, A2A receptor to inhibit platelet function 
(Offermanns, 2006). 
As discussed previously, vWF, which is a multimeric protein synthesised by 
endothelial cells plays an essential role in the adhesion of platelets to collagen 
under the high-flow conditions found in arteries. It is secreted in a high 
molecular weight form, that requires cleavage by the metalloprotease, 
ADAMTS13, thus preventing it from binding to platelets spontaneously and 
causing thrombus formation (Brass, 2003). 
Endothelial cell-mediated platelet inhibition is being characterised and the key 
mechanisms that are investigated involve PGI2 and NO, which elevate 
intracellular secondary messengers – cAMP and cGMP, respectively. Both 
cAMP and cGMP pathways involve a number of mechanisms including the 
inhibition of intracellular calcium elevation, cytoskeletal reorganisation, granule 
secretion and integrin activation required for suppressing platelet activation 
(Schwarz, Walter and Eigenthaler, 2001; Smolenski, 2012) 
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PGI2 is generated as result of serial enzymatic actions including conversion of 
prostaglandin H2 by PGI2 synthase. Inhibition of platelets occurs as a result of 
PGI2 receptor IP, activating Gs. This activation of Gs activates adenylyl cyclases 
(AC) which converts ATP to cAMP. cAMP influences activation of PKA and 
inhibits shape change (Aburima et al., 2013). PKA activation phosphorylates 
VASP at serine 157, thereby influencing the actin cytoskeleton (Bearer, Prakash 
and Li, 2002; Raslan and Naseem, 2014). Platelet activators such as ADP and 
thrombin block AC function through inhibitory Gi proteins, resulting in a drop in 
cAMP levels during platelet activation. PKA thus provides an inhibitory function 
during thrombus formation (Brass, 2003). 
NO is a gaseous free-radical, generated as a result of enzymatic reactions 
between NO synthase (NOS) and L-arginine. NO permeates into the platelet 
plasma membrane to stimulate soluble guanylyl cyclases (sGC) which convert 
GTP to cGMP, which acts a secondary messenger. cGMP then activates PKG, 
which in turn phosphorylates a number of activation inhibitory proteins, including 
VASP at serine 239 (Aburima, Riba and Naseem, 2010).  
Recent investigations have revealed a high degree of interconnection between 
activating platelets and cAMP/cGMP-dependent inhibitory signalling pathways 
at multiple levels, including cAMP/cGMP synthesis and breakdown, and 
PKA/PKG-mediated substrate phosphorylation (Smolenski, 2012).  
cAMP and cGMP pathways strongly inhibit the elevation of cytosolic Ca2+ 
concentrations in platelets by suppressing the IP3- receptor on DTS, required to 
76 
 
release intracellular Ca2+, in response to stimulation by thrombin or collagen 
(Bilodeau and Hamm, 2007).  
Additional regulation of PKA and PKG activation is carried out by 
phosphodiesterases (PDE) that hydrolyse cAMP and cGMP. Several isoforms of 
PDEs have been identified in platelets including PDE2, PDE3 and PDE5 
(Schwarz, Walter and Eigenthaler, 2001). PDE2 and PDE5 are stimulated by 
cGMP whereas PDE3 is inhibited by cGMP but stimulated by PKA. PDE3A acts 
on cAMP, PDE2A acts on both but is not abundant, whereas PDE5 
preferentially acts upon cGMP (Smolenski, 2012).  
VASP phosphorylation by PKA and PKG activation inhibits actin polymerisation 
and actin bundling, thus preventing cytoskeletal remodelling post-stimulation 
(Schwarz, Walter and Eigenthaler, 2001). VASP deficient mice showed a 
suppression in cAMP and cGMP-mediated platelet inhibition, fibrinogen binding 
was enhanced, which reiterated the importance of VASP in integrin regulation 
and actin cytoskeletal reorganisation (Aszódi et al., 1999).  
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1.5 The platelet cytoskeleton 
Platelet cytoskeleton is a series of molecular scaffolds that attribute platelets 
their characteristic discoid shape and comprises of microtubules, 
submembranous membrane skeleton and interconnected cytoplasmic actin 
cytoskeletal framework (Figure 1.6). The platelet cytoskeleton also binds and 
activates signalling molecules. In resting platelets, secondary messengers and 
signalling molecules are localised in compartments within the cytoplasm 
connected to the membrane cytoskeleton where they can be recruited to and 
activated in response to platelet stimulation. Complexes of receptors and 
signalling molecules therefore transmit signalling cascades enabling rapid 
cytoskeletal reorganisation. The cytoskeletal reorganisation then facilitates 
dynamic changes in platelets allowing them to aggregate, contract and spread 
at the site of injury (Fox, 2001). 
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Figure 1.6 Microtubule coil and actin cytoskeleton in the resting platelet. A 
single microtubule is coiled 8 to 12 times. The actin cytoskeleton is a three-
dimensional network of approximately 1μm long filaments (Michelson, 2012). 
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1.5.1 Cytoskeleton of the resting platelet 
In resting platelets, situated underneath the plasma membrane is a marginal 
circumferential band of 8-12 filamentous rings of microtubules, as polymers of 
αβ-tubulin dimers (Silver, 1966; Behnke, 1967). This microtubule coil is 
responsible for maintaining the discoid shape under the high shear forces that 
platelets experience when flowing in close proximity to the endothelium during 
circulation (White and Rao, 1998). Limited information is available with respect 
to the mechanisms involved in maintaining the microtubule coil in resting 
platelets or about depolymerisation and repolymerisation of microtubules during 
platelet activation (Patel-Hett et al., 2008). Evidence from cultured fibroblasts 
suggests that microtubules play a role in inducing integrin-based signalling 
events (Danowski, 1989; Kaverina, Rottner and Small, 1998). Transgenic mice 
lacking tubulin1 possess non-discoid platelets with defective marginal bands 
containing only 2 to 3 microtubule coils. β1-tubulin–deficient mice experience 
thrombocytopenia (platelet counts 50% of wild-type) and prolonged bleeding 
times and it has been suggested that microtubules might be responsible for 
spatial interconnections and activation of signalling molecules in platelets (Fox, 
2001; Patel-Hett et al., 2008). 
A spectrin-based membrane skeleton lies underneath the plasma membrane 
which is responsible for binding membrane glycoproteins like GPIb (Fox, 1985). 
Short actin filaments of 14 monomers (37nm length) are found connecting 
spectrin, actin-binding protein (ABP) and the plasma membrane. The 
ultrastructural investigations of membrane skeleton reveal that actin filament 
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ends that bind spectrin, arrive at the plasma membrane originating from 
filaments in the cytoplasm, therefore linking the cytoplasmic actin networks to 
the receptors present in the plasma membrane (Hartwig and Michelson 2012). 
Inspection of  platelets by transmission electron microscopy shows a 
cytoplasmic microfilamentous network in a mesh-like pattern in resting platelets 
(Bearer, 2005). 
The 42 kDa protein actin is present at 0.55mM concentration and accounts for a 
significant part of the platelet protein content constituting approximately 15-20% 
of total platelet proteins (Hartwig et al., 1999). The actin cytoskeleton exists in 
two distinct pools within platelets characterised by the difference in their 
sedimentation properties – the membrane-bound actin skeleton that mediates 
transmembrane signalling and the cytoplasmic actin network that provides the 
contractile component of the platelet (Fox et al., 1988). 
A number of key features of actin sequestration, nucleation, and assembly-
disassembly regulate the platelet cytoskeleton and changes upon stimulation. 
Actin filaments are polarised structures, where the barbed-end is the site of 
polymerisation and the pointed end is the site of depolymerisation. Actin exists 
in a state of dynamic equilibrium as filamentous, F-actin and globular, G-actin by 
a mechanism known as actin turnover, where depolymerised G-actin from the 
pointed-end of the aging actin filament is substituted by another molecule from 
the G-actin pool at the barbed end. Actin turnover is discussed is further detail in 
section 1.5.2 ahead. It is estimated that about 40% of actin in resting platelets is 
in its F-actin form. The actin molecule maintains its tertiary structure by retaining 
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in specific pockets, either ATP or ADP and divalent cations, Mg2+ or Ca2+. The 
nucleotide within the actin pockets defines its status in actin turnover, thus 
determining the rate of actin polymerisation. ATP-bound G-actin has affinity for 
the barbed-end, whereas the ADP-bound G-actin is depolymerised from the 
pointed end. Actin molecule has four functional sites – three sites interact with 
other actin monomers in a filament and one site which interact with actin binding 
proteins, which are responsible for nucleation of new filaments, bundling and 
stabilising filaments as well the depolymerisation and polymerisation of actin 
filaments required in actin turnover (Bugyi & Carlier 2010; Blanchoin et al. 2012; 
Bearer et al. 2002).  
In platelets, F-actin and G-actin are maintained in their respective states with 
the help of several actin associated proteins. Thymosin-β4 sequesters 
monomeric actin, specifically, making it unavailable for polymerisation (Xue and 
Robinson, 2013). Profilin, also a monomer sequestering protein, transfers the G-
actin from thymosin-β4 and acts as an ATP exchange factor for actin 
(Goldschmidt-Clermont et al., 1991). αγ-adducins and Capping protein/CapZ, 
cap the F-actin filaments at the membrane and prevents depolymerisation 
(Hartwig et al., 1999). Arp2/3, which is known as an actin-nucleator; in platelets, 
it also caps F-actin filaments (Falet et al., 2002). Additionally, vasoactive-
stimulated phosphoprotein (VASP) bundles actin filaments preventing the 
severing actions of gelsolin in resting platelets (Smolenski, 2012). Actin 
filaments are stabilised by filamin, tropomyosin and spectrin. Filamin connects 
cytoplasmic actin to the GP1b-IX-V complex at the platelet surface in 
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preparation of activation (Hartwig and Michelson 2012). Together, actin 
associated proteins and actin networks, help platelets maintain their discoid 
shape, prevent shape change by regulating the availability of G-actin and 
barbed-ends on F-actin (Bearer et al. 2002). Multivariate, synchronised 
choreography of myriad actin regulating proteins therefore controls the 
dynamics of all cellular actin. A number of proteins that affect actin dynamics 
are discussed in Chapter 5. 
 
1.5.2 Actin rearrangement in stimulated platelets: A CAP1 perspective 
Platelet actin assembly following the addition of agonists begins as the globular 
actin (G-actin) pool from the cytoplasm polymerises into dynamic filamentous 
actin (F-actin). Aging F-actin strands undergo disassembly by recycling actin 
from the cytoplasm pool controlled by multiple actin associated proteins. This 
process of actin turnover or treadmilling is regulated by ATP hydrolysis 
releasing inorganic phosphate (Pi) to generate G-actin subunits that are bound 
to ADP molecules. ADP-bound actin subunits are recognised by a number of 
proteins involved in accelerating the F-actin disassembly process. The binding 
of cofilin to actin filaments destabilises them, releasing G-actin subunits. Cofilin 
exists in a phosphorylated, inactive form in resting platelets (Mcgrath et al., 
2000). Further, it has been shown that cofilin becomes active upon 
dephosphorylation in stimulated platelets and can remain dephosphorylated for 
extended periods of time if integrins become ligated to it (Aslan et al., 2013). 
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Evidence from nucleated cells has shown that cofilin, which is inactive at neutral 
or acidic pH, is rescued by adenylyl cyclase-associated protein 1 (CAP1) which 
accelerates its ability of severing actin (Normoyle and Brieher, 2012). CAP1 is 
discussed in further detail in section 1.6. CAP1 is a key protein that affects the 
turnover of actin in spreading or motile cells in cooperation with cofilin and 
profilin and promotes the nucleotide exchange on the actin subunits 
(Goldschmidt-Clermont and Janmey, 1991; Zhou, Zhang and Field, 2014). As 
seen in figure 1.7, cofilin in conjunction with CAP1 severs F-actin from the 
pointed end to release ADP-bound G-actin complex. Upon severing the actin 
filament, cofilin dissociates from the complex followed by nucleotide exchange 
promoted by formation of a complex between CAP1 and profilin to efficiently 
recycle actin into ATP-bound G-actin which is then free to polymerise at the 
barbed end of the growing actin filament (Balcer et al., 2003). The N-terminus of 
CAP1 in yeast and mouse, forms hexamers that accelerate binding and 
recycling of cofilin during actin disassembly (Chaudhry et al., 2013; Jansen et 
al., 2014). Further, profilin-dependent nucleotide exchange is enhanced by the 
C-terminus of CAP1 thus aiding in elongating the actin filament (Balcer et al., 
2003). 
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Figure 1.7: CAP1-mediated actin turnover. During actin polymerisation, G-
actin subunits are added at the barbed end (1). CAP1 accelerates cofilin-
dependent severing of the actin filament at the pointed end, releasing ADP-G-
actin (2-3). CAP1 also enhances profilin-mediated nucleotide exchange on the 
actin subunit, which is then released as ATP-bound G-actin (4). ATP-actin is 
then free to bind to the leading edge (barbed end) of the actin filament (1). 
Taken from (Moriyama and Yahara, 2002).  
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1.5.3 Cytoskeleton of the activated platelet: Formation of actin structures 
In their primary role, platelets attach, change shape, spread, release their 
secretome and retract over the damaged vascular area to create a haemostatic 
plug. Reproducible temporal changes in the platelet cytoskeleton have been 
recorded mediating the formation of the haemostatic plug and are dominated by 
the cytoplasmic dynamics of actin polymers, their availability and assembly-
disassembly (Bearer, 2005).  
All platelet agonists initiate change in platelet shape from discoid into a rounded 
sphere owing to depolymerisation of cytoplasmic actin networks, consequently 
generating increased levels of ATP-bound G-actin and simultaneously creating 
multiple barbed ends that are available for nucleation of new actin filaments. 
Filopodia or finger-like projections begin emanating from the cell periphery and 
lamellipodial extensions are formed as the F-actin doubles compared to the 
content in the resting platelet. Actin nodules are formed that are thought to drive 
the actin filament assembly in the lamellipodia and bundling of filaments to form 
stress fibres, which then define the shape of a completely spread platelet 
(Calaminus et al., 2008). 
The platelet flattens as granules fuse with the OCS and they are squeezed with 
other organelles towards the centre of the platelet. It must be noted that 
secretion of granules is not dependent on the actin cytoskeleton, but their 
transport towards the centre is a function of actin depolymerisation 
(Flaumenhaft et al., 2005; Blair and Flaumenhaft, 2009; Fitch-Tewfik and 
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Flaumenhaft, 2013). Microtubule fragmentation and reassembly is thought to 
occur at this stage but evidence for it is still preliminary (Patel-Hett et al., 2008).  
A dynamic phase of membrane motility then proceeds with digestion of spectrin-
based membrane skeleton leading to formation of membrane ruffles which 
cause platelets to retract inwards. This is thought to be mediated by forces 
generated from actin-myosin interplay (Bearer, et al. 2002; Hartwig and 
Michelson 2012). Doubling of F-actin is achieved as cortical networks are 
derived from new actin filament polymerisation as blunt filopodia extend from 
the cell and are rotated around the periphery. 
 
 
Figure 1.8 Actin structures found developing in a spreading platelet. Upon 
activation of platelets with agonists, filopodia or finger-like projections begin 
emanating from the cell periphery and lamellipodial extensions are formed as 
the F-actin doubles compared to the content in the resting platelet. Actin 
nodules, adhesive actin structures, are formed that are thought to drive the actin 
filament assembly in the lamellipodia and bundling of filaments to form stress 
fibres, which then define the shape of a completely spread platelet. 
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1.5.2.1 Filopodia formation in platelets 
Filopodia are used by cells for accurately gauging extracellular matrix cues and 
for the identification of adhesion receptor proteins that bind to them. Filopodia 
are formed in activated platelets in response to signalling leading to actin 
polymerisation (Figure 1.8). Spatially restricted and temporally controlled actin 
filament nucleation is critical for generating membrane protrusions (Bearer, 
Prakash and Li, 2002; Yang et al., 2007). These actin filament-rich structures 
are formed, where barbed-end of filaments is observed at the protruding end of 
the filopodia. This actin polymerisation event is thought to occur via 
RhoGTPase, Cdc42, that regulates the formation of filpodia by interacting with 
WASP and Arp2/3 (Nobes and Hall, 1995; Li, Kim and Bearer, 2002). Further, 
the formation of parallel actin filaments in filpodia are bundled by proteins like 
formins that give filopodia their characteristic shape (Yang et al., 2007). 
 
1.5.2.2 Lamellipodia formation in platelets 
Lamellipodia are extensions of the cytoplasmic front and present as thin-sheet 
like actin-rich structures (Figure 1.8). Lamellipodia are thought to be formed to 
bridge gaps generated by filopodia. Activated platelets undergo membrane 
ruffling which acts as a precursor to formation of lamellipodia. The formation of 
lamellipodia is governed by small Rho GTPase, Rac1. Rac1 regulates the 
downstream signalling mechanisms via WAVE/Arp2/3 and PAK/Cofilin mediated 
actin polymerisation. Rac1 activated WAVE and Arp2/3 are responsible for actin 
nucleation and branching of existing actin filaments, whereas, PAK/Cofilin are 
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responsible for depolymerisation of F-actin fragments, thus ensuring availability 
of actin for the expanding actin network in the lamellipodia (Aslan and Mccarty, 
2013). 
 
1.5.2.3 Actin nodules in platelets 
Actin nodules are F-actin rich structures which were first identified and 
described in 2008 by Calaminus et al. Actin nodules are described as transient 
actin structures that disappear on the formation of stress fibres in a spreading 
platelet. Since then, actin nodules have been further characterised as 
podosome-like adhesive actin structures in a spreading platelet (Figure 1.8). 
The formation of actin nodules is driven by WASp mediated action of Arp2/3. 
Actin nodules were found to be enriched in Arp2/3 and other Tyr-phosphorylated 
proteins. Further, actin nodules were characterised as adhesive structures 
based on co-localisation of proteins around the site of the actin nodules –
adhesion-related proteins talin and vinculin in addition to integrins formed a ring-
like structure around the actin nodule (Poulter et al., 2015).  
 
1.5.2.4 Stress fibres in platelets 
In platelets, stress fibres are a characteristic of completely spread platelet 
(Figure 1.8). In non-muscle cells, stress fibres are used as contractile structures. 
Stress fibres provide contractility by the action of the actomyosin complex and 
are regulated by Rho GTPase, Rho A. Rho A mediates actin polymerisation by 
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regulating its kinases like ROCK, LIMK and their downstream effectors like 
myosin II and cofilin, respectively (Ridley and Hall, 1992; Aburima et al., 2013). 
Actin bundles of 20-30 parallel actin filaments are cross-linked by actin-binding 
proteins and provide structural stability to the spread platelet. Stress fibres act 
as the focal adhesions anchoring the platelet at the site of activation (Aslan and 
Mccarty, 2013; Goggs et al., 2015).  
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1.5.3 Brief overview of signalling related to actin cytoskeletal 
reorganisation 
The changes in the cytoskeleton described are complemented by cognate 
biochemical signalling pathway activation. Phosphoinositides serve to initiate 
actin filaments assembly directly and perform the critical function of targeting 
this assembly to the membrane-cytoskeleton interface. This is especially 
important as all filament assembly begins underneath the plasma membrane 
(Janmey 1995; Hartwig and Michelson 2012). 
Barbed-end capping proteins are inactive when bound to membrane 
phospholipids. Receptor ligation upon activation induces transient elevation in 
cytosolic Ca2+ levels, where platelets lose their discoid shape and become 
rounded. The increase in cytosolic Ca2+ is mediated by activation of PLC. PLC 
hydrolyses membrane bound phospholipid, PIP2 from its precursor 
phosphatidylinositol 4 phosphate (PIP) at the surface of plasma membrane and 
is regulated by profilin (Goldschmidt-Clermont et al., 1991). Profilin is thought to 
inhibit PLC and dissociate from the membrane upon hydrolysis giving rise to 
profilin-actin complexes that are able to polymerise on to barbed end of actin 
filaments.  
A major role in cytoskeletal regulation is played by phosphoinositide signalling 
which subsequently leads to elevation of Ca2+ levels is necessary for efficient 
interaction of actin binding proteins with actin monomers and filaments. A 
number of actin regulating proteins like gelsolin, require readily available Ca2+ 
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for severing actin and freeing it for polymerisation at alternative sites (Janmey 
and Matsudaira, 1988). 
Inhibition of phosphoinositides has been shown to impair production of barbed-
ends thereby decreasing the rate of actin assembly. In contrast, overproduction 
of phosphoinositides in neutrophils has revealed increased actin assembly due 
to increased barbed end exposure in addition to increase in membrane ruffling 
(Bezanilla et al., 2015). PI3K is stimulated directly or indirectly by 
phospholipases downstream of G-protein activation by cognate agonists like 
ADP, thrombin, epinephrine, TXA2. PI3K phosphorylates the D3-position of 
inositol lipids. Upon receptor ligation, dramatic increase in the D3-containing 
phosphoinositides has been shown to promote filpodia formation as a result of 
actin polymerisation (Guinebault et al., 1995; Hartwig et al., 1996). Actin 
polymerisation occurs at the newly created barbed-ends by activation of Arp2/3 
complex aided by actin sequestering proteins like profilin and thymosin β4. 
Polymerisation of actin filaments to form filopodia and lamellipodia therefore 
provides the protrusive force required in a spreading platelet. 
A brief overview of platelet agonists and pathways they trigger that lead to 
cytoskeletal reorganisation is found in Figure 1.9. 
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Figure 1.9 Biochemical signals affecting cytoskeletal reorganisation in 
platelets. A number of platelet agonists bind to receptors (α2A, P2Y12, GP-1b-
IX-V, αIIbβ3, CLEC-2, GPVI, P2Y1, TP, PAR1/4) and activate platelets leading to 
activation of phospholipase C (PLC) and activation of phosphatidylinositol 3 
kinase (PI3K) thereby elevating intracellular calcium levels, PKC activation and 
secondary agonist release, together contributing to cytoskeletal reorganisation 
in platelets (Bye, Unsworth and Gibbins, 2016). 
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In unstimulated platelets, actin and actin associated proteins such as talin, 
kindlin and α-actinin restrict αIIbβ3 by binding its cytoplasmic tail intracellularly, 
thereby preventing its association with fibrinogen. Talin-1 is an abundant 
cytoplasmic protein able to interact with other cytoskeletal proteins including 
actin and vinculin, thereby connecting the integrins with the actin cytoskeleton. 
These binding sites involved in actin-binding proteins and those for integrin β 
tails are buried in an auto-inhibited conformation and are only exposed during 
platelet activation. Talin-1 contains a FERM (band 4.1, ezrin, radixin, moesin) 
domain, approximately 150 amino acids long, that is involved in localising it to 
the plasma membrane (Goggs and Poole, 2012). When platelet agonists initiate 
actin turnover in the membrane skeleton by activation of actin-severing proteins 
like gelsolin and cofilin, they relieve the constraints on αIIbβ3 allowing it assume 
a high affinity conformation required for binding fibrinogen and subsequent 
platelet aggregation (Bennett et al., 1999). 
Receptor binding to extracellular matrix ligands initiates inside-out signalling, 
where integrins associate with the actin cytoskeleton through several molecular 
linkages and undergo conformational changes to become “active” (Shattil and 
Newman, 2004). Followed by a reorganisation in the actin cytoskeleton, outside-
in signalling occurs in a discrete pattern whereby ligand binding initiates integrin 
clustering and assembly of a nascent signalling complex proximal to the 
cytoplasmic tails of αIIbβ3, followed by the growth of a larger actin-based 
signalling complex (Shattil et al., 1996). F-actin is polymerised at adhesion sites 
or the integrin clusters, where actin binding proteins like profilin and VASP are 
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recruited. Additionally, recruitment of WASP and Arp2/3 at these sites lead to 
further actin polymerisation and reorganisation (Calderwood, Shattil and 
Ginsberg, 2000). Increase in Ca2+ towards the later stages, activates calpain, 
which is calcium-dependent protease, which cleaves the β3 cytoplasmic domain 
and initiates clot retraction (Moscardó et al., 2013). 
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1.6 Adenylyl cyclase-associated protein 1 (CAP1) 
Adenylyl cyclase associated protein 1 (CAP1) is an actin-monomer binding 
protein that plays a role in dynamic actin reorganisation, briefly introduced in 
section 1.5.2 (Ono, 2013; Xue and Robinson, 2013; S. Lee et al., 2014). It was 
first described in yeast, as suppressor of hyperactive RAS2(V19) (Srv2) (Field et 
al., 1988), a RAS and adenylyl cyclase pathway effector protein (Field et al., 
1990). Porcine CAP1 was found to have identical sequence to protein, ASP-56 
which was previously isolated from porcine platelets, , and described as an 
actin-monomer binding protein (Gieselmann and Karlheinz, 1992). The 
multifunctional role of CAP1 in the regulation of yeast cytoskeleton was 
identified much later (Freeman et al., 1996). A number of cytoskeleton 
regulatory functions for CAP1 have been described in mammalian cells (Ono, 
2013), without any role in adenylyl cyclase regulation and details can be found 
in sections, 1.6.1.1 and 1.6.2. 
 
1.6.1 CAP1 structure 
CAP1 is a 56 kDa protein containing 450-550 amino acids found in various 
mammalian cell-types, and it is 70 kDa (Srv2/CAP) in Saccharomyces 
cerevisiae (Field et al., 1990; Ono, 2013). Vertebrates have two isoforms of 
CAP – CAP1 and CAP2, which share 64% sequence homology and yet, have 
distinct, non-redundant functions (Peche et al., 2007, 2013). The expression 
profiles of the two CAP proteins also vary significantly, where CAP1 is widely 
expressed in a number of tissues, except skeletal muscle, and CAP2 is 
96 
 
expressed predominantly in brain, heart, skeletal muscle and testis (Bertling et 
al., 2004; Peche et al., 2007). While CAP1 and CAP2 both bind G-actin, CAP2 
was additionally found to regulate sarcomere assembly in heart and skeletal 
striated muscles (Yu, Swiston and Young, 1994; Bertling et al., 2004; Peche et 
al., 2007). In a CAP2 KO mouse model, CAP2 deficiency caused dilated cardiac 
myopathies (Peche et al., 2013) and impeded wound healing in human skin 
(Kosmas et al., 2015). CAP1, on the other hand determined cell polarity, motility 
and receptor mediated endocytosis along with mitochondrial shuttling of actin 
during apoptosis (Noegel et al., 2004; Sultana et al., 2005; Wang et al., 2008). 
There are no biochemical studies comparing CAP1 and CAP2, and differences, 
if any, are not documented (Peche et al., 2013). Although CAPs have distinct 
functions, they have similar domain structures as seen in figure 1.10.  
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Figure 1.10 Domain structure of CAP: The N-terminus contains a coiled coil 
domain, responsible for binding to adenylyl cyclase, followed by a helical fold 
domain (HFD) (crystal structure shown above the domain), which binds to 
cofilin. A WH2 domain responsible for nucleotide exchange during actin turnover 
is flanked by two proline-rich (P1, P2) domains, which bind other actin binding 
proteins like profilin, Abl and ABP-1. The C-terminal CARP domain binds ADP-
G-actin, followed by a dimerisation motif comprising of β-strands (dimerised 
crystal structure shown above it). [Figure adapted from (Ono, 2013)] 
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The N-terminus of CAP is comprised of a coiled-coil domain, which is 
responsible for binding adenylyl cyclase and stimulating cAMP activity and self-
oligomerisation of Srv2/CAP (Quintero-Monzon et al., 2009). The formation of 
coiled-coil domain is yet to be described in a crystal structure (Ono, 2013). The 
remainder of N-terminal CAP comprises of a helical fold domain (HFD) 
containing a stable bundle of six anti-parallel helices, which associate laterally 
with helices from another CAP molecule forming dimers (Yusof et al., 2005). 
The HFD is responsible for binding actin-depolymerising factor (ADF)/cofilin 
(Moriyama and Yahara, 2002) and the interaction between cofilin and CAP1 
enhances the severing of F-actin (Chaudhry et al., 2013). 
The central region of CAP1 contains two proline-rich domains – P1 and P2, 
where P1 is conserved across all eukaryotes and P2 is more variable ( Freeman 
et al., 1996; Yu et al., 1999). The P1 domain of CAP1 binds Src-homology 
domain (SH3) of tyrosine-kinase Abl (Freeman et al., 1996), and profilin 
(Makkonen et al., 2013). Actin-binding protein (ABP-1) binds to the P2 domain 
of Srv2/CAP ( Freeman et al., 1996). The Wiskott-Aldrich Syndrome protein 
homology domain 2 (WH2) is also located centrally and is responsible for CAP 
interaction with G-actin playing a key role in nucleotide exchange/ recharging of 
actin monomers during actin turnover (Chaudhry et al., 2010).  
The C-terminus of CAP comprises of β-strands which are arranged into six coils 
of right-handed β-helices, which enable dimerization of CAP molecule (Dodatko 
et al., 2004). The C-terminus also contains a sequence motif called the CARP 
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domain (Ono, 2013), that binds to G-actin, independent of the WH2 domain 
(Chaudhry et al., 2010; Nomura and Ono, 2013). 
CAPs have been identified in most representative eukaryotic species, where, 
during evolution, the domain structure of CAP has been conserved to a great 
extent among species - fungi, protists and invertebrates have one CAP gene, 
whereas multiple isoforms of CAP are found in vertebrates, nematodes and 
plants (Ono, 2013). The function of CAP as regulators of the cytoskeleton is 
also conserved among most eukaryotic species, with only a few species have it 
is as a component of the Ras-cAMP signalling pathway (Gerst et al., 1991; 
Hubberstey and Mottillo, 2002; Ono, 2013). 
Oligomerisation of CAP1 is an essential mechanism by which CAP1 carries out 
the modulation of actin turnover (Section 1.5.2, Figure 1.7). A high molecular 
mass complex of 600 kDa containing six molecules each of CAP1 and actin 
(CAP1-actin complex) is a conserved feature in multiple organisms (Balcer et 
al., 2003; Quintero-Monzon et al., 2009). Self-association of CAP1 is mediated 
by the N-terminal coiled-coil domain (Yu et al., 1999; Quintero-Monzon et al., 
2009), by the HFD (Yusof et al., 2005), and the C-terminal dimerisation motif 
(Dodatko et al., 2004; Iwase and Ono, 2016). Chaudhry et al. (2013) have 
elucidated that, in vitro, the C-terminal dimerises and helps organise the HFD 
oligomerisation to form a cluster of hexameric, symmetrical protrusions 
(shurikens-like structure) and enhances the CAP1-actin association. The 
observation that multimer formation enhances its function of regulating actin 
was reiterated by Iwase & Ono (2016) in relation to the C-terminal dimerisation 
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in relation to CAP isoform of C. elegans. They show that the evolutionarily 
conserved dimerisation motif of CAP is essential for its C-terminal region to 
exert the actin monomer-specific regulatory function. In summary, N-terminal 
CAP1 can bind N and C-terminal of a second CAP1 molecule for 
oligomerisation, while the C-terminal dimerisation motif is key for forming a 
complex with actin and thus hexamer formation via the HFD domain 
(Hubberstey et al., 1996; Zelicof et al., 1996; Chaudhry et al., 2013; Iwase and 
Ono, 2016). Observations in Dictyostelium suggests that several configurations 
of CAP dimer are possible but the actual arrangement of the molecules in vivo is 
currently unknown (Ono, 2013).  
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1.6.2 CAP1 function 
Although a number of CAP1 effector functions related to actin regulation and 
adenylyl cyclase association are known, the regulation of CAP1 itself and the 
underlying signalling mechanisms and pathways remain poorly investigated. 
The phosphorylation of mouse CAP1 reported by Zhou et al. (2014) suggests a 
kinase signalling pathway that regulates CAP1 localisation and function, where 
phosphorylation lead to inactivation of CAP1. Further, phospho-CAP1 was 
found diffused throughout the cytosol and CAP1 was found at the periphery. 
Additionally, CAP1 as an intracellular substrate of matrix metalloproteinase-9 
(MMP-9), suggests that levels of cellular CAP1 may be regulated by proteolysis 
(Cauwe et al., 2008; Ono, 2013; Xie et al., 2014). 
 
1.6.2.1 Adenylyl cyclase activity 
The original discovery in Saccharomyces cerevisiae assigned the role of 
adenylyl cyclase regulation to CAP (Field et al., 1990). In Saccharomyces 
cerevisiae, Ras and cyclic AMP (cAMP) signalling coordinates cell growth and 
proliferation with nutritional sensing (Suzuki et al., 1993; Wang et al., 1993). 
Similar role for CAP linking cell-growth and cAMP activity were also observed in 
Candida albicans and Magnaporthe oryzae (Bahn and Sundstrom, 2001; Zhou 
et al., 2012). The generation of cAMP is catalysed by conversion of ATP by 
adenylyl cyclase, and one of the stimulation mechanisms involves binding of 
GTP-bound Ras and Srv2/CAP proteins (Gerst et al., 1991; Freeman et al., 
1996). Elevation of cAMP levels leads to dissociation of the PKA regulator 
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proteins to yield active A kinases which affect processes such as cell cycle 
progression and cell migration in yeast, although direct cross-talk between 
adenylyl cyclase association and actin regulation are only conjectured in 
Dictyostelium (Noegel et al., 1999, 2004; Sultana et al., 2012). Further 
downstream effects of CAP-adenylyl cyclase interaction include reactive oxygen 
species (ROS) production as a stress response effect of cAMP elevation leading 
to apoptosis (Gourlay and Ayscough, 2006). 
Later, CAP1, as a mediator of similar adenylyl cyclase activity, was noted as a 
function linked to cell polarity determination and starvation-related aggregation 
in Dictyostelium cells, but there was no evidence of direct binding between CAP 
and adenylyl cyclases (Noegel et al., 2004; Sultana et al., 2012).  
 
1.6.2.2 Role of CAP1 in actin regulation 
The significance of CAP1 in binding actin monomers can be established by the 
number of domains present on CAP1 molecule that bind G-actin - the WH2-
domain, the CARP domain and HFD which binds to cofilin-G-actin complex 
(Chaudhry et al., 2010; Makkonen et al., 2013; Jansen et al., 2014; Iwase and 
Ono, 2016).  
CAP1 binds to G-actin in 1:1 ratio to inhibit spontaneous polymerisation in vitro 
and to F-actin at sub-stoichiometric ratios (Hubberstey and Mottillo, 2002). 
CAP1-actin binding does not affect filament formation but rather accelerates 
cofilin-mediated F-actin depolymerisation (Zhang et al., 2013). The mechanistic 
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role of CAP1 in actin turnover is mainly described in reference to its association 
to cofilin (Moriyama and Yahara, 2002). CAP1 acts as the fourth component of 
F-actin severing machinery which includes, AIP1, coronin and cofilin. AIP1 
prevents severed G-actin from reannealing to F-actin, coronin increases cofilin 
loading on F-actin and improves cofilin-mediated severing, while CAP1 is 
speculated to destabilise F-actin making it more susceptible to severing in 
addition to exchanging nucleotide and releasing cofilin thus acting as a cofilin 
recycling factor (Blanchoin et al., 2012; Normoyle and Brieher, 2012; Zhang et 
al., 2013). Additionally, at neutral and acidic pH where cofilin is rendered 
inactive, CAP1 rescues cofilin and increases severing frequency of cofilin by 
seven-folds (Normoyle and Brieher, 2012). Studies in CAP1 knockdown cell-
lines have revealed that CAP1 affects the phosphorylation state of cofilin, but 
the precise mechanism is yet unconfirmed (Zhang et al., 2013). 
Nucleotide exchange is the key to recycling actin monomers during actin 
turnover, where ADP-G-actin is severed from the pointed-end and ATP-G-actin 
then polymerises onto the barbed or elongating-end of F-actin. CAP1 catalyses 
nucleotide exchange in an evolutionarily conserved manner (Makkonen et al., 
2013). Traditionally, profilin, which can overcome the inhibitory effects of cofilin 
(Xue and Robinson, 2013), was thought to catalyse this reaction (Goldschmidt-
Clermont et al., 1991), but it was later demonstrated that profilin only weakly 
promotes nucleotide exchange on its physiological substrate, the cofilin-bound 
ADP-G-actin (Balcer et al., 2003). Instead now, CAP1 having similar affinities to 
ADP-G-actin and ATP-G-actin, has been shown to promote the nucleotide 
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exchange via its WH2 domain (Chaudhry et al., 2010; Nomura and Ono, 2013). 
The functional relation between CAP1 and profilin in mammalian cells is 
unclear, although CAP1 has binding site for profilin (Ono, 2013). It has been 
speculated that profilin and CAP1 catalyse nucleotide exchange independently 
and that CAP1-profilin interaction potentially enhances filament elongation, 
where profilin-actin monomer complex can dissociate from CAP1 and be used 
for formin- or Ena/VASP-catalysed filament polymerisation (Bugyi and Carlier, 
2010; Makkonen et al., 2013; Blanchoin et al., 2014). 
All scenarios described above provide evidence of a central role for CAP1 in 
modulating actin cytoskeleton. CAP1 knockdown in cell-lines have shown that 
cells show alterations in cell motility due to increase in lamellipodia and stress 
fibres (Zhou, Zhang and Field, 2014). CAP1 knockdown in HeLa cells presented 
a role for CAP1 in cell adhesion. In the CAP1 knockdown cells, focal adhesion 
kinase (FAK), an important regulator of cell adhesion, is activated by 
phosphorylation of its Tyr397 residue thus promoting its association with Src 
and affecting cell motility. Additionally, FAK and talin, which is a key component 
of focal adhesions that provides link between integrin activation and actin 
cytoskeleton, were identified in co-IP of cells overexpressing CAP1, which 
emphasises the role of CAP1 in cell adhesion and motility (Zhang et al., 2013). 
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1.6.2.2.1 In vivo effects of CAP1-mediated actin regulation 
Several CAP1 binding partners have been identified that suggest involvement of 
CAP1 in plethora of physiological functions – CAP1 in chemotaxis, cell motility, 
cytokinesis and membrane trafficking in Dictyostelium (Noegel et al., 1999, 
2004; Sultana et al., 2005), endocytosis and neuronal development in 
Drosophila (Stevenson et al., 2000; Hubberstey and Mottillo, 2002) and 
neuronal growth cone formation in rats (Lu et al., 2011), Arp2/3-mediated actin 
regulation in plant development in Arabidopsis (Deeks et al., 2007), and 
extracellular function as it is implicated as an autoantigen in rheumatoid arthritis 
(Kinloch et al., 2005; Ono, 2013), along with a role in tumourigenesis.  
In yeast and Dictyostelium, CAP1 localises to the cortical regions (Yu, Swiston 
and Young, 1994; Noegel et al., 1999). In mammalian cells, it was found in 
dynamic actin structures like membrane ruffles, lamellipodia (Moriyama and 
Yahara, 2002; Bertling et al., 2004) and also in stress fibres in fibroblasts 
(Freeman and Field, 2000) (Figure 1.11). CAP1 promotes actin filament 
dynamics, thus playing a key role in cell migration, adhesion and cytokinesis. 
Overexpression of CAP1 is evident in several cancer phenotypes like pancreatic 
cancer (Yamazaki et al., 2009), breast cancer ( Liu X et al., 2014), 
hepatocellular carcinoma ( Liu Y et al., 2014), ovarian cancer (Hua et al., 2015), 
lung cancer (Tan et al., 2013) by affecting the invasiveness of the cancer cells 
contributing towards tumourigenesis (Ono, 2013; Zhou, Zhang and Field, 2014).  
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Figure 1.11 CAP1 localisation in mammalian cells. F-actin is observed by 
phalloidin staining, CAP1 localisation is identified using isoform specific antibody 
and AC-15 antibody is used to stain monomeric actin. CAP1 is diffused in the 
cytoplasm and localises at the leading edge of the cortical region in both cell 
types – NIH3T3 fibroblast cells and B16F1 melanoma cell lines. CAP1 is also 
seen to be abundant in the regions with higher proportions of monomeric actin. 
Scale bar = 10µm [Image from Bertling et al.(2004)]. 
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Recent evidence has suggested a pro-apoptotic role for CAP1 in mammalian 
cells (Wang et al., 2008). In the paper, they show that CAP1 translocates to 
mitochondria in response to endogenous apoptosis inducers independent of its 
role in actin depolymerisation, but instead acts in a shuttling mechanism with 
cofilin transporting actin to mitochondria (Wang et al., 2008). Further, an 
interesting observation was that the translocation of CAP1 appeared as distinct 
structures, similar to CAP1-mediated actin-aggregate translocation to 
mitochondria seen during apoptosis in yeast (Gourlay and Ayscough, 2006). 
Characteristic apoptosis markers like release of cytochrome c and ROS 
accumulation were found to be reduced in CAP1 knockdown mammalian cells, 
where the deficiency of CAP1 protected cells from apoptosis (Wang et al., 
2008).  Interestingly, yeast CAP, links actin cytoskeleton and Ras-cAMP 
pathway. Actin stabilisation (actin-aggregates) signal to activate Ras, which 
subsequently leads to ROS production, suggesting that the function of CAP in 
apoptosis is conserved but are governed by distinct mechanisms in yeast and 
mammalian cells respectively (Gourlay and Ayscough, 2006; Wang et al., 2008). 
These observations that propose that CAP1 is pro-apoptotic further corroborate 
the role of elevated CAP1 in cancer progression and invasion. 
A recent investigation revealed CAP1 as a receptor for adipokine, resistin, 
where it activates adenylyl cyclase pathway, triggering NF-ƙB pathway mediated 
cytokine expression in monocytes (Lee et al., 2014). This study provides 
preliminary evidence for a potentially novel mechanism for CAP1 in mediating 
adenylyl cyclase activity in mammalian cells independent or partially dependent 
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on its known role in regulation of actin dynamics (Ono, 2013; Blanchoin et al., 
2014; Al Hannan and Culligan, 2015). A number of questions remain 
unanswered following this study in respect to the circumstances of CAP1-
resistin interaction and its relation to the actin cytoskeletal dynamics in 
mammalian cells, thus making it difficult to establish their mode of action in 
disease states like metabolic syndrome, and regulation of haemostasis and 
glucose homeostasis.  
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AIMS AND OBJECTIVES 
 
Obese, diabetic patients (300 million adults worldwide in 2012) suffering from 
MetS have increased levels of resistin in their circulation. Elevated levels of 
resistin have since been established as a contributor to IR and correlated to the 
progression of CVD. Platelets play a key role in CVD and yet little is known 
about the effects of elevated resistin levels on their physiological function and if 
this affects the severity of CVD in patients suffering from MetS. We therefore 
address this by characterising the effects of increased resistin in platelet 
function. Additionally, the mechanism of action of resistin in its target cells is 
unclear including identification of a receptor mediating resistin signalling, which 
is still under considerable debate. Recently, Lee et al (2014) reported CAP1 to 
be a ‘bonafide’ receptor for resistin. They suggested that CAP1 performed its 
role as a resistin-receptor by triggering its adenylyl cyclase function, a role 
which is not commonly reported in mammalian cells. Since CAP1 is 
predominantly known as a cytoskeletal protein, a preliminary investigation into 
the localisation of it and other cytoskeletal components within platelets was 
carried out which would aid in further delineating the role of platelet cytoskeletal 
proteins. 
The key focus of this thesis is investigating how resistin affects human platelets, 
a cell model presenting dynamic cytoskeletal changes when stimulated with 
agonists, and establish and characterise CAP1 in platelets.  
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Objectives achieved in this thesis are outlined here: 
1. Understanding the effect of resistin on platelet activation by assessing 
platelet functional assays including aggregation, secretion and spreading. 
 
2. Characterising the cytoskeletal protein, CAP1, by investigating its 
localisation within platelets and its translocation during stimulation of 
platelet regulatory pathways – activation by thrombin and collagen and 
inhibition by prostacyclin. 
 
3. Establishing the significance of cytoskeletal proteins in platelets using 
proteomics based data mining and establishing the localisation of 
selected cytoskeletal proteins in platelets by investigating their 
distribution pattern in spread platelets and in the platelet subcellular 
fractions of resting platelets. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Preparation of human blood platelets 
2.1.1 Isolation of human blood platelets 
Human blood was taken from drug-free volunteers by clean venepuncture using 
acid citrate dextrose (ACD) (29.9 mM of sodium citrate, 113.8 mM of glucose, 
72.6 mM of sodium chloride, and 2.9 mM of citric acid (pH 6.4) as anticoagulant. 
Platelet-rich plasma was obtained by centrifugation of whole blood at 200xg at 
20°C for 20 minutes. Platelet-rich plasma was treated with prostacyclin (50 nM) 
or citric acid (6mM) and was centrifuged at 800xg for 12 minutes. Platelets were 
washed in modified Tyrode’s buffer (150 mM NaCl, 5 mM HEPES, 0.55 mM 
NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, and 5.6 mM D-glucose) 
containing 50nM prostacyclin, when isolated using prostacyclin or washed using 
wash buffer (0.036 mM citric acid, 0.01 mM EDTA, 0.005 mM D-glucose, 0.05 
mM KCl, 0.09 mM NaCl) and centrifuged at 800xg for 12 minutes. Sedimented 
platelets were finally resuspended at required concentration in modified 
Tyrode’s buffer and incubated at 37°C for 45 minutes prior to use for 
experiments (Aburima et al., 2013). 
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2.1.2 Determination of platelet count 
Washed platelets (5 µL) were suspended in 10 mL of IsotonII Diluent (Coulter) 
and platelet count per millilitre was determined using Beckman Coulter Z1 D 
counter. 
 
2.2 Turbidimetric analysis of platelet aggregation 
Washed platelet count was adjusted to 2.5 x108 platelets/mL and platelet 
suspension was used in aggregometer cuvettes for measurement using 
aggregometer (Aggrolink, Chrono-log/490-D) and output was recorded using 
AggroLink software. The turbidimetric assay is based on the principal of light 
transmission through platelet suspension which is detected by a photocell. 
Suspended platelets scatter light and inhibit it from reaching the photocell. 
When an agonist is introduced in the suspension, platelets start aggregating 
causing more light to pass through to the photocell and this transmission of light 
is directly proportional to the degree of platelet aggregation. The aggregometer 
was calibrated, where washed platelet suspension indicated 0% aggregation 
and Tyrode’s buffer indicated 100% aggregation (Born and Cross, 1963). All 
agonists were diluted to required concentration in modified Tyrode’s buffer. 
 
2.3 Measurement of platelet dense granule secretion 
Platelet dense granule secretion is quantified as being proportional to the 
release of ATP from the granules. ATP-dependent luciferin-luciferase assay 
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determines the ATP-release. Chrono-Log lumi-aggregometer was used to 
measure ATP release. Platelets (2.5 x108 platelets/mL) were pre-incubated with 
Chronolume (luciferin-luciferase reagent #395) for 1 minute prior to stimulation 
in the lumi-aggregometer. As described in section 3.2.1.6, stimulation was 
carried out using varying doses of thrombin (Sigma) for 2 minutes to record 
secretion and aggregation in real-time. ATP standard was added at the end of 
stimulation, which serves as an internal standard for each experiment. The lumi-
aggregometer was calibrated, where washed platelet suspension indicated 0% 
aggregation and Tyrode’s buffer indicated 100% aggregation; whereas the 
baseline for secretion was obtained after one minute pre-incubation with 
Chronolume and maximum was determined by addition of the ATP standard at 
the end of stimulation (White and Jennings, 1999). Secretion from dense 
granules was then determined by the comparison of test to the ATP standard 
using following formula. 
𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐴𝑇𝑃 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =  
𝐺𝑎𝑖𝑛 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝐺𝑎𝑖𝑛 𝑖𝑛 𝐴𝑇𝑃 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
× 2𝑛𝑀 
 
 
2.4 Platelet visualisation 
2.4.1 Spreading on fibrinogen or collagen  
The platelet count was adjusted before seeding at 2x107 platelets/mL. Platelet 
suspension (200 μL) was applied to 12-mm glass coverslips that were pre-
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coated with fibrinogen [100 µg/mL in PBS - phosphate buffered saline (137 mM 
NaCl; 2.7 mM KCl; 4.3 mM Na2HPO4; 1.47 mM KH2PO4. pH of 7.4)] (Human 
fibrinogen plasminogen - Enzyme Research Swansaea, UK) or collagen (10 
µg/mL in SKF solution) (collagen type IV and SKF solution form Horm-
Kollagenreagens, Takeda) in 24-well cell culture plates (Corning) overnight at 
4˚C. Platelets were allowed to adhere and spread for 30-45 minutes (in a humid 
chamber at 37°C) (variations in experiments have been noted in the figure 
legends) (Gibbins and Mahaut-Smith, 2004). In experiments that assess effects 
of resistin (Peprotech, USA), platelets were pre-incubated with resistin prior to 
spreading on fibrinogen. In experiments requiring further activation, spreading 
on fibrinogen was followed by stimulation with 0.1 U/mL thrombin (Sigma) for 
designated time periods (ranging from 0 to 180 seconds) at room temperature 
without shaking. The platelets were fixed at the end of stimulation period using 
ice-cold 4% paraformaldehyde (PFA) (Sigma) in PBSfor 10 minutes. Any 
unbound platelets were removed by aspiration and washed with PBS prior to 
blocking with PBG (0.5% BSA, 0.05% Fish gelatin in PBS).  
 
2.4.2 Platelet stimulation in suspension 
Washed platelets (5x108 platelets/mL) were stimulated with 0.1U/mL thrombin in 
suspension (shaking) and fixed at the end of stimulation using 1:1 ice-cold 4% 
PFA. Platelet suspension was then applied to poly-L-lysine (Sigma) (0.01% in 
PBS) pre-coated 12-mm glass coverslips and centrifuged at 3,440xg for 10 
minutes to allow fixed platelets to attach to the matrix. Any unbound platelets 
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were removed by aspiration and washed with PBS prior to blocking with PBG 
(For ingredients see 2.4.1).  
 
2.4.3 Immunostaining platelets 
Human platelets that have previously adhered and/ or spread on coverslips (see 
sections 2.4.1 and 2.4.2) were permeabilised using 0.3% Triton-X 100 solution 
(Roth, UK) in PBS before immunostaining with primary (see Appendix 2) and 
corresponding fluorescent-tagged secondary antibodies [Alexa 488 (Molecular 
Probes) or Alexa 568 (Molecular Probes) – (1:2000 in PBS)]. When staining for 
actin, FITC-phalloidin (Sigma) or TRITC-phalloidin (Sigma) was used. 
Intermediate washing steps were carried out using PBG (For ingredients see 
section 2.4.1). 
 
2.4.4 Imaging platelets 
Platelets were imaged using a fluorescence microscope (Olympus XL-100) at 
100x magnification (Chapter-4), using Zeiss Axio VertA.1 at 100x magnification 
(Chapter-3), and Zeiss ApoTome.2 (Chapter-5) and images were captured by 
Micropublisher 3.3RTV camera or XM10 CCD camera or AxioCam 506, 
respectively. All images were processed using PhotoShop 5.5 (Adobe) and 
CorelDRAW X6 (Corel). 
 
116 
 
2.4.5 Analysis of imaged platelets 
Analysis of unprocessed images (see section 2.4.4), saved in TIFF format, was 
carried out using ImageJ software. Signal intensities, cell size, and cell numbers 
were measured using ImageJ and were recorded in MS Excel. When 
comparisons were carried out, values were normalised to respective controls. 
For classification of platelets according to the actin structures, following criteria 
were used – cells having actin nodules, and cells having stress fibres. Platelets 
having both actin nodules and stress fibres were classified twice. Platelets 
showing a bright spots were not characterised as they are not spread platelets. 
Figure 2.1 shows a representative classification of platelets. 
 
 
Figure 2.1 Classification of platelets for characterisation of actin 
structures in platelets. All platelets labelled (1) are classified as having actin 
nodules and (2) represent all platelets having stress fibres. Platelets showing a 
bright spot are not characterised as they are not spread platelets. Scale bar - 
10µm. 
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2.5 Preparation of whole cell lysate 
Washed platelets were adjusted to 5 x 108 platelets/mL and treated with platelet 
agonists at required concentration under stirring condition. Reaction between 
platelets and agonist was stopped using 1:1, ice-cold lysis buffer [1% TX-100, 
10 mM Tris-HCl, 10 mM EGTA, 1:100 (v/v) protease inhibitor cocktail, 1:200 
(v/v) phenylmethanesulfonylfluoride (PMSF)]. 20µL aliquot was stored at 4°C to 
measure protein concentrations (see section 2.6) . 2X SDS sample buffer [100 
mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.2% bromophenol blue, 4% β-
mercaptoethanol] was added to remainder of reaction mixture and boiled at 
95°C for 5 minutes. 
 
2.6 BCA (Bicinchoninic acid) Protein determination assay 
Protein concentrations of platelet lysates (see section 2.5) and mammalian cell 
lysates (see section 2.10.4) were measured with Pierce® BCA Protein Assay Kit 
according to manufacturer’s protocol. Absorption was measured at 563 nm 
using a TECAN 2000 plate reader. 
 
2.7 Subcellular fractionation of platelets 
Human blood platelets, 3 x 108, were lysed in an isotonic sucrose solution [100 
mM Sucrose, 4 mM HEPES, 0.5 mM Na3VO4, 1:100(v/v) Protease inhibitor 
cocktail, 1:200 (v/v) PMSF] by 5-6 cycles of rapid freeze thaw in liquid nitrogen. 
Cell debris and unlysed platelets were removed by centrifugation of lysates at 
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1,000xg at 4˚C for 3 minutes. Supernatant lysates were then spun at 100,000xg 
for 1 hour using Beckman Coulter Optima MAX-XP ultracentrifuge (Castle, 
2004). Pellet contained the membrane fraction which was resuspended in 2X 
SDS sample buffer (1:1 (v/v)) and boiled at 95°C for 5 minutes. Supernatant 
contained the cytosolic fraction and prepared by adding 2X SDS buffer (1:1) 
followed by a boiling step at 95°C for 5 minutes.  
 
2.8 Isolation of the detergent insoluble pellet  
Human blood platelets, 3 x 108 ,were lysed in TX-100 containing lysis buffer [2% 
TX-100, 10 mM Tris-HCl, 10 mM EGTA, 1:100 (v/v) protease inhibitor cocktail, 
1:200 (v/v) PMSF]. Lysates were spun at 15,600xg (low speed) or 100,000xg 
(high speed) as indicated (Fox, 1985). Pellet containing the detergent insoluble 
proteins were resuspended in 2X SDS sample buffer (see section 2.7) and 
supernatant was prepared by adding 2X SDS buffer. Pellet and supernatant 
were boiled at 95°C for 5 minutes and samples were resolved using Western 
blotting (see section 2.9).  
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2.9 Immunoblotting 
Specific proteins of interest were identified from lysates containing complex 
mixture of proteins using Western blotting. Western blotting constitutes protein 
separation based on their molecular weight under denaturing conditions of SDS-
containing polyacrylamide gel. Separated proteins are then electrophoretically 
transferred to adhesive membranes to enable protein detection using protein 
specific antibodies. Unspecific binding sites on the membranes are then blocked 
using casein or serum albumin followed by incubation with antibodies generated 
against the proteins or peptides of interest. Fluorescently or HRP-tagged 
secondary antibodies then help to generate a signal equivalent to the 
concentration of protein that is transferred onto the membrane.  
 
2.9.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated according to their molecular weight under denaturing 
conditions of SDS-PAGE. Samples resuspended in (1:1 2xSDS buffer) were 
resolved on gels and electrophoresis was done using MiniPROTEAN® (BioRad, 
UK) system. 10% or 12% separating gels were prepared according to the 
following proportions (Table 2.1). The gels were placed in the gel chambers 
containing 1X SDS running buffer (25 mM Tris-base, 192 mM glycine, 0.1% 
SDS, pH 8.3). The samples and molecular weight ladder (EZ-Run TM 
Prestained Rec Protein Marker, Fisher Scientific, UK) were loaded into wells 
and run at 80-150V until the bromophenol dye containing loading front ran out 
the bottom of the gel.  
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Table 2.1: Composition of SDS-PAGE 
Chemicals 
12% 
(Separating 
gel)  
10% 
(Separating 
gel)  
4% 
(Stacking 
gel)  
Acrylamide:Bisacrylamide 
(37.5:1) (Rotiphorese 30%) 
(CarlRoth, Germany) 
12 mL 10 mL 4.08 mL 
1.5 M Tris-HCl pH 8.8 ((Sigma, 
UK) 
7.5 mL 7.5 mL -- 
10% SDS (Melrose, UK) 300 µL 300 µL 300 µL 
Distilled water 9.9 mL 12.9 mL 17.16 mL 
10% Ammonium persulphate 
(APS) (Sigma, UK) 
300 µL 300 µL 225 µL 
TEMED (Sigma, UK) 30 µL 30 µL 150 µL 
0.5 M Tris-HCl pH 6.8 (Sigma, 
UK) 
-- -- 8.4 mL 
 
 
2.9.2 Blotting of proteins onto PVDF or nitrocellulose membranes 
Gels were equilibrated in ice-cold blotting buffer (25 mM Tris-base, 193 mM 
Glycine, 20% Methanol) for 2-3 minutes. PVDF membranes were activated by 
soaking in methanol for one minute. Nitrocellulose membranes were activated 
by soaking in distilled water. Blotting paper soaked in blotting buffer was used 
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on either side to form a cassette. Wet-blot transfer was carried at 100V for 1.5 
hours in a MiniPROTEAN® gel chamber (Biorad, UK) under constant stirring at 
4˚C. 
 
2.9.3 Immuno-detecting proteins bound to membranes  
PVDF or nitrocellulose membrane carrying the blotted protein was first 
equilibrated in TBS-T buffer [150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.1 % 
Tween-20] before blocking any unspecific binding sites using 5% BSA prepared 
in TBS-T for 45 minutes. Membrane was washed and incubated with primary 
antibodies at appropriate dilutions overnight. Membrane was washed again 
before incubating it with appropriate peroxidase-coupled or fluorescently-tagged 
secondary antibodies. The chemiluminescence reaction for detecting 
peroxidase-coupled antibodies was carried out using peroxide containing ECL 
buffer 1, and luminol containing ECL buffer 2 (See Table 2.2). The membrane 
was exposed on Amersham HyperFilm ECL (GE Healthcare, UK) and 
developed using developer and fixer solutions (Kodak, UK). Developed films 
were scanned and densitometric analysis was carried out using ImageJ 
software(version 1.50b). Fluorescently-tagged secondary antibodies were 
detected using LiCor Odyssey CLx Imaging System and densitometric analysis 
was carried out using ImageStudio software (Image Studio lite version 5.2). 
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Table 2.2: Composition of enhanced chemiluminescence (ECL) buffers 
Chemical Volumes 
ECL1 ECL2 
10% Tris base (Sigma, 
UK) 
100 mM 100 mM 
Hydrogen peroxide 
(Sigma, UK) 
-- 30% (v/v) 
Luminol (Sigma, UK) 250 mM -- 
Coumaric acid (Sigma, 
UK) 
90 mM -- 
 
2.9.4 Processing of the densitometric values for graphical representation 
After densitometric analysis was carried out using ImageStudio software (Image 
Studio lite version 5.2), the values were exported to MS Excel for further 
processing. The densitometric values of protein of interest were first normalised 
to the loading control (GAPDH, CD36, Integrinβ3 or beta-actin, as relevant and 
is specified in the respective experiments and the figure legends). In situations 
where treatment conditions were compared to the basal or untreated, resting 
platelets, the values that were normalised to the loading control were further 
normalised to the basal to allow clear comparison of changes post-treatments, if 
any. Graphical representations were generated in MS Excel, while statistical 
analysis was carried out as specified in section 2.11. 
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2.10 Cell culture and transfection 
2.10.1 Culture of mammalian cells 
293T HEK cells (Human Embryonic Kidney cells) and HeLa (carcinoma cell line) 
were retrieved from frozen stock vial (5 x 106 cells/mL) and warmed to 37°C and 
resuspended in DMEM. The cells were centrifuged at 200xg for 5 min and 
resuspended in fresh medium for seeding on a 10 cm culture dish (Corning, 
UK). Cells were incubated at 37°C in a humidified incubator supplied with 5% 
CO2 in appropriate culture medium (Supplemented DMEM – see below). The 
medium was changed the following day and cells were allowed to proliferate 
until confluent before passaging. 
Supplemented DMEM: 
DMEM high glucose (Sigma, UK) 
10% heat-inactivated FCS (Life Technologies, UK) 
2 mM glutamine (Sigma, UK) 
100 U/mL penicillin, 100 µg/mL streptomycin (PAA, UK) 
1 mM sodium pyruvate (Sigma, UK) 
 
 
2.10.2 Transfection of mammalian cells 
293T HEK cells and later HeLa were transiently transfected with either 
IQGAP1WW-GFP plasmid, or IQGAP2-WW-GFP plasmid, in addition to myc-
CAP1 plasmid using Lipofectamine 2000 (Invitrogen, Life Technologies Ltd.) 
according to manufacturer’s recommendations (GFP-CAP1 was used to 
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generate a control sample). All plasmids were generated previously in the lab of 
Dr Rivero and their details can be found in Table 2.3.  
Table 2.3 List of plasmid constructs 
Plasmid name Vector Insert 
pRK5-myc-HsCAP1-C (242-
475) pRK5 myc HsCAP1 C terminus (242-475) 
pRK5-myc-HsCAP1-N (1-324)  pRK5 myc HsCAP1 N terminus (1-324) 
pGEM-Teasy/HsCAP1  
pGEM-
Teasy Hs CAP1 
HsIQGAP2-WW/pEGFP-C2 pEGFP-C2 
HsIQGAP2 WW-region (542-
686) 
HsIQGAP1-WW/pEGFP-C3 pEGFP-C3 
HsIQGAP1 WW-region (626-
767) 
 
 
Transfection was confirmed using fluorescence microscope using GFP 
expression as marker for successful transfection. Transfection efficiency is 
shown in Figure 2.2. 
 
Figure 2.2 Transfection efficiency. Plasmids were transfected transiently in 
HEK cells and efficiency was assessed by viewing under a fluorescence 
microscope. GFP-CAP1 and IQGAP2-WW (GFP) transfection was highly 
efficient. IQGAP1-WW (GFP) transfection was minimal. 
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2.10.3 Cryopreservation of mammalian cells 
A confluent monolayer of 293T HEK cells on a 10 cm culture plate was 
trypsinised using Trypsin/EDTA (Life Technologies, UK) for 5 min at 37˚C and 
resuspended in cold DMEM (without FCS). The cells were centrifuged for 10 
min at 200xg at 4°C. The pellet was resuspended in 1 mL of freezing medium 
(see below) and transferred to cryotubes. The cryotubes were placed in pre-
cooled cryorack Nalgene® Mr FrostyTM Cryo (soaked in isopropanol) and left at -
80°C overnight before transferring to liquid nitrogen until further use. For reusing 
the frozen cells method is as described in section 2.10.1. 
Freezing medium: 
70% DMEM High glucose (Sigma, UK) 
20% FCS (Life Technologies, UK) 
10% DMSO (Sigma, UK) 
 
 
2.10.4 Lysis of mammalian cells 
A confluent layer of mammalian cells was washed with PBS and lysed using a 
lysis buffer (see below). Lysates were then collected and centrifuged at 2000xg 
for 10 min at 4°C and stored at -20°C until further use. 
Lysis buffer: 
150 mM NaCl (Merck, UK) 
1% Triton-X 100 (Roth, Germany) 
50 mM Tris-HCl (pH 8.0) (Sigma, UK) 
0.5 mM PMSF (Sigma, UK), 1:100 Protease Inhibitor Cocktail (Sigma, UK)  
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2.10.5 Immunoprecipitation: Transfected mammalian cells 
Cell debris was removed from lysed, transfected mammalian cells by 
centrifugation at 10,000xg at 4°C for 10 minutes and epitope tagged proteins 
were immunoprecipitated using a μMACS epitope tag protein isolation kit with 
magnetic beads conjugated with anti-Myc antibody (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to manufacturer’s protocol.  
 
2.11 Statistical analysis 
All data was primarily computed in MS Excel and used to produce graphs. 
Statistical analysis was carried out using IBM SPSS 23 software. Student’s t-
test (two-tailed, unpaired) was carried out when comparing two individual 
sample sets. One-way ANOVA was carried out when data of more than two sets 
was compared to a control or basal sample set. LSD (Fisher’s least significant 
difference) post-hoc correction was applied for smaller data sets (For example, 
control is compared to two other variable treatment conditions) and Bonferroni 
correction was applied for larger and/ or multiple data sets (including n numbers 
greater than 4). P-values are presented in the figure legends. Parametric tests 
were undertaken assuming normal distribution of data, owing to random 
selection of blood donors from the population, thus ensuring a more robust 
statistical analysis. 
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2.12 Source of chemicals and reagents 
All solvents (methanol, ethanol, isopropanol) were bought from Fischer 
Scientific, UK and unless otherwise stated, remainder of the chemicals and 
reagents were bought from Sigma, UK. A list of antibodies used and their test 
conditions can be found in Appendix 2. 
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CHAPTER 3  
EFFECT OF ELEVATED RESISTIN LEVELS ON PLATELET 
FUNCTION 
 
High levels of circulating resistin are present in patients with MetS and 
associated conditions. Several studies correlate elevated levels of resistin to 
obesity, T2DM and CVDs suggesting that resistin might play a major role in 
aetiology of MetS and therefore contribute towards CVD development and 
progression leading to complications (Miranda et al., 2005; Vykoukal and 
Davies, 2011). Resistin promotes atherogenesis by virtue of its pro-inflammatory 
effects on vascular endothelial and smooth muscle cells (Jung et al., 2006; 
Pirvulescu et al., 2014). In atherosclerotic lesions elevated resistin levels were 
found associated with macrophages and, when present at high levels locally in 
the arterial vessel wall, resistin significantly contributed to an enhanced 
accumulation of macrophages by increasing monocyte chemotaxis 
(Manduteanu et al., 2010; Cho et al., 2011). Also, evidence from endothelial cell 
lines suggests that resistin increases procoagulability in T2DM by upregulation 
of TF, which is required for thrombin generation, in addition to upregulation of 
PAI and t-PA, which are required for fibrinolysis – together leading to the 
procoagulatory state (Bobbert et al., 2011). 
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The imminent question in understanding the correlation between the hormone 
and disease is to find out if and how far these elevated levels of resistin affect 
thrombotic events. Platelets, as first responders to the site of vascular injury, are 
exposed to dynamic thrombotic microenvironments during the process of 
haemostasis, presenting as an interesting model cell to investigate the effect of 
resistin on their function. Although there is evidence in the literature that a 
strong link exists between elevated resistin levels and MetS-associated CVD 
(Bełtowski, 2003; Reilly et al., 2005; Anfossi, Russo and Trovati, 2009; Piya, 
McTernan and Kumar, 2013; Huang and Yang, 2015), there are no thorough 
reports outlining the effects of resistin on platelet function. Additionally, there are 
discrepancies surrounding research on resistin (Lee et al., 2003) – resistin 
secretory cells vary between mice and humans as do the target cells and the 
effects they cause. In mice, resistin is secreted by adipocytes and acts in an 
autoregulatory manner (Steppan et al., 2001) with supplementary endocrine 
effects like causing IR in obese, diabetic mice (Steppan et al., 2005). In 
humans, however, monocytes and macrophages (Patel et al., 2003; S. Lee et 
al., 2014) are the main cells responsible for resistin secretion and its effects on 
IR and glucose metabolism are keenly debated and evidence for and against it 
exits depending on the experimental designs of various investigators (Cho et al., 
2001; Zhang et al., 2003; Banerjee, 2004; Manduteanu et al., 2010; Piya, 
McTernan and Kumar, 2013; Huang and Yang, 2015).  
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This chapter therefore narrows the scope of study and aims to broadly 
investigate how recombinant human resistin affects platelet activation in 
functional studies involving platelet aggregation, secretion and adhesion assays. 
Additionally, biochemical signalling pathways involving activation of integrin 
αIIbβ3 and its downstream effector proteins in PI3K and MAPK pathways are 
briefly examined.  
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3.1 Aims and objectives 
The aim of this chapter is to examine the effects of resistin on various platelet 
activation processes using agonists that stimulate platelets through distinct 
pathways and carry out a preliminary evaluation of potential biochemical 
signalling pathways involved therein. 
The objectives are: 
1. Investigating the effect of resistin on platelet aggregation: 
- In GPCR mediated platelet activation using thrombin 
- In tyrosine kinase mediated platelet activation using collagen 
- Evaluating the time and dose response to resistin pre-treatment of 
platelets 
 
2. Examining the effect of resistin on secondary platelet response by 
- Inhibiting ADP and TXA2 and assessing effect on platelet aggregation 
- Assessing dense granule secretion/ATP release using luciferase 
assay in platelet aggregation 
 
3. Investigating the effect of resistin on integrin-mediated platelet spreading 
by 
- Evaluation of time and dose response of resistin on immobilised 
fibrinogen 
- Understanding the effect of resistin on secondary response during 
spreading 
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4. Assessing the effect of resistin on potential biochemical signalling 
pathways by 
- Evaluating phosphorylation by AGC kinases  
- Assessing phosphorylation of PI3K/Akt and MAPK, ERK1/2, in 
response to resistin stimulation.  
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3.2 Results 
3.2.1. Effects of resistin in suspended platelets 
3.2.1.1 Effects of resistin on platelet aggregation 
In order to study the effects of resistin on platelets, a preliminary functional 
study was carried out to assess if resistin caused platelets to aggregate in a 
dose dependent manner. In figure 3.1, it was observed that treatment of 
platelets with various doses of resistin alone did not have any effect on platelet 
aggregation, similar to basal platelets left stirring in the aggregometer with no 
agonist stimulation.  
The doses were chosen in the high physiological range to severe disease 
conditions (50ng/mL to 1µg/mL) (Qiu et al., 2014). In order to account for the 
competency of platelets post-preparation, a positive control test was carried out 
using 0.1U/mL of thrombin. 
Therefore, resistin does not appear to act as a platelet agonist. 
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Figure 3.1: Effect of resistin on platelet aggregation: Multiple doses of 
resistin (Res) were tested to assess effect on aggregation response of 2 x 108 
/mL blood platelets in aggregometer. 0.1U/mL thrombin is used as a positive 
control to assess platelet function and basal was the negative control which 
received no agonist. Aggregation traces are representative of four independent 
experiments. 
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3.2.1.2 Effects of resistin on platelet aggregation driven by agonists 
Having shown that resistin doesn’t act as an agonist itself, we asked whether it 
may modulate the response to well characterised agonists. 
Physiologically platelets are exposed to resistin in circulating blood before they 
encounter thrombotic conditions in the vascular system (Vykoukal and Davies, 
2011). In order to simulate that, washed platelets were exposed to resistin prior 
to agonist stimulation.   
 
3.2.1.2.1 Effect of resistin on thrombin-stimulated aggregation  
Thrombin is a strong platelet agonist. In vivo it is generated by adhered platelets 
to enhance thrombus formation by causing recruitment and activation of 
quiescent platelets from circulation, further helps demonstration of a thrombotic 
event. Thrombin causes platelets to generate an inside-out signal through the 
G-protein (Gq) coupled receptors PAR1 and PAR4 (in humans) leading to 
activation of integrin αIIbβ3 required for platelet aggregation (Coughlin, 2000; 
Brass, 2003). 
Blood platelets were treated with 200ng/mL resistin for 5 minutes prior to 
stimulating them with thrombin in a dose dependent manner, where untreated 
platelets were used as positive control for each dose of thrombin. Figure 3.2 
shows percent aggregation of platelets upon thrombin stimulation. It was 
observed that resistin pre-incubation caused a small reduction in aggregation of 
platelets across multiple doses of thrombin stimulation. The most significant 
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reduction in aggregation of ~30% (p=0.006, one-way ANOVA) was observed 
when resistin pre-treated platelets received 0.025U/mL thrombin dose.  
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Figure 3.2: Effect of resistin pre-incubation on platelet aggregation with 
thrombin: Human blood platelets (2 x 108 /mL)were incubated with 200ng/mL 
resistin for 5 minutes before assessing the effect on thrombin stimulation. 
Untreated platelets were used as a control against resistin treatment for each 
dose of thrombin agonist tested in the aggregometer. Basal indicates platelets 
with no agonist stimulation, while “Res” indicates 200ng/mL resistin with no 
thrombin agonist. Data are represented as mean ± standard error of mean of 
three independent experiments. Statistical significance calculated using one-
way ANOVA (**p = 0.006).  
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3.2.1.2.2 Effect of resistin on collagen-stimulated aggregation  
The inhibition of aggregation upon resistin treatment of platelets after thrombin 
stimulation prompted an assessment to identify if this effect was thrombin 
pathway specific. Collagen, another strong platelet agonist, upon vascular 
injury, acts as the most thrombogenic component of the endothelium initiating 
platelet activation. Similar to thrombin dose response (section 3.2.1.2.1), 
collagen agonist was examined inresistin pre-treated platelets. Since collagen 
acts via binding glycoprotein receptors distinct from thrombin receptors, it was 
considered as an alternative agonist to assess changes in platelet aggregation 
post resistin treatment. Collagen binds tyrosine kinase-linked receptors GPVI-
FcR-γ activating PLCγ2, leading to inside-out signal causing integrin αIIbβ3 
activation required for platelet aggregation (Watson et al., 2005). 
The experimental set-up was similar to that of section 3.2.1.2.1.  Platelets were 
pre-incubated with 200ng/mL resistin for 5 minutes before stimulation with 
collagen in an aggregometer. Aggregation of untreated platelets with respective 
collagen doses were used as controls for resistin treatment. Figure 3.3 shows 
that platelet aggregation of resistin-treated platelets was slightly less than 
control at all collagen doses, but this reduction was not statistically significant 
(ANOVA). Like thrombin (Figure 3.2), figure 3.3 also showed a trend towards 
collagen responding to resistin by causing reduction in aggregation at lower 
doses greater than that at higher doses.  
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As the effects of resistin in collagen-stimulated platelet aggregation were 
relatively mild compared to thrombin stimulation, further investigation of the 
effects of resistin on platelet function were only restricted to GPCR-related 
stimulation using thrombin and tyrosine-kinase related stimulation by collagen 
was not investigated more in this chapter. 
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Figure 3.3: Effect of resistin pre-incubation on collagen stimulated platelet 
aggregation: Human blood platelets (2 x 108 /mL) were incubated with 
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200ng/mL resistin (Res) for 5 minutes before assessing the effect on 
aggregation with collagen (Coll). Untreated platelets were used as a control 
against resistin treatment for each dose of the agonist stimulation. Data are 
represented as mean ± standard error of mean of three independent 
experiments. Statistical significance calculated using one-way ANOVA, but no 
significance within each collagen dose was observed.  
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3.2.1.3 Characterisation of resistin pre-incubation on thrombin stimulation 
of platelets 
A preliminary hypothesis emerged that resistin inhibits platelets when stimulated 
with thrombin. It was important to assess if it was the time of resistin pre-
incubation that had an effect on the outcome or if it was the dose of resistin 
used for the treatment of washed platelets. Hence, it was important to 
investigate time and dose dependence of the effect of resistin on aggregation 
when stimulated with a fixed dose of thrombin. 
 
3.2.1.3.1 Time dependence of resistin pre-incubation on thrombin related 
platelet aggregation 
Washed platelets were incubated with 200ng/mL resistin for varying times to 
assess effects on aggregation (Figure 3.4). Resistin and thrombin were 
administered together, which was considered first time point at zero minutes 
and showed minimal change in aggregation compared to control which only 
received 0.025U/mL thrombin and no resistin. Following time points at 1, 5, 15, 
30 minutes pre-incubation show decline in percent aggregation compared to 
control. This might have indicated when changes were triggered in platelets that 
lead to dampening of platelet activation, useful for further investigation. 
Statistically significant (p≤0.001, one-way ANOVA) reduction was observed 
when washed platelets were incubated with resistin for 15 and 30 minutes 
compared to percent aggregation of control samples. Multiple control samples 
were run on the aggregometer for the later incubation times to account for loss 
144 
 
of platelet activity, if any, during the long incubation in buffer between tests, but 
only one representative control aggregation trace is shown in figure 3.4. 
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Figure 3.4 Time response of resistin pre-incubation on thrombin related 
platelet aggregation: Human blood platelets (2 x 108 /mL) were incubated for 
146 
 
increasing length of time with 200ng/mL resistin before assessing the effect on 
aggregation with 0.025U/mL thrombin. Aggregation of platelets when stimulated 
with 0.025U/mL thrombin was used as control. Fold change in aggregation was 
calculated with respect to aggregation of control test in order to normalise data 
from multiple experiments. Data are represented as mean ± standard error of 
mean of four independent experiments. Statistical significance is calculated 
using one-way ANOVA (*p≤ 0.001). 
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3.2.1.3.2 Dose dependence of resistin pre-incubation on thrombin related 
platelet aggregation 
The conclusion which emerged from Figure 3.2 and 3.4 was that 30 minutes of 
resistin incubation caused maximum inhibition of platelets in aggregation when 
stimulated with 0.025U/mL thrombin. It was important to identify if the 
appropriate dose of resistin was used in the pre-incubation and that the effect 
sustained or varied when the dose of resistin was altered. Hence, resistin doses 
which range from early disease on-set to chronic hyperresistinemia were 
chosen - 50ng/mL to 1µg/mL, respectively, were tested in aggregation. As 
previously shown, in figure 3.1, these doses alone do not initiate aggregation of 
platelets. 
As seen in figure 3.3, 100ng/mL and 200ng/mL dose of resistin during platelet 
incubation caused statistically significant (p≤0.05) reduction in percent 
aggregation compared to control (which only received 0.025U/mL thrombin with 
no resistin). Further doses did not result in an increased reduction in platelet 
aggregation. 
500ng/mL resistin dose led to similar reduction in aggregation as 50ng/mL 
resistin. Maximum effect was achieved around 200ng/mL and higher doses did 
not produce any further effect, hence the following experimental analyses were 
carried out using 200ng/mL resistin pre-incubation of washed platelets for 30 
minutes before further testing. 
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The dose and time dependent reduction in aggregation upon stimulation with 
thrombin also suggested that platelets were likely not inhibited, but rather pre-
activated. An assessment of these emerging hypotheses is carried out in the 
forthcoming sections. 
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Figure 3.5 Dose response of resistin pre-incubation on thrombin related 
platelet aggregation: Human blood platelets, 2 x 108 /mL, were incubated with 
various doses of resistin for 30 minutes before assessing the effect on 
stimulation with 0.025U/mL thrombin. Aggregation of platelets in response to 
0.025U/mL thrombin is used as control. Fold change in aggregation upon 
resistin pre-incubation was calculated with respect to aggregation control test in 
order to normalise data. Data are represented as mean ± standard error of 
mean of four independent experiments. Statistical significance is calculated 
using one-way ANOVA (*p ≤ 0.05).  
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3.2.1.4. Validating recombinant human resistin activity 
Recombinant human resistin was used in all experiments and it was important 
to validate the following listed assumptions that were made before investigating 
the role of resistin further. The assumptions were: (1) Recombinant human 
resistin was the only active compound that was received from the supplier and 
contained no other substances which might inhibit platelets; (2) Resistin itself 
did not react with thrombin or was not a substrate for thrombin protease activity. 
These assumptions were corroborated by (A) heat-inactivating recombinant 
human resistin at 95˚C for 5 minutes before incubating with washed platelets for 
30 minutes at 37˚C and (B) by creating a pre-mix of thrombin and resistin, 
incubating for 10 minutes on ice and testing in aggregation with untreated 
platelets. 
Doses of 0.025U/mL thrombin and 200ng/mL resistin that were recorded as 
significant in previous experiments were used in this validation experiment. The 
outcome, as seen in figure 3.6, confirms all the assumptions of the previous 
investigations, as there was no difference in aggregation when comparing the 
test samples to the control, whereas platelets that were treated for 30 minutes 
with active recombinant human resistin (200ng/mL) showed expected decrease 
in platelet aggregation when stimulated with 0.025U/mL thrombin.  
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Figure 3.6 Effect of resistin inactivation and pre-mixing resistin and 
thrombin in platelet aggregation: Platelets were pre-incubated with resistin or 
heat-inactivated resistin (200ng/mL) for 30 minutes before assessing the effect 
on thrombin stimulation in aggregation. 0.025U/mL thrombin was incubated with 
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200ng/mL resistin for 10 minutes and the pre-mix was tested in untreated 
platelets. Aggregation of 0.025U/mL thrombin in untreated platelets was used as 
a control. Aggregation traces are representative of two independent 
experiments and data are represented as mean ± standard deviation of the 
mean of the same.  
154 
 
3.2.1.5 Effect of resistin on aggregation of indomethacin and apyrase 
inhibited platelets 
In order to isolate effects of primary and secondary aggregation, platelets were 
inhibited using indomethacin and apyrase. These inhibitors prevent secondary 
aggregation by blocking two potent agonists secreted by platelet granules upon 
stimulation of primary aggregation: TXA2 and ADP. Indomethacin inhibits 
cyclooxygenases, preventing the conversion of arachidonic acid to TXA2 
(Ruggiero and Lapetinat, 1986; Y. Qiu et al., 2014), whereas apyrase degrades 
ADP (Damman et al., 2012; Y. Qiu et al., 2014).  
Washed platelets were inhibited by treating them with 10µM indomethacin and 
1U/mL apyrase for 10 minutes followed by incubation in the presence or 
absence of 200ng/mL resistin for another 30 minutes before examining the 
effect on aggregation with 0.1U/mL thrombin. Since platelets were inhibited 
using strong, irreversible inhibitors, 0.025U/mL thrombin showed no effect on 
aggregation (data not shown), hence a stronger dose of 0.1U/mL thrombin had 
to be used to reliably measure percent aggregation upon stimulation. In figure 
3.7, similar to the observation from figure 3.2, there was no significant reduction 
in resistin-treated platelets when compared to control. Additionally, aggregation 
of indomethacin and apyrase inhibited platelets in response to thrombin did not 
vary significantly when compared to their resistin-treated equivalent samples. 
The only valid statistical significance, as would be expected, was seen between 
control and indomethacin and apyrase inhibited platelets (p=0.059, one-way 
ANOVA). 
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Figure 3.7 Effect of resistin on aggregation in indomethacin and apyrase 
inhibited platelets: Platelets were pre-incubated with indomethacin (10µM) and 
apyrase (1U/mL) in the presence or absence of 200ng/mL resistin for 30 
minutes before assessing the effect on thrombin stimulation. 0.1U/mL thrombin 
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stimulation of untreated platelets was used as a control. Percent aggregation of 
tests were normalised to the percent aggregation of the control test in order to 
generate data representing a fold change compared to control. Aggregation 
traces are representative of three independent experiments and data are 
represented as mean ± standard error of the mean of the same. Statistical 
significance is calculated using one-way ANOVA but no significance was 
observed between control and resistin-treated groups. 
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In conclusion, there were no statistically significant differences between control 
and resistin-treated platelet aggregation and between inhibited control and 
inhibited, resistin-treated platelet aggregation. Forthcoming sections in this 
chapter will help shed more light on the underlying mechanisms of resistin 
effects. 
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3.2.1.6 Effect of resistin on granule secretion upon thrombin stimulation 
The effect of resistin on reduction of platelet aggregation when stimulated with 
thrombin together with blunting of that effect upon apyrase treatment suggested 
that resistin might have an effect on granule secretion. When platelets undergo 
activation, they release their secretome, which is contained within its alpha (α) 
and dense granules. While dense granules release small signalling molecules 
like serotonin, ATP, ADP and polyphosphates (McNicol and Israels, 1999; 
Murugappan et al., 2004), α-granules release the bulk of the secretome which 
includes hemostatic factors, cytokines, angiogenic and anti-angiogenic factors, 
proteases, and necrotic factors, which aid in augmenting the platelet response 
(Furie, Furie and Flaumenhaft, 2001).  
An established method of assessing platelet secretion is by using 
lumiaggregometry where ATP release is measured along with aggregation 
(Flaumenhaft, 2003; Woulfe et al., 2004a). In order to substantiate the 
hypothesis that resistin affects granule secretion, ATP release from 200ng/mL 
resistin-treated platelets was compared to untreated platelets after stimulation 
with thrombin. In figure 3.8, panel A shows representative secretion traces of 
ATP release during thrombin stimulation, where green traces correspond to 
resistin treatment and black traces are their respective controls. An internal 
control (ATP standard) to account for loss of luciferase-luciferin substrate 
activity was used for all samples. Panel B shows ATP release values that were 
normalised to the maximum dose of thrombin (0.1U/mL) to eliminate donor 
variations in total secretion. A statistically significant decrease in ATP release 
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was observed when comparing resistin treatment to untreated platelets. Since, 
ATP is released from dense granules, it can be concluded that dense granule 
secretion is negatively affected by treatment of platelets with resistin. 
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Figure 3.8 ATP release in resistin treated platelets: ATP release by 2.5 x 
108/mL platelets upon stimulation with thrombin was tested in untreated and 
200ng/mL resistin treated platelets. (A) Representative secretion traces – 
control and resistin are shown and arrows indicate the addition of thrombin 
and ATP standard (2nM). Traces were normalised to the effect of adding ATP to 
the control (B) ATP release was calculated using in gain in sample compared to 
gain in ATP standard and normalised to maximum thrombin dose (0.1U/mL). 
Values of ATP release used are relative to control and represent mean ± 
standard error of the mean of three independent experiments. Statistical 
significance is calculated using one way-ANOVA, where resistin treated 
samples were compared to the control (**p=0.009).  
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3.2.2. Effect of resistin on platelet spreading 
Upon vascular injury, platelets are exposed to agonists in the subendothelial 
matrix which cause activation leading to shape change and adhesion to the 
subendothelium and to each other, forming a thrombus to regain haemostasis. 
Further evaluation of resistin effects on platelet function was therefore carried 
out using adhesion assays where fibrinogen was used as the activating matrix 
protein. Immobilised fibrinogen helped to investigate integrin αIIbβ3 activation 
more specifically (Parise, 1999; Payrastre, Missy and Trumel, 2000; Shattil and 
Newman, 2004).  
 
3.2.2.1 Time dependence of effect of resistin on fibrinogen spreading 
When clot formation begins, platelets are exposed to fibrin matrices and are 
activated by binding integrin αIIbβ3 (Qiu et al., 2014). Adhesion of platelets to 
immobilised fibrinogen and the average surface area of the spread platelets 
have been used as parameters for assessment of integrin activation 
(Schachtner et al., 2013). The effect of resistin pre-treatment of platelets was 
assessed by allowing them to spread on fibrinogen coated coverslips for 
variable lengths of time. Platelets were treated with 200ng/mL resistin for 30 
minutes, as in previous experiments, followed by incubation on 100µg/mL 
fibrinogen-coated coverslips for 10, 20 and 45 minutes at 37˚C; all time points 
had respective controls without resistin pre-treatment. Time points indicate the 
length of time platelets were incubated before fixing with 4% PFA. 
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Figure legend on following page. 
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Figure 3.9 Time dependence of resistin treatment on platelet spreading: 
(Figure on previous page) Platelets were pre-treated for 30 minutes with 
200ng/mL resistin and allowed to spread for 10, 20 and 45 minutes on 
100µg/mL fibrinogen and stopped using paraformaldehyde. Untreated platelets 
allowed to spread under similar conditions were used as control for each time 
point. FITC-phalloidin was used for highlighting actin structures in platelets 
(actin nodules/stress fibres) using fluorescence imaging techniques. All 
comparisons between basal and resistin-treated outcomes were analysed using 
one-way ANOVA and LSD post-hoc correction. (A) Images are representative of 
three independent experiments.Actin nodules and stress fibres used for 
classification for platelets in (E) and (F) are labelled adjacent to the panel for 
control images for 20 minutes and 45 minutes, respectively. Scale bar =10µm. 
(B) Surface area (µm²) of spread platelets is represented as frequency (with 
0.5µm² interval) of approximately 300 platelets per experimental condition. (C) 
Number of cells adhering to the fibrinogen matrix was recorded. Data represent 
mean ± standard error of the mean of three independent experiments across 5 
fields of view (12,406µm²) per experiment and represented as cells observed 
per unit area (µm²) (D) Surface area of platelets is represented as mean ± 
standard error of the mean of 300 individual platelets across three independent 
experiments. (E) Spread platelets showing presence of actin nodules are 
represented as percent of total platelets adhered per image. Classification 
criterion for spread platelets was based as either platelets showing presence or 
absence of actin nodules. (F) Spread platelets showing presence of stress fibres 
are represented as percent of total platelets adhered per image. Classification 
criterion for spread platelets was based as either platelets showing presence or 
absence of stress fibres. 
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As seen in figure 3.9 (A), representative images of fixed platelets show an 
expected outcome – there is an increase in number of platelets attaching to the 
fibrinogen surface as the length of incubation on the matrix increases. No 
differences, however, were observed in the numbers adhering (per field of view) 
when platelets were pre-treated with resistin compared to controls (Figure 3.9 
C). Similarly, surface area measurement, indicated that at 10 minutes the 
average platelet surface area was moderately low compared to the control 
(Figure 3.9 D). Statistical significance between surface areas of spread platelets 
was not observed at later time points.  
During measurement of surface area it became apparent that although the 
average surface area of spread platelets was not different, platelets appeared to 
spread better, where the curve of surface distribution shifts to higher values, 
when pre-treated with resistin compared to their respective untreated controls. 
In order to quantitate this observation, a frequency distribution graph was 
generated using 0.5µm2 as the interval width – number of platelets with their 
surface area within 0.5µm2 range was considered as one group. Figure 3.9 (B) 
shows that at 20 minutes and 45 minutes, more number of platelets with surface 
area of 25µm2 and over were present in the resistin-treated groups compared to 
their respective controls. Additionally, at 20 minutes, most platelets in the control 
group were smaller than 25µm2, while the resistin treated showed the maximum 
surface area of spread platelets of more than 75µm2. 
The above observation meant that although the average surface area and 
number of cells adhering to fibrinogen was not altered, a resistin effect was 
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clear in the way platelets spread. In order to understand if there were any 
morphological differences upon resistin treatment, adhered platelets were 
further analysed and classified based on the presence of different cytoskeletal 
features – actin nodules and stress fibres (Calaminus, Thomas, McCarty, 
Machesky, & Watson, 2008; Schachtner et al., 2013).  
Figure 3.9 E and F, show that there were no statistical differences in the 
proportion of platelets showing actin nodules or stress fibres. In Figure 3.9 E 
though, after 45 minutes of incubation on fibrinogen, a trend is observed, where 
more resistin treated platelets had actin nodules compared to their control– this 
was consistent with visual observation that platelets with large surface area, 
which normally would only display stress fibres, showed a high number of actin 
nodules. This observation was difficult to quantify but a representation can be 
observed in Figure 3.9 A. 
In conclusion, resistin treatment had an apparently mild effect on platelet 
cytoskeleton as seen from the surface area distribution (Figure 3.9 B) and actin 
nodule data (Figure 3.9 E), but there was no effect on overall adhesion of 
platelets on the immobilised fibrinogen.  
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3.2.2.2 Dose dependence of effect of resistin on platelet spreading on 
fibrinogen 
In order to assess the effect of elevated levels of circulating resistin on platelets 
it was important to identify if higher doses of resistin treatment augmented or 
altered the behaviour of platelets spreading on fibrinogen. Also, a trend showing 
that there were differences in number of actin nodules observed in resistin 
treated platelets after spreading on fibrinogen for 45 minutes, meant the 
investigation could reveal if resistin concentration affected their adhesive 
properties. 
Platelets were incubated with 100ng/mL, 200ng/mL, 500ng/mL and 1µg/mL 
resistin for 30 minutes and were incubated on 100µg/mL fibrinogen coated 
coverslips for 45 minutes and compared to untreated platelets incubated under 
similar conditions. As in section 3.2.2.1, adhesion of platelets per field of view 
and surface area were measured as relevant parameters for integrin αIIbβ3 
activation on fibrinogen. 
In Figure 3.10 A and C, it can be observed that there was no statistically 
significant difference between the adhesion numbers of any dose of resistin 
treatment or when compared to untreated control. Also, no differences were 
observed in the surface area of spread platelets under all the different resistin 
treatments (Figure 3.10 D).  
Although mean surface area of platelets across all treatment groups was not 
different, visual observation that all resistin doses of platelet treatment had more 
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surface area than control was quantified using a frequency distribution graph 
(where the interval width was 0.5µm2 (Figure 3.10 B). Larger surface area (more 
than 75µm2) of platelets was observed in all resistin treated samples compared 
to control – where maximum number of platelets with large surface area was 
seen at 200ng/mL resistin pre-treatment dose. 
Adhered platelets were further characterised to identify cytoskeletal differences, 
as in section 3.2.2.1 and classified into cells showing actin nodules and/or 
stress fibres. No statistical differences in the proportion of cells displaying actin 
nodules or stress fibres were observed across all treatment groups (Figure 3.10 
E and F). Although statistically not significant, a higher proportion of resistin 
treated platelets had stress fibres compared to control (Figure 3.10 F). 
  
168 
 
 
169 
 
Figure 3.10 Dose dependence of resistin treatment on platelet spreading: 
Platelets were pre-treated for 30 minutes with various doses of resistin and 
allowed to spread for 45 minutes on 100µg/mL fibrinogen-coated coverslips and 
stopped using paraformaldehyde. Untreated platelets allowed to spread under 
similar conditions were used as control. FITC-phalloidin was used for 
highlighting actin structures in platelets (actin nodules/stress fibres) using 
fluorescence imaging techniques.(A) Images are representative of three 
independent experiments. Scale bar =10µm. (B) Surface area (µm²) of spread 
platelets is represented as frequency (with 0.5µm² interval width) of 
approximately 300 platelets per experimental condition. (C) Number of cells 
adhering to the fibrinogen matrix per unit area (µm²) is recorded relative to 
control, as different microscope and image-recorder was used for one set of 
data. This was performed in order to normalise all values. Data represent mean 
± standard error of the mean of three independent experiments across 5 images 
per experiment. (D) Surface area of platelets is represented as mean ± standard 
error of the mean of 300 individual platelets across three independent 
experiments. (E) Spread platelets showing presence of actin nodules are 
represented as percent of total platelets adhered per image. Classification 
criterion for spread platelets was based as either platelets showing presence or 
absence of actin nodules.  (F) Spread platelets showing presence of stress 
fibres are represented as percent of total platelets adhered per image. 
Classification criterion for spread platelets was based as either platelets 
showing presence or absence of stress fibres. Statistical significance between 
and within doses of resistin was calculated using one-way ANOVA, but no 
significance was observed. 
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3.2.2.3 Effect of resistin treatment on platelet spreading using inhibitors 
Platelet activation upon adhesion onto immobilised fibrinogen can cause 
secretion of agonists such as TXA2 and ADP, which in turn can lead to 
paracrine activation of neighbouring platelets (Qiu et al., 2014). In order to 
narrow the reason for the observed differences of surface area distribution 
between resistin treated and untreated groups, was an effect of agonist 
secretion or resistin pre-treatment, platelets were treated with inhibitors like 
indomethacin and apyrase to block TXA2 synthesis and degrade ADP, 
respectively.  
The presence of inhibitors caused less total adhesion of platelets to immobilised 
fibrinogen compared to control but no statistical difference in the number of 
adherent cells was observed between inhibitor treated group and inhibitor + 
resistin treated group (Figure 3.11 A and D). When surface area of spread 
platelets was analysed, the inhibitor treated groups, in the presence or absence 
of resistin, did not show any significant variation (Figure 3.11 C). The surface 
area frequency distribution, on the other hand, showed that the most platelets in 
the resistin treated group were around the 25 µm2 range (Figure 3.11 B), 
whereas the untreated (inhibitor) group included platelets that covered larger 
surface area.  
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Figure 3.11 Effect of resistin treatment on platelet spreading using 
inhibitors: Platelets were pre-treated for 30 minutes with indomethacin (10µM), 
apyrase (2U/mL) in presence and absence of 200ng/mL resistin and allowed to 
spread for 45 minutes on 100µg/mL fibrinogen-coated coverslips and stopped 
using paraformaldehyde. Untreated platelets allowed to spread under similar 
conditions were used as control. FITC-phalloidin was used for highlighting actin 
structures in platelets (actin nodules/stress fibres) using fluorescence imaging 
techniques. (A) Images are representative of three independent experiments. 
Scale bar =10µm. (B) Surface area (µm²) of spread platelets is represented as 
frequency (with 0.5µm² interval width) of approximately 300 platelets per 
experimental condition.  (C) Surface area of platelets is represented as mean ± 
standard error of the mean of 300 individual platelets across three independent 
experiments. (D) Number of cells adhering to the fibrinogen matrix is recorded 
relative to control, as different microscope and image-recorder was used for one 
set of data. This was performed in order to normalise all values. Data represent 
mean ± standard error of the mean of three independent experiments across 5 
images per experiment. (E) Spread platelets showing presence of actin nodules 
are represented as percent of total platelets adhered per image. Classification 
criterion for spread platelets was based as either platelets showing presence or 
absence of actin nodules.  (F) Spread platelets showing presence of stress 
fibres are represented as percent of total platelets adhered per image. . 
Classification criterion for spread platelets was based as either platelets 
showing presence or absence of stress fibres. Statistical significance was 
calculated using one-way ANOVA; significance of p<0.05 was observed when 
comparing means of control with indomethacin and apyrase treatment when 
measuring surface area and the percent of platelets with actin nodules, rest of 
the comparisons show no significance. 
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3.2.3. Effect of resistin on platelet signalling pathways 
Resistin has been investigated in monocytic cell lines, endothelial cells, smooth 
muscle cells and adipocytes in some detail for its role in causing IR (Nagaev et 
al., 2006; Manduteanu et al., 2009; Cho et al., 2011). While there is still much 
speculation about a specific receptor that binds resistin (Tarkowski et al., 2010; 
Lee et al., 2014; W. Qiu et al., 2014), downstream events are better 
characterised. Evidence from smooth muscle cells and endothelial cells 
indicates that resistin induces adhesion between the cells via an ERK1/2 MAPK 
dependent pathway (Calabro et al., 2004). Evidence from adipocytes indicated 
that resistin play a role in SOCS3 activation (inhibitor of insulin signalling) by 
phosphorylation of insulin receptor and substrate, activation of PI3K, which 
subsequently phosphorylates and activates Akt (which is required for stimulation 
of glucose transport) (Steppan et al., 2005).  
 
Recombinant human resistin was tested in human umbilical vein endothelial 
cells (HUVEC) to reiterate evidence from literature and to assess if resistin 
potentiated similar effects under present laboratory conditions. It can be seen 
from Figure 3.12 that resistin caused phosphorylation of PI3K/Akt and MAPK, 
ERK1/2. 
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Figure 3.12 Effect of recombinant resistin in HUVEC lysates: Human 
umbilical vein endothelial cells were treated with 50ng/mL resistin for 15 minutes 
and phosphorylation of Akt and ERK1/2 was compared to untreated basal. 
Lysates of the above conditions were prepared using RIPA buffer and equal 
amounts of protein were loaded on 12% SDS-PAGE prior to immunoblotting 
using the indicated antibodies. p38 is the loading control. Image is 
representative of one duplicate of the experiment. 
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With confidence that recombinant human resistin affected signalling in human 
cells, it was further tested in human blood platelets to understand if there were 
similarities in signalling effects of resistin. Phosphorylation of PKC substrates in 
relation to signal transduction events like adhesion, secretion and cell migration 
upon external stimulation has been previously noted in literature (Newton, 1995; 
Murugappan et al., 2004; Cimmino and Golino, 2013) and from our observations 
can be extended to stimulation by resistin.  
In order to assess resistin effect in platelets, platelets were treated with 
200ng/mL resistin for 30 minutes. A positive marker for PKC activation is 
phosphorylation of its substrates at Ser residues surrounded by Arg or Lys at 
the -2 and +2 positions and a hydrophobic residue at the +1 position on PKC 
substrates. PKC substrate phosphorylation levels upon resistin treatment were 
compared to basal levels in platelets. Interestingly, three independent 
experiments showed an increase in total PKC substrate phosphorylation in 
response to resistin stimulation. Figure 3.13 represents an array of proteins that 
were phosphorylated at Ser residues on PKC substrates more than in the basal 
platelet lysates.  
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Figure 3.13 Phosphorylation of PKC substrates: PKC dependent serine 
phosphorylation in basal and resistin treated (200ng/mL - 30 minutes) platelet 
whole cell lysate (8 x108 /mL) was identified by immunoblotting using a 
phosphor-serine PKC substrate antibody. Ladder is indicated by (L) in the 
image. Densitometric measurements were carried out to observe change in 
phosphorylation. Values for the whole lane are indicated at the bottom of the 
respective lanes. The values in the adjacent boxes indicate respective locations 
of the rectangles identified in the lanes –these are specific proteins that would 
potentially be of interest as they show maximum change in phosphorylation 
upon resistin treatment. 
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Further, involvement of resistin in PKA and PKG activation was evaluated to 
underscore the effect of resistin on thrombin induced aggregation. Increased 
PKA/PKG activity due to resistin treatment would support the argument in favour 
of platelet inhibition as opposed to platelet pre-activation. 
Phosphorylation of VASP at two distinct serine residues 157 and 239 were used 
as markers of PKA and PKG activation respectively. Known PKA and PKG 
activators, PGI2 and S-nitrosoglutathione (GSNO), respectively, were used as 
positive control to assess relative platelet activation. Basal and 200ng/mL 
resistin treated platelets were compared using one-way ANOVA. The 
phosphorylation of VASP at both serine residues 157 and 239 are statistically 
significant (p<0.05) when comparing basal to PGI2. All other comparisons are 
not significant. As the aggregation traces and relevant protein kinase inhibitors 
indicating these compounds were functionally competent are lacking, the 
tentative conclusion drawn from the graphs in Figure 3.14, is that resistin most 
likely does not have an effect on PKA or PKG activation. 
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Figure 3.14 Effect of resistin treatment on PKA and PKG activation of 
platelets: Whole cell lysates of 8 x 108 /mL platelets stimulated using 200ng/mL 
resistin (30minutes) (Res), 100µM prostaglandin I2 (5 minutes) (PGI2) and 20µM 
S-Nitrosoglutathione (20 minutes) (GSNO) were tested using immunoblotting for 
phosphorylation of VASP Serine 157 and Serine 239. Lysates containing equal 
total protein were loaded on 12% SDS-PAGE before immunoblotting using the 
indicated antibodies. Densitometry data are normalised first, to loading control 
(GAPDH) and then calculated relative to basal (untreated) whole cell lysates. 
Data represent mean ± standard error of the mean of three independent 
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experiments. Statistical significance is calculated using one-way ANOVA 
(*p<0.05). 
  
180 
 
As it was noted in smooth muscle cells and endothelial cells (Calabro et al., 
2004) that resistin stimulation caused phosphorylation of PI3K/Akt and MAPK, a 
similar test was carried out using platelets. Phosphorylation of Akt, as a marker 
for PI3K activation (Steppan et al., 2005), and phosphorylation of ERK1/2, as 
indicator for MAPK activation, were investigated in platelets treated with in 
200ng/mL resistin for 30 minutes. As seen in Figure 3.15, phosphorylation of Akt 
at Ser473 was significantly increased (p<0.001). Phosphorylation of ERK1/2 
was also significantly increased (p<0.01) at only one site of phosphorylation. 
Unfortunately, the site of phosphorylation could not be positively identified as 
being either threonine 202 or tyrosine 204 in this preliminary assessment. 
Despite this, it can be convincingly deduced that downstream effectors of PI3K 
and MAPK are involved in stimulation of platelets in response to resistin. As 
resistin itself did not stimulate or cause aggregation of platelets, it can be 
implicated to have an effect on PI3K and MAPK pathways. 
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Figure 3.15 Activation of PI3K and MAPK: Phosphorylation of AKT and 
ERK1/2 in basal and resistin treated (200ng/mL - 30 minutes) platelet whole cell 
lysate (8 x108 /mL) was measured by loading equal proteins (loading control 
GAPDH) on 12% SDS-PAGE and tested using immunoblotting for the indicated 
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antibodies. Densitometry data are normalised to loading control and 
represented as mean of three independent experiments ± standard error of the 
mean. Statistical significance was calculated using one-way ANOVA (*p≤0.01 
and **p≤0.001).  
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3.3 Discussion 
Resistin, like other adipokines including leptin and adiponectin, increases the 
risk of thrombosis in patients with T2DM (Bełtowski, 2003; Kato et al., 2006). 
Adiponectin stimulates fatty acids oxidation, decreases plasma triglycerides, 
and improves glucose metabolism by increasing insulin sensitivity. In platelets, 
adiponectin has a dual role; globular adiponectin induces platelet aggregation 
via GPVI-FcRγ interaction but not the full-length adiponectin (Riba et al., 2008), 
whereas full-length adiponectin inhibits platelet aggregation and activates eNOS 
to attenuate its response to oxidative stress (Wang et al., 2011). Leptin, another 
adipokine, described to play an important role in atherogenesis in obese 
patients with T2DM, has been revealed to elevate platelet aggregation 
responses via interactions with specific leptin receptor found in platelets 
(Konstantinides et al., 2001). 
In non-platelet cell models like monocytes and macrophages, leptin and resistin 
induce procoagulability in T2DM by upregulating PAI and t-PA, disturbing the 
balance of the fibrinolytic system (Bobbert et al., 2011). Additionally, full-length 
adiponectin inhibits resistin mediated induction of ICAM-1 and VCAM-1 in the 
vascular endothelial cell model (Kawanami et al., 2004). Together, above 
evidence indicates a potential role for adipokines in regulating each other in vivo 
or in disease states. 
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3.3.1 Resistin treatment causes a thrombin dependent reduction in platelet 
aggregation  
A prothrombotic role for resistin has been hypothesised owing to elevated levels 
found in circulation of patients suffering from metabolic syndrome (Jamaluddin 
et al., 2012;  Lee et al., 2014; Huang and Yang, 2015). Interestingly, we 
observed that resistin pre-treatment caused attenuation of platelet aggregation 
when stimulated via the GPCR targeting agonist thrombin, but not significantly 
when stimulated with the tyrosine kinase-activating agonist collagen.  This 
inhibitory effect of almost 30% of the untreated control was most pronounced 
when stimulation was carried out with 0.025U/mL dose of thrombin (Figure 3.2). 
The results suggested that resistin might affect the G-protein coupled receptor 
pathway that leads to integrin αIIbβ3 activation and PLC-related activation of 
PKC leading to αIIbβ3 activation (Li et al., 2010). The observation that endothelial 
cells and smooth muscle cells signal via TLR-4 and Gi/o pathway in response to 
resistin helps substantiate the claim that a GPCR pathway is affected in 
platelets (Pirvulescu et al., 2014). 
We report that as dose and time of resistin pre-treatment increased, the platelet 
aggregation reduced significantly (Figure 3.4 and 3.5). The experiments helped 
to identify 30 minutes and 200ng/mL resistin doses as ideal for all experimental 
purposes. Under physiological conditions, 0.1U/mL-10U/mL thrombin 
concentrations are present at the site of a haemostatic plug (Angiolillo et al. 
2010), whereas lower doses seem to make platelets prone to activation without 
causing aggregatory effects. In vitro however, since platelets are devoid of 
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plasma containing clotting factors and they are not subjected to circulation 
where agonists undergo continuous dilution, 0.025U/mL thrombin is sufficient to 
cause significant aggregation even in untreated platelets, as seen in Figure 3.2. 
Hence, it makes for a very interesting observation that only 0.025U/mL thrombin 
stimulation caused reduction of aggregation of resistin pre-treated platelets 
whereas higher and lower doses of thrombin caused minimal inhibition. 
These observations therefore led to the preliminary conclusion that platelets 
were inhibited by resistin and that the inhibition levels increased with higher 
doses and longer incubation times. On prolonged resistin exposure platelets 
were basally inhibited compared to untreated control. This inhibition, therefore, 
caused them to aggregate less and not reach similar aggregation levels as 
untreated controls post thrombin stimulation.  
 
3.3.1.1 Resistin negatively affects platelet dense granule secretion. 
Since a higher dose of thrombin, 0.1U/mL instead of 0.025U/mL had to be used 
to assess detectable difference in platelet aggregation with the secondary 
aggregation inhibitors, it wasn’t sufficient to make conclusions about the effect 
of resistin on secondary platelet responses. Further analysis of dense granule 
secretion was carried out to clarify the effect of resistin.  
It was observed that 200ng/mL resistin caused a significant decrease in ATP 
release when stimulated with 0.025U/mL thrombin, which suggested that dense 
granule secretion was attenuated by resistin treatment. Although not 
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investigated in this chapter, α-granule secretion by platelets, using P-selectin 
(released from α-granules on platelet activation)  was carried out by Qiu et al., 
(2014). They show a concentration dependent increase in P-selectin expression 
after resistin treatment of platelets. The P-selectin expression was further 
enhanced upon resistin treatment of platelets with subsequent thrombin 
stimulation. Their study lacks key controls making it difficult to make definitive 
conclusions. If their conclusions are assumed to be true and correct, then it 
would suggest that that resistin might differentially affect alpha and dense 
granule secretion. The suggestion that granular systems are uniquely affected 
by chemical agents has been previously shown in literature with regards to the 
actin cytoskeletal inhibitors like cytochalasin E (Flaumenhaft et al., 2005). 
The inhibitory effect of resistin was further substantiated by examining the 
results in presence of secondary aggregation mediators like TXA2 and ADP 
(Flaumenhaft, 2003) as discussed ahead. The caveat here is that a higher dose 
of thrombin was used, thus making an unbiased conclusion difficult (see section 
3.2.2). In order to circumvent the issue of incomparable data, owing to 
difference in agonist concentration, another experimental set up could be used 
to give more definitive conclusions. An investigation into P-selectin expression 
in response to thrombin receptor agonists, which is a platelet marker for 
procoagulability, could be assessed using FACS. Experimental set up would 
include positive controls for the thrombin receptor agonists, in addition to 
independent controls for each inhibitor (resistin, indomethacin, apyrase), before 
using a combination of the inhibitors in tests. The increase or decrease in P-
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selectin exposure in platelets in response to inhibitors would allow for unbiased 
conclusion in understanding if platelets are truly inhibited in the presence of 
resistin. This would also shed light on the effect resistin has on secondary 
activation mediated by α-granule secretion in platelets, either supporting or 
rejecting the data presented by Qiu et al (2014) and the hypothesis of 
differential regulation of α- and dense granule secretion by resistin (Flaumenhaft 
et al., 2005). 
 
3.3.3 Resistin affects integrin αIIbβ3-mediated surface area distribution of 
platelets 
When investigating the effects of resistin on platelet adhesion on immobilised 
fibrinogen, it was observed that there were no apparent differences between 
resistin treated and control platelets. Similarly, there were no significant 
differences in the average surface area of platelets between resistin pre-
treatments and control. Remarkably though, when frequency distribution of 
surface area was plotted, more resistin-treated platelets had larger surface area 
when spread on immobilised fibrinogen compared to their respective controls, 
suggesting that resistin affected platelet cytoskeletal proteins. There was lack of 
any obvious difference between the experimental groups in their platelet 
morphology markers- number of platelets displaying actin nodules and/or stress 
fibres. Nevertheless, visual observation indicated that resistin-treated platelets 
contained more number of actin nodules than their respective controls. It was an 
observation that was very difficult to quantify owing to the fact that there were 
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large number of actin nodules present per platelet. Additionally,these actin 
nodules lay in different planes and not always clearly visualised, thus 
introducing error due to the lack of accuracy in identifying spots as actin nodules 
from background noise.  
Previous research by Calabro et al. (2004), has shown that human aortic 
smooth muscle cell proliferation is promoted by resistin via activation of ERK1/2 
and PI3K pathways, which suggests that the cytoskeletal differences in resistin-
treated platelets could be owing to activation of similar pathways in platelets. 
The reason for the derivation being that cell proliferation pathways coincide with 
cytoskeletal pathways (Parise, 1999; Barry et al., 2003; Woulfe et al., 2004a; Li 
et al., 2010; Senis, Mazharian and Mori, 2014).  
Further, in the experiment where secondary aggregation was blocked using 
inhibitors like indomethacin and apyrase, the frequency distribution of surface 
area highlighted relatively large size of platelets when compared to similarly 
inhibited platelets that were also treated with resistin. Pre-treatment with 
inhibitors obstructed the granule secretion and therefore explains the lack of 
higher surface area platelets in the resistin treated groups. This corroborates the 
previous observation from aggregation and secretion data (section 3.2.1.6) that 
resistin affects platelet granule secretion, which consequently causes platelets 
to spread more and have larger surface area in the resistin treated groups when 
compared to control, as seen in the sections, 3.2.2.1 and 3.2.2.2. 
 
189 
 
Platelet cytoskeleton is responsible for transporting granules to the centre of 
platelet during stimulation, where the secretome is released. As granule 
secretion is tightly regulated by the platelet cytoskeleton (Flaumenhaft, 2003; 
Murugappan et al., 2004; Woulfe et al., 2004a; Flaumenhaft et al., 2005; Zelen, 
2012), it was important to understand if it was the cytoskeleton that was affected 
by resistin treatment. CAP1, which is an actin binding protein (Moriyama and 
Yahara, 2002; Jansen et al., 2014), was recently shown to be a receptor for 
resistin ( Lee et al., 2014) and its presence and function in platelets will be 
investigated in the following chapter 4. 
 
3.3.5 Resistin affects downstream effectors of PI3K and MAPK pathways 
PKC substrate activation occurs downstream in platelets undergoing GPCR-
related stimulation (Parise, 1999; Murugappan et al., 2004; Watson et al., 2005; 
Cimmino and Golino, 2013). Evidence of elevated PKC substrate 
phosphorylation at serine residues was observed in resistin-treated whole cell 
lysates compared to basal platelet lysates thus introducing a contradiction to the 
observation that resistin inhibits platelets. Interestingly, a study investigating a 
downstream effector of PKC, PKD2, showed a similar inhibition pattern of 
differential granule secretion in its gene knock-in mouse model. They show that 
dense granule release and secretion is affected but not α-granule secretion 
(Konopatskaya et al., 2011). It may be that resistin alters phosphorylation sites 
downstream of PKC activation as an inhibitory mechanism in platelets, as yet 
undefined. 
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Additionally, the minimal phosphorylation upon PKA and PKG activators (PGI2 
and GSNO, respectively) further substantiates the lack of activation of the 
traditional platelet inhibition pathways, suggesting that alternative inhibitory 
mechanisms in platelets were activated in response to resistin exposure of 
platelets.  
Due to constraints in the availability of inhibitors of the respective AGC kinases, 
confirmation of resistin activity was sought by investigating its known activators - 
PI3K effector protein Akt and MAPK effector protein, ERK1/2 (Calabro et al., 
2004). Statistically significant phosphorylation of Akt and ERK1/2 in resistin 
treated whole cell lysates was observed on comparison with control. This meant 
that the mechanism of action of resistin clearly involved activation of PI3K and 
MAPK in platelets. Although enhanced phosphorylation of ERK1/2 was 
observed in smooth muscle cells (Calabro et al., 2004) contradicting data was 
shown in platelets ( Qiu et al., 2014), which suggested that p38 MAPK was 
phosphorylated in response to resistin and not ERK1/2 by assessing P-selectin 
expression using their respective inhibitors. The lack of immunoblotting data 
supporting the observation by Qiu et al., (2014), that resistin treatment of 
platelets caused selective phosphorylation of p38 instead of ERK1/2 meant that 
firm conclusions cannot be sought in the literature for identifying which or if 
multiple MAPK proteins’ phosphorylation affected resistin activity in platelets. 
Evidence by Flevaris et al., (2009) show that phosphorylation of p38 and 
ERK1/2 in platelets is transient in nature owing to its negative regulation by 
integrin outside-in signalling. Put together, these observations conflicts with the 
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results from Qiu et al. (2014) where they only assessed platelets for P-selectin 
expression. 
Phosphorylation of Akt is mediated by PI3K and evidence only adds strength to 
the evidence from literature relating to resistin activity (Steppan et al., 2005). 
Another interesting observation from platelets isolated from Akt2 deficient mice 
was that they present an agonist-specific defect (Gq and Gi receptor binding– 
like thrombin) in platelet aggregation, fibrinogen binding and secretion (Woulfe 
et al., 2004a), all of which were overcome at higher agonist concentrations, 
similar to observations from resistin-treated platelet aggregation (Figure 3.2). 
Further, another research group showed that Akt2 deficient mice present T2DM 
like  IR and impaired glucose homeostasis (Cho et al., 2001).  
All the evidence together with observations from resistin-treated platelets 
suggests that resistin causes attenuation of platelet aggregation and dense 
granule secretion response. Prolonged resistin exposure also affects the platelet 
cytoskeleton by causing them to spread more than control platelets. 
Biochemical signalling data however, contradicts the inhibition hypothesis in 
response to resistin. Although resistin inhibits platelets, it can be inferred that it 
likely occurs downstream of GPCR-related agonist activation, PKC activation, 
and is mediated by Akt/PI3K and tentatively by ERK1/2 MAPK. This also 
suggests that alternative, as yet undefined platelet inhibitory pathway must be 
activated by resistin exposure, thus dampening the platelet aggregation and 
secretion responses to thrombin.  
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3.3.6 Extension of the study of resistin effect on platelet function 
Resistin levels in circulation vary greatly between individuals. Further, the 
observations made in this chapter that prolonged exposure to high doses of 
resistin affects platelet function makes it necessary to step back and look at the 
circulating resistin levels in the healthy blood donors prior to blood donation. In 
order to facilitate the analysis and normalise the overall resistin exposure in 
vitro, an estimation of serum resistin levels using ELISA kits that are 
commercially available, prior to experimentations would have improved the 
credibility of the results. Once this estimation was carried out, it would provide 
ideal conditions to study effect of thrombin in resistin treated plasma using 
thrombin receptor agonists, PAR1 or PAR4 to isolate the potential downstream 
pathways that are triggered. 
Insulin is known as a platelet inhibitor (Trovati et al., 1997; Santilli et al., 2016). 
Since resistin is believed to work antagonistically to insulin, a direct comparison 
of the two (insulin and resistin) in platelet aggregation would improve the 
conclusions of the experiments, thus providing a clearer context to resistin 
effects on platelet activity. 
Limitations of this chapter in elucidating the complete mechanism of action of 
resistin on platelets are owing to lack to negative controls to give more 
confidence in the data obtained. Rosiglitazone, a TZD and a generic PPARγ 
inhibitor, known to sensitise cells to insulin, has been previously used as a 
resistin inhibitor by  Steppan et al. (2001), in experiments to aid more robust 
conclusions, although, admittedly, it is not a resistin-specific inhibitor.  
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Since resistin plays a key role in glucose metabolism (Nogueiras et al., 2009), 
glucose enriched media, glucose analogues, or use of sugars not recognised by 
insulin receptors, to study aggregation, adhesion, and secretion in platelets in 
the presence and absence of resistin would have enabled a better 
understanding of its role in glucose homeostasis with reference to thrombosis.  
The observation that platelet cytoskeleton was affected when platelets were 
exposed to resistin meant that interesting findings can be sought by 
depolymerising actin using various cytoskeleton disrupting agents like 
latrunculins and cytochalasins to assess if resistin effects were altered in any 
way. 
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CHAPTER 4 
 CHARACTERISATION OF CAP1 IN THE PLATELET 
CYTOSKELETON 
 
In chapter 3, when platelets were exposed to resistin, a cytoskeletal effect was 
observed owing to mild activation of platelets. Actin rearrangement drives 
platelet activation by receptor mediated signalling mechanisms. Platelets 
change shape when they adhere to blood vessel wall and spread by flattening at 
the site of injury. In this process, platelets are required to reorganise their 
cytoskeleton to accommodate for the shape change. Membranes of activated 
platelets undergo changes in lateral distribution of glycoprotein and integrin 
receptors to achieve directional spreading (Li et al., 2010). Actin 
assembly/disassembly and proteins involved therein during this reorganisation 
elicit a number of physiological responses of platelets like formation of filopodia 
and lamellipodia and granule release including signal transduction pathways 
with active participation of actin associated proteins (Hartwig, Steffen and Cell, 
1992). This process of receptor redistribution then triggers inside-out signalling 
pathways which change the conformation of major platelet integrins like αIIbβ3, 
all of which act in a paracrine manner to help recruit more platelets to the site of 
repair (Shattil and Newman, 2004).  
One of the major functions of CAP1 lies in actin rearrangement and turnover, 
details of which can be found in section 1.5 of the introduction (Figure 1.7). 
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In a recent study, CAP1 was identified as a receptor for resistin ( Lee S et al., 
2014). In CAP1 knockdown and overexpression monocyte cell models, the 
authors showed that the effects of resistin - NF-ƙB mediated cytokine 
expression and PKA activation were modulated by CAP1. They also showed 
that the SH3-binding domain (P1 domain) (Figure 1.8) of CAP1 was responsible 
for binding resistin. The main criticism of this publication is that CAP1 is not a 
transmembrane protein and is therefore unlikely to bind resistin under 
physiological conditions as resistin binds receptors on the plasma membrane. 
Alternatively, internalisation of resistin by cells has not been reported. Most 
importantly, a possible role of CAP1 in activation of adenylyl cyclases in 
mammalian cells has not been elucidated yet (Ono, 2013; Zhou, Zhang and 
Field, 2014).  
In the light of our evidence that resistin affects the platelet cytoskeleton, in 
addition to the potential link between resistin and CAP1, as a resistin receptor, 
along with CAP1 playing a major role in actin rearrangement, we aim to 
investigate the role of CAP1 in platelet biology. In this chapter, we characterise 
CAP1 subcellular localisation in resting platelets and in platelets stimulated by 
activation of distinct signalling pathways, as an initial step in establishing the 
role of CAP1 in platelet actin dynamics and how it might be affected in the 
presence of resistin. 
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4.1 Aims and objectives 
CAP1 is an important actin regulatory protein and yet there are no reports 
investigating CAP1 in human platelets (Gieselmann and Karlheinz, 1992). A 
lack of information on the presence and distribution pattern of CAP1 in human 
platelets therefore prompted us to initially investigate these aspects. The current 
chapter therefore aims to establish the presence of CAP1 in human blood 
platelets and examine the effect of agonist stimulation on the subcellular 
localisation of CAP1. 
The objectives are: 
1. Characterise the localisation and distribution of CAP1 in human platelets 
using immunofluorescence and multiple subcellular fractionation 
approaches 
 
2. Investigate the dynamics and actin dependence of CAP1 localisation 
upon thrombin and collagen stimulation  
 
3. Investigate the dynamics of CAP1 localisation upon prostacyclin 
treatment and assess how it affects the changes elicited by subsequent 
thrombin stimulation  
 
4. Preliminary assessment of the effect of resistin on CAP1 distribution 
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4.2 Results 
4.2.1. CAP1 in resting platelets 
4.2.1.1 Characterisation of CAP1 antibodies 
Prior to collecting data using the anti-CAP1 (rabbit monoclonal -ab133655, 
Abcam, UK) antibody it was important to characterise it for its specificity towards 
CAP1 in human platelets. 
In order to test if the antibody could identify the presence of CAP1 in human 
platelets and be reliably used to quantitate a range of CAP1 concentrations, 
varying amounts of whole platelet lysates of known total protein concentration 
were immunoblotted for CAP1. CAP1 protein is ~55-60 kDa and a clear band at 
56 kDa is observed in the blot presented in Figure 4.1 A indicating that the 
antibody was highly specific to CAP1. Additionally, it was observed that an 
increase in protein concentration was accompanied by a proportional increase 
in band density. 
GAPDH, which is a cytosolic marker, was used as a loading control and 
proportional variations were observed in the control as well, indicating that there 
was no loading error. We conclude that anti-CAP1 antibody was a reliable tool 
to study CAP1 in human platelets. 
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Figure 4.1 Specificity of anti-CAP1 antibody: (A) Variable protein 
concentrations of human blood platelets. Whole cell lysate of human 
platelets (3 x108 /mL platelets) was loaded (between 50µg - 5µg total protein), 
resolved on 12% SDS-PAGE, blotted onto PVDF membrane and probed with 
antibodies for the indicated proteins, where GAPDH is a loading control. (B) 
Various animal tissue and cell line lysates (30µg total protein) were 
resolved on a 12% SDS gel, blotted onto PVDF membrane and probed with 
antibodies for CAP1. The blots were probed for beta-actin as a loading control. 
Human platelets (Hs platelets), human melanoma (Hs melanoma), human 
colorectal cancer cell line (HT29), human embryonic kidney 293 cell line (HEK), 
human umbilical vein endothelial cells (HUVEC), fibroblast-like tissue from 
monkey kidney tissue (Cos 7), murine (Mm) and bovine (Bt) tissue lysates were 
prepared from freshly collected tissue from culled animals or from cultured cells. 
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(C) Investigating the localisation of CAP1 in platelets using different 
fixation methods. Human platelets (2 x107 platelets/mL) were allowed to 
spread on fibrinogen-coated (100µg/ml) coverslips for 30 minutes and were 
fixed using either ice-cold methanol or 4% paraformaldehyde for 20 min. The 
platelets were then permeabilised and immunostained using anti-CAP1 antibody 
and Alexa 568-coupled secondary antibody. Images were captured using a 
fluorescence microscope. Scale bar = 10µm 
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Various animal tissue lysates were obtained and samples were resolved and 
blotted to investigate the specificity of the anti-CAP1 (rabbit monoclonal 
ab133655) antibody. Figure 4.1 B shows that only human and monkey cells/cell 
lines gave positive results for presence of CAP1.  
Human platelets were chosen as they were the main tissue type of interest 
followed by human melanoma cells from a patient and HT29, a colorectal 
cancer cell line, as altered CAP1 expression in cancer cells has been reported 
previously (Li et al., 2013; X. Liu et al., 2014). Human embryonic cell lines like 
HEK and HUVEC were also investigated. Most importantly we validate the 
presence of CAP1 in human blood platelets.  
The anti-CAP1 antibody (ab133655) did not identify the CAP1 protein in murine 
or bovine tissue lysates. However, unpublished work from our lab using an 
alternate CAP1 antibody has detected CAP1 in murine platelets. Previous 
research in CAP1 has illustrated that most murine tissues including heart, lungs 
and liver expressed CAP1 in abundance and skeletal muscle expressed the 
least CAP1 (Peche et al., 2007; Kosmas et al., 2015). The β-actin control shows 
that there indeed was protein transferred after a Western blot and that it was not 
a loading error. It can therefore be concluded that the ab133655 antibody 
specifically recognises human CAP1 and cannot be used to investigate CAP1 
expression in murine and bovine samples. 
 
201 
 
 
A suitable fixation method for spread human blood platelets needed to be 
identified for use of anti-CAP1 in immunofluorescence experiments to assess 
CAP1 localisation. Two common fixatives, ice-cold methanol and 4% 
paraformaldehyde (PFA) were tested for their effectiveness on platelets spread 
on fibrinogen (Figure 4.1 C). Reassuringly, the localisation of CAP1 was similar 
using both fixatives but the appearance of CAP1 varied - PFA fixation led to 
more punctate staining of CAP1, whereas methanol fixation led to more 
continuous staining along the cortical regions. Overall, ice-cold methanol fixation 
gave clearer and more defined localisation signals for CAP1 than 4% PFA. 
Phalloidin, which specifically stains F-actin, cannot be used in conjunction with 
methanol fixation as methanol disrupts actin during fixation, thus leading to 
inaccurate representation of actin when stained with phalloidin (Small et al., 
1999). Therefore, 4% PFA was deemed the preferred method of fixation as it 
provided relatively better conditions for immunostaining for CAP1 and allowed 
visualising actin filaments simultaneously without compromising on the quality of 
staining. 
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4.2.1.2 Subcellular localisation of CAP1 in resting platelets 
Platelets are highly specialised cell fragments which made it very important to 
verify if the localisation of CAP1 is similar to that observed in other cell types. It 
is known from several other cell types and various organisms that some CAP1 
localises at the cell cortex and most of it is cytosolic (Peche et al., 2007; Lee et 
al., 2014). 
 
4.2.1.2.1 Visualisation of CAP1 in spread platelets 
In order to visualise the CAP1 distribution platelets were spread on fibrinogen-
coated or on collagen-coated coverslips, fixed, permeabilised, immunostained 
using anti-CAP1 antibody and counterstained with FITC-phalloidin for actin. It 
was observed (Figure 4.2 A and B) that CAP1 is mostly cytosolic with some 
peripheral localisation. CAP1 co-localises with actin in the cortical regions but is 
missing near the cytosolic regions presenting stress fibres. CAP1-actin co-
localisation is also observed centrally, where the platelet granulomere is 
expected. 
 
4.2.1.2.2 Subcellular distribution of CAP1 
In order to quantify CAP1 distribution we carried out a simple subcellular 
fractionation.  Resting platelets were resuspended in an isotonic sucrose 
solution and lysed using rapid freeze-thaw in liquid nitrogen before spinning 
them at 100,000xg to separate cytosol and membrane fractions. As seen in 
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Figure 4.2C, most (77%) of CAP1 is cytosolic and the rest associates with the 
membrane fraction. CD36, a platelet membrane marker and Syk, a cytosolic 
marker in resting platelets confirmed that membrane and cytosol fractions were 
free from cross-contamination. 
Since CAP1 is an actin-binding protein, further investigations were made to 
identify if this membrane association is actin mediated. Resting platelets were 
treated with Latrunculin B (LatB, 20µM) to depolymerise F-actin prior to 
subcellular fractionation. 
There was no statistically significant difference in CAP1 association to the 
membrane in the absence (23%) or presence (27%) of LatB using Student’s t-
test and therefore it can be inferred that the association of CAP1 to platelet 
membranes is independent of its association with F-actin. 
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Figure 4.2 Subcellular localisation and distribution of CAP1. Platelet 
spreading: Human blood platelets (2 x 107 platelets) were allowed to spread on 
(A) fibrinogen coated coverslips or (B) collagen coated coverslips. Platelets 
were fixed, immunostained for CAP1 (Alexa 568, secondary antibody, red) and 
counterstained for actin filaments (FITC-phalloidin, green). Scale bar = 10µm. 
(C) Subcellular fractionation: Human blood platelets (8 x 108/mL platelets) 
were lysed by freeze-thaw in liquid nitrogen. Samples were then spun at 
100,000xg for 1 hour to separate membrane and cytosolic fractions. The 
cytosolic (C) and membrane (M) fractions were normalised by volume and 
resolved on 12% SDS-PAGE gel, blotted onto PVDF membrane and probed 
with antibodies for the indicated proteins. CD36 was used as membrane marker 
and Syk as a cytosolic marker in resting platelets. Latrunculin B (LatB; 20µM; 20 
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min) was used to depolymerise F-actin prior to lysis. CAP1 distribution was 
quantified by densitometry and expressed as percent relative to the total CAP1 
in the lysate. Data are presented as mean ± standard deviation of two 
independent experiments. 
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4.2.1.3 Association of CAP1 to the detergent insoluble pellet 
The most described role of CAP1 in mammalian cells is in coordinating actin 
turnover. In order to assess this role in platelets, detergent insoluble fractions of 
platelets were isolated. The rationale behind isolating this pellet lies in the fact 
that most proteins are soluble in detergents, but actin filaments and associated 
proteins remain insoluble. The contents of the insoluble fractions depend on the 
extent of crosslinking of the actin filament networks and can be sedimented at 
various g-forces from the detergent lysates. Most of the actin filaments are 
cross-linked into networks that can be sedimented at low speed (15,600xg) 
(Fox, 2001). These are thought to represent the filaments that course 
throughout the body of the platelet. The filaments that are crosslinked to the 
plasma membrane and which form part of the membrane skeleton are 
sedimented at high speed (100,000xg). The proteins that are sedimented at this 
speed are associated with the lipid bilayer in the membrane (Fox, 1985; Fox et 
al., 1988). In order to characterise the association of CAP1 to actin in platelets, 
resting platelets were lysed in a buffer containing the detergent, Triton X-100, 
and separated into soluble and insoluble fractions by centrifugation at low and 
high speeds. Detergent soluble fraction is the supernatant and the insoluble 
fraction is the pellet containing F-actin and associated proteins. Supernatant 
comprises of mostly G-actin and its associated proteins. Experiments were 
carried out in the presence and absence of LatB, which was used to 
depolymerise F-actin. 
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Figure 4.3 Association of CAP1 to actin in detergent insoluble pellet. 
Human blood platelets (8 x 108/mL platelets) were lysed in the presence of 1% 
TX-100 and lysates spun at low speed (15,600xg) for 20 min and high speed 
(100,000xg) for 1 hour. (A) The supernatant (SN) and pellet (P) were 
normalised by volume and resolved on 12% SDS-PAGE gel, blotted onto PVDF 
membrane and probed with antibodies for the indicated proteins. Latrunculin B 
(LatB; 20µM, 20 min) was used to depolymerize F-actin prior to lysis. (B) CAP1 
concentration in pellet and supernatant were quantified by densitometry as 
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percent of total (pellet + supernatant). Data are presented as mean ± standard 
deviation of three independent experiments. 
 
 
In Figure 4.3 it was observed that CAP1 was not present in the low speed pellet 
where only long actin filaments and associated proteins are sedimented but 
strong bands for CAP1 appear in the high speed pellet, where membrane-
associated or lipid bilayer complexed cytoskeletal proteins are present. 17% of 
CAP1 was found in the high speed detergent insoluble pellet of resting platelets. 
Notably, no significant difference in CAP1 was observed in the LatB treated 
samples (19%). An important conclusion is that the presence of CAP1 in the 
high speed detergent insoluble pellet is independent of its association with actin, 
similar to the observations from the previous fractionation experiments (Figure 
4.2, Section 4.2.1.2.2) indicating that the membrane association was 
independent of actin. 
CD36, which is a membrane protein, is mainly observed in the supernatant, but 
significant amount remains in both the low and high speed detergent insoluble 
pellet, probably attached to lipid rafts. 
Syk and GAPDH, which are cytosolic proteins in resting platelets, were only 
observed in the supernatant fraction across the two isolation speeds, which 
confirmed the absence of cytosolic proteins in the pellets. 
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Further, cofilin and profilin, which are known to interact with actin in co-
ordination with CAP1 in actin turnover were also characterised in the samples to 
see if all results were consistent (Balcer et al., 2003; Zhang H et al., 2013). 
Interestingly, profilin is only observed in the supernatant, owing to its association 
to only monomeric actin. On the other hand, cofilin, which interacts with F-actin 
in addition to G-actin, is observed in high and low speed detergent insoluble 
pellets, but not in the low speed pellet of LatB treated platelets. Coronin1a, 
which specifically binds F-actin is observed in the low speed detergent insoluble 
pellet, but is absent when platelets were treated with LatB. Further discussion 
about these proteins can be found in the following chapter 5. 
In the following experiments, the behaviour of CAP1 will be examined only in the 
high speed detergent insoluble pellet. 
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4.2.2. Dynamics of CAP1 upon thrombin stimulation 
Thrombin is a potent platelet activator and causes cytoskeletal changes through 
G-protein coupled receptors PAR1 and PAR4, leading to shape change, platelet 
aggregation and spreading (Kahn et al., 1999; Coughlin, 2000) and 
subsequently in high speed detergent insoluble pellet to assess any potential 
effects on the localisation of CAP1.  
 
4.2.2.1 CAP1 moves away from the detergent insoluble pellet in response 
to thrombin stimulation 
To assess which concentration of thrombin would give a significant cytoskeletal 
change in platelets, different doses were tested in aggregation and 
subsequently in high speed detergent insoluble pellet. As seen in Figure 4.4 A, 
0.1U/mL thrombin caused the greatest response in terms of aggregation. In this 
particular case, less aggregation was observed for 0.5U/mL dose of thrombin 
compared to 0.1U/mL. Work in our and other labs show maximum aggregation 
response to thrombin at 0.1U/mL. 
CAP1 localisation was assessed in the presence and absence of the TXA2 
synthesis-blocker, indomethacin prior to thrombin stimulation to prevent 
paracrine activation of platelets. Platelets were treated with indomethacin (10µM 
– 20 minutes), followed by thrombin stimulation for one minute and lysis in 
buffer containing 1% Triton X-100 before centrifugation at high speed 
(100,000xg). 
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Figure 4.4 (from previous page) Response of CAP1 in detergent insoluble 
pellet upon thrombin stimulation: (A) Representative aggregation traces 
upon thrombin stimulation are shown. The X-axis shows the time post-
stimulation with agonist, while the Y-axis shows percent light transmitted 
through the platelet suspension. (B) Detergent insoluble high speed (HS) pellet 
upon stimulation of resting platelets with the indicated thrombin doses for 1 
minute followed by lysis in Tritin-X-100 based buffer. The experiment was 
performed in the presence or absence of indomethacin (10µM).  In all 
experiments, pellet and supernatant were normalised by volume and resolved 
on 12% SDS-PAGE gel, blotted onto PVDF membrane and probed with 
antibodies for the indicated proteins. Beta-actin was used as loading control. In 
the graph, CAP1 was normalised to the actin control and represented relative to 
the corresponding basal pellet samples. Data are represented as mean ± 
standard deviation of three independent experiments. Statistical significance 
calculated compared to basal using one-way ANOVA. (C) Actin concentration in 
pellet and supernatant of low speed samples (LS) were quantified by 
densitometry and expressed as percentage of platelet fraction. This percentage 
is represented relative to basal to enable clear visualisation of any changes. 
Data are presented as mean ± standard deviation of three independent 
experiments.  
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Interestingly, CAP1 in the high speed pellet decreased with increasing dose of 
thrombin. This decrease in CAP1 from the detergent insoluble pellet upon 
thrombin stimulation was more noticeable in the indomethacin pre-treated group 
(Figure 4.4 B). Although statistical analysis did not reveal any significant 
differences, the loss of CAP1 from the pellet after stimulation with thrombin is 
clear from the immunoblots. This observation will be investigated further to 
assess if the response is time dependent in the following sections of this chapter 
(4.2.2.4). 
In the high speed detergent insoluble pellet, 0.1U/mL and 0.5U/mL of thrombin 
both caused a significant increase in actin in the pellet fractions (data not 
shown, only representative blot in Figure 4.5 B). The change in actin 
concentration in the pellet was more apparent in the low speed pellets (Figure 
4.4 C) compared to high speed pellets, where smaller fragments of F-actin are 
sedimented skewing the results for total actin polymerisation.  
The expected actin response to thrombin stimulation is a significant increase in 
F-actin to aid platelet spreading; this was not clear in the high speed detergent 
insoluble pellet. As a confirmation of the anticipated actin response to thrombin 
stimulation of platelets, detergent insoluble pellets were obtained at low speed 
and actin concentration was evaluated upon thrombin stimulation in Figure 4.4 
C. The concentration of actin in the low speed pellet increased with increasing 
doses of thrombin and decreased in the supernatant thus providing a control 
measure for high speed detergent insoluble pellet experiments. 
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4.2.2.2 Time course of CAP1 translocation upon thrombin stimulation 
When platelets experienced dose-dependent thrombin stimulation, there was a 
shift in CAP1 concentration in the detergent insoluble pellet. We assessed this 
change in association of CAP1 further in a time course experiment. Platelets 
were stimulated with 0.1U/mL thrombin and the reaction was stopped with lysis 
buffer at time points from 15 seconds to 5 minutes after stimulation. High speed 
detergent insoluble pellets were then generated to assess any time-dependent 
changes in association of CAP1 to the detergent insoluble fraction. 
CAP1 concentration in the high speed detergent insoluble pellet shows a 
decrease of over 40% upon thrombin stimulation, becoming statistically 
significant after 3 minutes (80% reduction).  
In Figure 4.5, actin concentrations in the low speed detergent insoluble pellet 
shows a statistically significant increase compared to basal within 30 seconds, 
reaches a maximum (1.8 fold increase) around 60 seconds and decreases 
further to reach a plateau after that. This experiment helps to illustrate that F-
actin in the cytoskeleton increases after thrombin stimulation but a comparable 
increase cannot be noted in the high speed detergent insoluble pellet due to 
limitations that have been described previously (Section 4.2.1.3). Assessing the 
changes in actin in the high speed detergent insoluble pellet therefore does not 
give an accurate representation of the dynamic changes in F-actin concentration 
occurring after thrombin stimulation.  
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Figure 4.5 CAP1 in the high speed detergent insoluble pellet of thrombin 
stimulated platelets decreases with time. Human blood platelets (8 x 108/mL 
platelets) were stimulated with 0.1U/mL thrombin prior to lysis in Triton X-100 
based buffer and spun at high speed (100,000xg) for 1 hour. Only pellet 
samples were resolved on 12% SDS-PAGE gel, blotted onto PVDF membrane 
and probed with antibodies for the indicated proteins. CAP1 concentration in 
pellet was quantified by densitometry and expressed as values relative to the 
basal pellet fraction. The experiment was repeated with centrifugation at low 
speed (15,600xg) to indicate increase in actin in pellet. Data is represented as 
mean ± standard error of the mean of four independent experiments. Statistical 
significance relative to basal is calculated using one-way ANOVA, *p ≤ 0.05, **p 
≤ 0.005.  
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4.2.2.3 CAP1 translocates from membrane into cytosol upon thrombin 
stimulation 
The decrease in CAP1 in the high speed detergent insoluble pellet after 
thrombin stimulation suggested that there was CAP1 movement that occurred 
after activation. In order to further investigate this we observed changes in 
CAP1 in different platelet fractions upon thrombin stimulation. Platelet fractions 
were generated upon increasing duration of thrombin stimulation, from 15 
seconds to 3 minutes.  
Platelets were stimulated with 0.1U/mL thrombin and were subsequently 
fractionated into membrane and cytosol as previously described (section 
4.2.1.2). A clear reduction of CAP1 in the membrane fraction is observed with 
increasing time post-thrombin stimulation (Figure 4.6). A corresponding 
increase, as would be expected after thrombin stimulation, is not observed in 
actin, perhaps due to the fact that fractionation of platelets into membrane and 
cytosol is not based on the F-actin content. All CAP1 concentration values were 
therefore normalised to actin before normalising to basal values for this reason. 
CD36, which is a platelet membrane marker, shows no change in band 
intensities reinforcing that the lack of change in actin concentration is not a 
loading error. Further cytosolic control, GAPDH, confirms that all membrane 
fractions were devoid of cytosolic contamination. 
Consistent with observations in spread platelets, a statistically significant (p ≤ 
0.01, ANOVA) reduction of 50% membrane bound CAP1 is observed around 
30-60 seconds. Statistical significance in reduction of CAP1 in membrane 
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fractions further increases around 3 minutes (p ≤ 0.001, ANOVA) post-
stimulation. 
This is mostly consistent with the decrease in CAP1 concentrations in the 
detergent insoluble fraction as time after thrombin stimulation increases which 
suggests that the membrane association of CAP1 reduces and therefore less 
CAP1 associates with the detergent insoluble pellet which contains lipid raft 
associated proteins. Figure 4.2 has shown that membrane association of CAP1 
is actin independent, and together with observations from Figure 4.5, leads to 
the inference that CAP1 translocation occurs independent of its association with 
actin and most likely due to its association with lipid bilayer associated proteins 
in the platelet membrane. 
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Figure 4.6 Reduced membrane-associated CAP1 upon thrombin 
stimulation. (A) Human blood platelets (8 x 108/mL platelets) were treated with 
0.1U/mL thrombin for indicated times prior to lysis by freeze-thaw in liquid 
nitrogen. Samples were then spun at 100,000xg for 1 hour to separate 
membrane and cytosolic fractions and resolved on 12% SDS-PAGE gel, blotted 
onto PVDF membrane and probed with antibodies for the indicated proteins –
CD36, membrane marker; GAPDH, cytosolic marker. (B) CAP1 was quantified 
by densitometry and expressed relative to the CAP1 in the basal (0”) membrane 
fraction. CAP1 was normalized to actin in the membrane fraction. Data are 
represented as mean ± standard error of the mean of four independent 
experiments. Statistical significance is calculated using one-way ANOVA, *p ≤ 
0.01, **p ≤ 0.001 relative to 0”.  
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4.2.2.4 Visualisation of the effect of thrombin stimulation on CAP1 
localisation 
4.2.2.4.1 Visualisation on fibrinogen 
In order to visualise the CAP1 localisation upon thrombin stimulation, platelets 
were spread on immobilised fibrinogen (100µg/mL) for 30 minutes followed by 
stimulation with 0.1U/mL thrombin for increasing durations before fixing with 
PFA. 
Confirming the observations from Figure 4.2, most CAP1 is mainly cytosolic and 
some outlines the peripheral membrane in platelets spread on fibrinogen without 
additional stimulation. Upon stimulation of spread platelets with thrombin (Figure 
4.7), peripheral CAP1 seems to disperse into the cytosol with increasing length 
of thrombin stimulation. At 60 seconds, all CAP1 is cytosolic and negligible 
amounts localise near the periphery of platelets. After 3 minutes of thrombin 
stimulation, CAP1 seems more punctate and overall reduced but localisation 
appears more cortical than observed after one minute.  
A profile of CAP1 distribution was generated from the processed images which 
helps elucidate the movement of CAP1 from the membrane into cytosol in a 
time dependent manner upon stimulation with thrombin (Figure 4.8). It can be 
seen from the control image that peaks for presence of CAP1 at the membrane 
reduce dramatically after stimulation with thrombin and the loss from the 
membrane is the greatest around 60 seconds post-stimulation.  
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Figure 4.7 CAP1 re-localisation in spread platelets stimulated with 
thrombin. Human platelets (2 x 107 platelets) were allowed to spread on 
fibrinogen-coated coverslips for 30 minutes. This was the “control” condition. 
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Platelets were then stimulated with 0.1U/mL thrombin for the indicated times, 
fixed with 2% PFA and immunostained for CAP1 (red). Actin filaments were 
visualized by FITC phalloidin staining (green). Images were captured using a 
fluorescent microscope. Scale bar = 10µm 
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Figure 4.8 (previous page) CAP1 translocation profile upon thrombin 
stimulation of spread platelets. Human platelets (2 x 107 platelets) were 
allowed to spread on fibrinogen-coated coverslips for 30 minutes. This was the 
“control” condition. Platelets were then stimulated with 0.1U/mL thrombin for the 
indicated times, fixed with 2% PFA and immunostained for CAP1.  Images 
obtained in the previous figure (Figure 4.8) were further analysed by plotting a 
profile of CAP1 distribution across a spread platelet for each condition. Each 
yellow line in the left panel is represented as the cross-sectional profile of that 
platelet in the right panel. Using ImageJ, the signal intensity of CAP1 across the 
cross-section of a single platelet (Y-axis) was plotted against the arbitrary units 
of distance (X-axis). The changes in distribution pattern of CAP1 are evident 
with increasing stimulation with thrombin. 
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4.2.2.4.2 Visualisation on poly-L-lysine  
It was important to investigate if CAP1 translocation effect was evident only in 
spread platelets that have already undergone activation when adhering to 
fibrinogen matrix, or if this can already be visualised in platelets that were 
stimulated with thrombin in suspension. In order to achieve this, platelets were 
stimulated with 0.1U/mL thrombin in suspension, fixed and then adhered onto 
poly-L-lysine coated coverslips. The outcomes in a time course experiment were 
inconclusive as the platelets stimulated in suspension did not dramatically 
increase in size as observed on fibrinogen but maintained their discoid shape 
and some filopodia were observed in platelets stimulated with thrombin for over 
one minute (Figure 4.9). As the platelets remained in their smaller, discoid 
shape, visualisation of CAP1 changes in distribution was rendered impossible 
under available microscopy capabilities. 
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Figure 4.9 CAP1 visualisation of thrombin stimulation of platelets in 
suspension. Human platelets (2 x 107 platelets) were stimulated with 0.1U/mL 
thrombin in suspension in a time dependent manner, fixed with 2% PFA in 
suspension, followed by centrifugation at 4000xg to adhere to poly-L-lysine 
coated coverslips. Platelets were immunostained for CAP1 (red). Actin filaments 
were stained green with FITC-phalloidin. Scale bar = 10µm  
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4.2.2.5 Assessing involvement of thrombin receptor agonists in CAP1 
translocation from membrane to cytosol 
Thrombin stimulates platelets by cleavage of G-protein coupled receptor. 
Specifically, thrombin cleaves protease-activated receptors (PAR) and exposes 
tethered ligands to induce self-activation. Human platelets express two PARs – 
PAR1 and PAR4. It has been established that PAR1 and PAR4 differentially 
regulate downstream signalling in platelets (Coughlin, 2000). PAR1 is known to 
be activated at lower concentrations of thrombin compared to PAR4 (Kahn et 
al., 1999), and PAR4 leads to elevated thrombin production by mediating 
secretion and microparticle generation (Duvernay et al., 2013), and increased 
calcium mobilisation (Holinstat, 2006) compared to PAR1. The following 
experiment using PAR1-activating peptide – SFLLRN and PAR4-activating 
peptide AYPGKF to specifically target their respective PARs will enable us to 
evaluate their involvement during CAP1 translocation. 
PAR1-activating peptide did not alter CAP1 localisation in the membrane at 
higher doses but at very low concentration, it was comparable to response of 
0.1U/mL thrombin, with no statistical significance observed. PAR4-activating 
peptide on the other hand caused a moderate decrease in CAP1 concentration 
in the membrane at low concentration but indicated a dose-dependent increase 
to reach basal levels and a dramatic loss of CAP1 from the membrane at the 
highest tested dose of 100µM. It might be inferred from Figure 4.10, although 
insufficiently, that PAR4-activating peptide caused a greater translocation of 
CAP1 from the membrane to the cytosol compared to PAR1-activating peptide. 
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Figure 4.10 Subcellular localisation of CAP1 upon stimulation with 
thrombin receptor agonists: Dose response to thrombin receptor agonists 
PAR1 (SFLLRN) and PAR4 (AYPGKF) was compared to basal using 0.1U/mL 
thrombin stimulation as standard from previous experiments. Platelets were 
stimulation was for 3 minutes for each condition prior to subcellular fractionation. 
Membrane fractions were resolved on 12% SDS-PAGE and probed for the 
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presence of CAP1. CD36 was used as a loading control and marker for 
membrane fraction. Data represent mean of two independent experiments.   
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4.2.3. Dynamics of CAP1 distribution in collagen-stimulated platelets 
Collagen is one of the key platelet agonists and acts via activation pathways 
distinct to thrombin. It was therefore important to understand if the CAP1 
translocation event observed upon thrombin stimulation of platelets was agonist-
specific. Collagen concentration of 10µg/mL which resulted in maximal 
aggregation (as observed in figure 3.5) was used for stimulation to assess 
CAP1 translocation. Although collagen mechanistically acts in a different 
manner to thrombin, stimulation times used was three minutes to provide easy 
comparison between the two agonists. 
CAP1 localisation was simultaneously compared by fractionating platelets into 
membrane and cytosol and in high speed detergent insoluble pellet upon 
collagen stimulation. It was observed in Figure 4.11 that collagen stimulation did 
not cause any alterations in levels of CAP1 at the membrane or its cross-linking 
to the membrane based on the observations from the high speed detergent 
pellet. 
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Figure 4.11 Distribution of CAP1 in collagen stimulated platelets. 
Subcellular localization: Platelets were stimulated with 10µg/mL collagen and 
subcellular localization was compared to basal, untreated platelets. Detergent 
insoluble pellet: Platelets were lysed using a Triton-X 100 based lysis buffer and 
centrifuged at high speed (100,000xg) for one hour to separate pellet and 
supernatant. Cytosol and supernatant were 6 times more diluted than the 
corresponding membrane and pellet samples. All samples were resolved on 
12% SDS-PAGE and probed for the indicated proteins. Blots are representative 
of three independent experiments of subcellular fractionation and one detergent 
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insoluble pellet experiment. Data in bar graph are presented as mean ± 
standard error of the mean of three independent experiments.  
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4.2.4. Dynamics of CAP1 in PGI2 treated platelets 
In a recent study Lee et al. (2014) put forth their finding that CAP1 is a receptor 
to adipokine, resistin, which has been described in chapter 3. They present an 
increase in PKA activation recorded as a response to elevated secondary 
messenger (cAMP) upon exposure to resistin in a monocytic cell line 
overexpressing CAP1. A role for CAP1 in cAMP elevation and activation of 
adenylyl cyclases has been described in Saccharomyces but no such evidence 
has been documented in mammalian cells yet (Hubberstey and Mottillo, 2002; 
Ono, 2013).  
In platelets, PGI2 is known to activate PKA via adenylyl cyclase activation, thus 
inhibiting platelets (Aszódi et al., 1999). As an initial step in considering a role 
for CAP1 in PKA activation in highly specialised cells like platelets, an alteration 
in CAP1 localisation in response to PGI2 treatment was investigated. 
Figure 4.12 A clearly shows a dose dependent elevation of up to 50% in CAP1 
in the membrane fraction in response to 3 minute PGI2 treatment. Statistically 
significant increase in CAP1 level at the membrane was observed when 
platelets were treated with 100nM dose of PGI2. Phosphorylation of VASP at 
Ser157 is used as a positive control for PGI2 treatment. 
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Figure 4.12 Subcellular localisation of CAP1 upon stimulation with 
prostacyclin: (A) CAP1 localisation was assessed as dose response to 
prostacyclin (PGI2) and compared to basal, resting platelets. Platelets were 
treated with various doses of PGI2 for 3 minutes prior to subcellular 
fractionation. Only membrane fractions were resolved on 12% SDS-PAGE and 
probed for the presence of CAP1. Beta-actin was used as a loading control and 
pVASP as a treatment control. Data represent mean of two independent 
experiments. (B) Effect on CAP1 localisation upon PGI2 treatment followed 
by thrombin stimulation. Platelets were treated with 100nM PGI2 for 3 minutes 
followed by 0.1U/mL thrombin for further 3 minutes prior to subcellular 
fractionation. Membrane fractions were resolved on 12% SDS-PAGE and 
probed for the presence of CAP1. Beta-actin was used as a loading control. 
Data represent mean of two independent experiments.  
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4.2.4.1 CAP1 localisation upon PGI2 pre-treatment followed by thrombin 
stimulation 
PGI2, which is a known PKA activator, led to increased CAP1 association to the 
membrane. Thrombin, which is known to negatively regulate PKA activation, led 
to decrease in CAP1 association to the membrane. Although, PKA activation is 
not directly assessed in our experiments, a speculation can be made suggesting 
it might play a role in CAP1 translocation and initial investigations are made in 
this section.  
The logical step was to identify differences in CAP1 translocation from the 
membrane when platelets are pre-treated with PGI2 followed by stimulation with 
thrombin. As expected, 100nM PGI2 pre-treatment for 3 minutes followed by 
0.1U/mL thrombin stimulation for 3 minutes caused CAP1 levels in membrane to 
be higher when compared to thrombin stimulation alone and lower when 
compared to PGI2 treatment alone (Figure 4.12 B). When compared to basal, 
the difference in CAP1 localisation was not found to be statistically significant in 
any of the cases, but a trend is observed which would require substantially more 
data to corroborate it. 
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4.2.5. Dynamics of CAP1 in resistin-treated platelets 
In the study published by Lee et al. (2014) CAP1 is identified as a receptor for 
resistin mediating its role in inflammation. In the previous chapter (Chapter 3) 
we note that resistin pre-treatment caused an attenuation of the thrombin 
response in platelet aggregation. In the present chapter we show that CAP1 
translocated from membrane into cytosol upon thrombin stimulation. The above 
observations together prompted an investigation to establish CAP1 localisation 
upon resistin treatment. 
Platelets were treated with 0.1U/mL thrombin or 200ng/mL resistin and then 
fractionated into membrane and cytosol. As established before in Figure 3.5, 
24% CAP1 is membrane associated under basal conditions and the membrane 
association reduces upon thrombin stimulation to 15%. Interestingly, when 
platelets were treated with resistin, the membrane association of CAP1 greatly 
diminished compared to basal, at 11% (Figure 4.13). 
Clear conclusions cannot be derived from the observations as only one 
experiment was performed to test CAP1 localisation upon resistin treatment, but 
the definite reduction in CAP1 levels are promising and resistin pre-treatment in 
addition to thrombin stimulation would have added value to the observations. 
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Figure 4.13 Subcellular localisation of CAP1 upon resistin treatment: 
Platelets were treated with 0.1U/mL thrombin for 3 minutes or with 200ng/mL 
resistin for 15 minutes before fractionating them into membrane and cytosolic 
fractions. Samples were resolved on 12% SDS-PAGE and probed with anti-
CAP1 antibody. CAP1 concentrations were normalised to the whole cell lysates 
(assuming that whole cell lysate = membrane + cytosol) and values depicted in 
the graph are relative to the basal, untreated platelets from one experiment. 
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4.3 Discussion 
4.3.1 Membrane association of CAP1 is independent of its association to 
actin 
CAP1 which is a cytoskeletal, actin-binding protein, was interesting to study in 
human blood platelets owing to their rapid cytoskeletal reorganisation upon 
stimulation with agonists. It was reaffirming to find out that highly specialised cell 
fragments like platelets expressed CAP1 (Figure 4.1) and that the distribution in 
membrane (~20%) and cytosol (~80%) in resting platelets (Figure 4.2). The 
localisation of CAP1 in the cortical regions of cells was consistent with 
observations made in other cell types like Dictyostelium (Noegel et al., 1999), 
Arabidopsis (Deeks et al., 2007), fungi like Magnaporthe (Zhou et al., 2012), 
mitochondrial membrane association in mammalian cell lines (Wang et al., 
2008), and THP-1 monocytic cell line (Wakeel, Kuriakose and McBride, 2009; 
Lee S et al., 2014).  
Interestingly, depolymerisation of F-actin with LatB did not result in significant 
changes in the levels of CAP1 observed in the membrane fraction, which 
suggested that membrane association of CAP1 was independent of actin in 
resting platelets. Additionally, observations using the high speed detergent 
insoluble fraction of platelets (Figure 4.3), which contains F-actin and its 
associated proteins, confirmed that CAP1 behaved independently of actin. The 
presence of CD36, a membrane protein in the detergent insoluble fractions 
indicated that membranous proteins, most likely associated to lipid rafts, were 
also sedimented with actin-associated proteins. The observations together with 
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the cortical localisation of CAP1 signify high probability of CAP1 association to 
lipid rafts or other membrane associated proteins. Another speculation is 
derived that CAP1 might play a role at the membrane of platelets as a receptor 
or a protein closely bound to a transmembrane receptor, evidence for which has 
been recently shown by Lee et al., 2014, where they propose CAP1 to be a 
mediator of inflammatory responses by interacting with the cytokine resistin in 
monocytic cells. Further investigations into the platelet response to resistin and 
its effect on CAP1 affecting the underlying mechanisms of CAP1 at the 
membrane of platelets are discussed ahead. 
 
4.3.2 CAP1 translocates from membrane to cytosol upon thrombin 
stimulation 
Platelets regulate their dynamic shape change upon stimulation through a 
number of mechanisms. As an initial step in investigating a role for CAP1 in 
response to external stimuli, a potent platelet agonist which leads to cytoskeletal 
rearrangement, thrombin was tested in established experimental systems. Both 
in membrane and in detergent insoluble pellet, CAP1 levels diminished in a time 
dependent manner upon thrombin stimulation, making it a novel finding in 
platelet biology. The only reference to CAP1 translocation was described by 
Wang et al. (2008), where CAP1 shuttled actin to mitochondria in apoptotic 
mammalian cell line. Our observations suggested that although the membrane 
bound CAP1 does not interact with F-actin under resting state, it could likely be 
interacting with actin as it translocates from membrane into cytosol owing to the 
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fact that there is quantifiable increase in F-actin as it polymerises during shape 
change in platelets. 
This observation becomes more interesting by the fact that F-actin disassembly 
is required for normal granule secretion (Flaumenhaft et al., 2005) and that one 
of the key known functions of CAP1 is F-actin depolymerisation by binding 
cofilin ( Zhang H et al., 2013; Makkonen et al., 2013). Further experiments using 
LatB to depolymerise F-actin would have shed light on the actin dependence of 
the CAP1 translocation event. If CAP1 translocation is prevented or reduced 
after depolymerising F-actin, then it would prove that CAP1 translocation occurs 
because of its interaction with actin. If CAP1 translocation was dependent on 
actin, cytochalasins, which prevent actin polymerisation, would add to the 
understanding of the specific role CAP1 might play in stimulated platelets, 
where G-actin from cytoplasm polymerises to F-actin as platelet changes shape. 
Additional experiments using indomethacin (to block TXA2 signalling) and 
apyrase (to prevent ADP signalling) to block the platelet secretome release 
would clarify involvement of CAP1 in granule release as co-localisation of CAP1 
and actin was observed in fibrinogen spread platelets (Figure 4.8). 
In spread platelets (on fibrinogen), time dependence of translocation of CAP1 
from membrane to cytosol after thrombin stimulation was observed, suggesting 
that CAP1 might be involved in either aiding in actin turnover or might be 
involved in an actin independent event considering the platelets are already 
completely spread on fibrinogen having undergone prior stimulation and release 
of its secretome. Platelet secretome inhibition will give more information about 
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CAP1. The lack of evidence from thrombin-stimulated platelets in suspension 
makes further analysis of visualisation of CAP1 translocation controversial. 
It was recently documented that CAP1 provides a connection between actin 
cytoskeleton to mitochondria by shuttling actin in response to apoptosis-
signalling pathways (Wang et al., 2008). The authors also showed that CAP1 
translocates to mitochondria to promote apoptosis, an event which they prove is 
independent of actin binding. Considering subcellular fractionated platelet 
membrane fractions include all cellular and organelle membranes, this decrease 
might not be limited to peripheral membrane but an event occurring at organelle 
membranes, including mitochondrial membrane. These findings, therefore, add 
value to our CAP1 movement related observations so far and it would be 
interesting to investigate if CAP1 translocates to mitochondria in platelets as 
well. In light of the finding that resistin also causes similar translocation of CAP1 
from membrane into cytosol (Figure 4.6) together with the fact that resistin is 
intricately involved in mitochondria-regulated metabolism (Jamaluddin et al., 
2012) a potential biochemical link begins to emerge between CAP1 and resistin. 
 
4.3.3 PAR4 mediated PI3K pathway may be responsible for translocation 
of CAP1  
PAR1 and PAR4 differentially regulate platelet response upon thrombin 
stimulation (Coughlin, 2000; Duvernay et al., 2013). Observations that PAR4 
receptor agonist lead to CAP1 translocation equivalent to or greater than 
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thrombin indicated that PAR4 receptor was most likely involved in engaging with 
CAP1 directly or through other proteins that interact with CAP1 and aid in the 
translocation of CAP1 from the membrane.  
Evidence from inhibiting TXA2 signalling in figure 4.4, where CAP1 translocation 
is greater in indomethacin treated platelets compared to resting platelets 
suggesting a trend that secondary platelet mediators inhibit the movement of 
CAP1. This means that CAP1 might, at the membrane, potentially interact or 
bind GPCRs that are engaged when the platelet secretome is released after 
activation. This also helps explain the increase in CAP1 at the membrane at 
lower doses of PAR4 agonist but likely surpasses the interaction at higher 
doses. 
Evidence in the literature is that tethering of PAR4 at the membrane initiates 
activation of SFK which lie upstream of PI3K and work in conjunction with PKC 
to propagate PAR4 signalling to induce calcium mobilisation (Holinstat, 2006; 
Senis, Mazharian and Mori, 2014), by extension to the observations from CAP1, 
provide justification for investigation into PI3K dependent protein Akt. Also, a 
recent study in CAP1 signalling has demonstrated that a PI3K inhibitor caused 
modest stimulation in phosphorylation of CAP1 (Zhou et al., 2014). The 
activation of PI3K and MAPK have been previously reviewed under stimulation 
by thrombin in platelets (Li et al., 2010). 
A broad hypothesis can be formulated from figures 4.8, 4.9 and 4.10 that the 
decrease in membrane bound CAP1 upon thrombin stimulation follows a 
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comparable time pattern of increase in phosphorylation of the PI3K-dependent 
protein Akt and that a trend is observed, where PAR4 may be responsible for 
triggering it. 
It is further noted that the translocation of CAP1 is agonist dependent. The 
stable nature of membrane bound CAP1 in collagen stimulated platelets 
indicates that collagen has little effect on receptors or proteins interacting with 
CAP1 that enable its migration. From the lack of CAP1 translocation upon 
collagen stimulation, which is not dependent on GPCRs, together with evidence 
from thrombin and PGI2 stimulation, which are dependent on GPCRs, it can be 
deduced that CAP1 localisation is dependent on binding GPCR.  
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4.3.4 Membrane bound CAP1 increases in response to prostacyclin  
CAP1 studies in Saccharomyces cerevisiae have revealed a Ras-mediated 
elevation in cAMP levels owing to interaction of adenylyl cyclases and CAP1 
under nutritional deprivation. Hubberstey & Mottillo (2002) further suggest two 
independent roles for CAP1; one in modulating the PKA pathway by generation 
of secondary messengers (cAMP) and a second pathway independent of PKA 
in regulation of the actin cytoskeleton. Although mammalian CAP1 has not been 
shown to be involved in Ras signalling directly, the results from Lee et al. (2014) 
have shown CAP1-dependent changes in cAMP in a knockdown and 
overexpression monocytic cell model in response to resistin. They infer that this 
CAP1 dependent change in PKA activation is responsible for resistin-induced IR 
in monocytic cells, thus mimicking an equivalent event of nutritional stress. 
Hubberstey & Mottillo (2002) propose that CAP1 might be indirectly participating 
in PKA pathway via interacting with one or several of the Ras effector proteins, 
including PI3K and members of the Rho family of G-proteins that remodel the 
actin cytoskeleton. They propose this interaction might present links to a 
potential role for CAP1 in Ras signalling in mammalian cells. Further, there is 
scientific evidence that has shown decreased CAP1 phosphorylation in 
presence of a PKA activator (Zhou et al., 2014). 
PGI2, a physiological platelet inhibitor, is a known activator of the PKA pathway 
and activates, via GPCR, adenylyl cyclases (Goggs and Poole, 2012). PGI2 
treatment of platelets provided an ideal set up to assess CAP1 localisation 
during PKA activation. A dose dependent increase in membrane bound CAP1 
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was observed in PGI2 treated platelets. This indicated an increased association 
of CAP1 to the membrane in signal transduction pathway during PKA activation. 
Although actin dependence of this association was not validated, an explanation 
for the increased presence of CAP1 in the membrane could be attributed to (a) 
direct association with the a membrane receptor that was active during PGI2 
treatment, or (b) an interaction with other membrane-associated proteins linked 
to Ras signalling pathways, like scaffold protein IQGAP1, which is known to 
regulate PI3K (White, Erdemir and Sacks, 2012) and which is discussed in 
detail in the chapter 5. 
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4.3.5 Extension of the study on CAP1 translocation in platelets 
CAP1 knock-out mice or inhibitors to block the function of CAP1 are unavailable 
and silencing proteins is not established in platelets due to their obvious lack of 
nucleus and their limited ability to translate proteins, which makes it difficult to 
attribute a precise role for CAP1 in platelets. Extensive experimentation is 
required to completely justify the CAP1 translocation, including selective 
inhibition of PARs to critically assign a role in CAP1 translocation. Additionally, it 
may be useful to assess changes in membrane bound CAP1 in response to 
PKC-inhibitors and calcium chelators to help identify which stage in the 
signalling pathway is actually responsible for the translocation effect, or which 
step requires CAP1 translocation to occur beforehand. In a study investigating 
phosphoproteome of platelets, Serine 307 on CAP1 was identified as a 
phosphorylation-site (Zahedi et al., 2008). It is also known than mouse CAP1 is 
phosphorylated by GSK3β at Ser309 (GSK3β dependent phosphorylation of 
CAP1 is dependent on primary phosphorylation by other kinases at Thr314). 
They suggest that phosphorylation of CAP1 renders it inactive by indirectly 
decreasing its association with cofilin (Zhou et al., 2014) and it would provide 
great insight in how this might be regulated in human platelets by using a 
combination of signalling pathway activators and inhibitors – for example 
investigating the phosphorylation profile of CAP1 in thrombin stimulated 
platelets by initial treatments using GSK3 inhibitors (LiCl, 6-BIO, SB216763), 
inhibitors of PI3K (LY294002), ERK inhibitor (U0126) and activators of PKA 
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(Forskolin) and PKC (PMA) to shed light on the role in biochemical signalling 
pathways. 
A study involving platelets of Akt knock-out mice, where secretion and 
aggregation defects in platelets are already described (Woulfe et al., 2004a) 
would enable establish a role for CAP1, if any, in platelet functional over 
biochemical aspects. In order to extend observations from thrombin stimulation, 
other GPCRs can be investigated to understand if the effect is truly linked to G-
proteins or if other protein complexes that bind G-proteins are responsible for 
binding CAP1 at the membrane. In addition, immunoprecipitation with potential 
protein candidates from the Ras effector proteins that might interact with CAP1 
would help identify if CAP1 plays a distinct role in PKA activation, independent 
of its role in actin remodelling.  
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4.3.6 Model of CAP1 localisation in platelets in response to agonists 
 
Figure 4.14 Model for CAP1 translocation in response to agonists in 
platelets: The speculative model is derived from evidence from endothelial and 
embryonic cell systems. CAP1 (red) represents the inactive form, whereas, 
CAP1 (green) represents its active form. Phosphorylation of CAP1, Akt and 
GSK3β substrates are indicated by (P). CAP1 phosphorylation occurs in 
response to thrombin stimulation and initiates its translocation from membrane; 
Phospho-CAP1 (phosphorylation by GSK3β at Ser 309) localises to the cytosol 
in its inactive form. In order for GSK3β to potentially phosphorylate CAP1 at Ser 
309, CAP1 first is primed by phosphorylation by kinases like PKC at Thr 314. 
Therefore, CAP1 is rendered inactive by phosphorylation upon platelet 
activation. CAP1 dephosphorylation is enhanced by PI3K/Akt-dependent 
phosphorylation of GSK3β (inhibiting its enzymatic ability). Dephosphorylated 
CAP1 shows enhanced cofilin-binding and localises more cortically. Adenylyl 
cyclases activated in response to PGI2 mediate phosphorylation of GSK3β, this 
in turn leads to dephosphorylation of CAP1 increasing its association to the 
peripheral membrane and cofilin. Therefore, platelet inhibitory mechanisms lead 
to CAP1 dephosphorylation.  
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When all the data is compiled and analysed against evidence from other cell 
types, a model of CAP1 translocation begins to emerge (Figure 4.14). 
Established scientific evidence suggests that (a) GSK3β causes CAP1 
phosphorylation (Zhou et al., 2014), (b) phosphorylation of GSK3β, which 
inhibits its enzymatic capability and increases sensitivity of platelets to agonist-
induced aggregation, itself is mediated by PI3K dependent phosphorylation of 
Akt (Li, August and Woulfe, 2008), (c) Akt phosphorylation increases with 
thrombin stimulation (Woulfe, 2010), (d) thrombin negatively regulates PKA 
activation (Zhang and Colman, 2007), (e) PKA enhances phosphorylation of 
substrates by GSK3β (Zhang et al., 2003), (f) GSK3β phosphorylation mediates 
cell survival (Jacobs et al., 2012), and (g) CAP1 is pro-apoptotic (Wang et al., 
2008). These observations complement the data presented in this chapter, 
where thrombin causes translocation of CAP1 from membrane into cytosol and 
PKA activation via PGI2 treatment and enhances its association with the 
membrane. Hypothetically, therefore, CAP1 dephosphorylation would cause it to 
localise to the membrane and phosphorylation would cause it to translocate to 
the cytosol, where the phosphorylation is regulated by GSK3β in response to 
PI3K pathway. Phosphorylation of CAP1 most likely renders it inactive in its role 
in actin filament turnover (as it indirectly undergoes a loss in its association with 
cofilin), a phenomenon similar to its binding partner cofilin (Paavilainen et al., 
2004; Zhou et al., 2014). 
  
250 
 
Further, it can be deduced that thrombin stimulation most likely causes platelets 
to undergo apoptosis-like signalling (Leytin, 2012), where CAP1 would feature in 
its pro-apoptotic role acting as link between actin cytoskeleton and 
mitochondrial membrane where additional cell death pathways are triggered. 
The schematic depicted in Figure 4.14 helps in illustrating the CAP1 localisation 
occurring upon agonist stimulation. 
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 CHAPTER 5 
INVESTIGATIONS ON THE ACTIN CYTOSKELETON OF 
PLATELETS 
 
The cytoskeletal protein, CAP1, was investigated in the chapter 4, owing to 
evidence that it may play roles as a receptor for resistin. CAP1 is responsible for 
actin remodelling, an event that it co-ordinates in association with several other 
actin binding proteins like cofilin and profilin. Our investigations revealed a 
change in localisation pattern of CAP1 in stimulated platelets compared to 
resting platelets. Also, changes in the phosphorylation patterns of cytoskeletal 
proteins in activated versus resting platelets are known (Zelen, 2012; Burkhart 
et al., 2014) and are briefly summarised in a proteomics meta-analysis below 
(section 5.2.1).   
The investigations into the platelet cytoskeleton have traditionally used 
approaches that include protein inhibitors, signalling pathway inhibitors, specific 
stimulators or mouse knock out models and the role of these proteins are 
reviewed in several key publications (Hartwig et al., 1999; Fox, 2001; Bearer, 
Prakash and Li, 2002; Cerecedo, 2013; Goggs et al., 2015). Additionally, 
platelets being anucleate, enforces that they cannot be cultured in great 
abundance or manipulated using common recombinant DNA technologies 
(Senis and García, 2012). As a result, platelet research has lagged behind that 
of nucleated cells. During the last decade proteomics allowed the discovery of 
many platelet receptors and additional insights into signalling proteins, some of 
which are being studied as antithrombotic drug targets (Vélez and García, 
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2015). Proteomics, using mass spectrometry approaches, is ideally suited for 
identifying low-abundance proteins, protein-protein interactions, and post-
translational modifications in complex protein mixtures (Senis and García, 2012; 
Burkhart et al., 2014; Vélez and García, 2015), and a general schematic is 
shown in figure 5.1. 
 
 
Figure 5.1 Schematic representation of platelet proteome analysis. 
Platelets isolated from human samples are subjected to lysis followed by gel-
sectioning using SDS-PAGE, reduction/alkylation of extracted proteins. The 
proteins then undergo in-gel digestion and clean-up before being separated 
using light chromatography (LC). When generating the phosphoproteome, 
extracted proteins are incubated with IMAC beads to help enrich the 
phosphorylated proteins. Nanospray allows fine spraying of proteins and these 
are then detected using a mass spectrometer (MS). Data curation softwares 
then identify the proteins based on databases to generate the platelet proteome. 
Taken from (Qureshi et al., 2009)  
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An analysis of platelet subproteomes (secretomes, exosomes, and 
microvesicles) has been most popular strategy for investigations into platelet 
biochemistry leading to higher sensitivity in identification of critical protein 
complexes (Vélez and García, 2015). The main drawback though is that this 
strategy ignores a number of other crucial proteins that do not necessarily fall 
into the subproteome categories.   
The key proteins of interest to our lab are platelet cytoskeletal proteins. The 
crucial role that the cytoskeleton plays in platelet function is highlighted 
evermore when assessing the outcomes from studies carried out in the platelet 
proteome. Figure 5.2 shows that half of all platelet proteins are cytoskeletal 
proteins, where surprisingly, 37% are actin-myosin cytoskeleton proteins 
(Burkhart et al., 2014). Although cytoskeletal proteins are identified as a result of 
proteomics analysis, we found that these studies lacked critical assessment of 
these proteins from a proteomics standpoint, including a lack of focus on the 
changes in these proteins upon thrombin stimulation. Phosphorylation of 
proteins is a key mechanism for proteins to become active or inactive and their 
phosphorylation determines the role they play in regulating multiple signalling 
pathways (Johnson and Barford, 1993). 
Our proteomics meta-analysis indicated vast phosphorylation changes in actin 
and its associated proteins upon thrombin stimulation. We therefore pursued 
them in our investigations to include IQGAP, a scaffold protein interacting with 
multiple actin binding proteins; Arp2/3 complex, which nucleates and branches 
actin filaments, coronin 1a, which interacts with the Arp2/3 complex and is an F-
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actin binding protein; villin, which is normally found in epithelial cells to perform 
the function of severing and capping of actin filaments, l-plastin, which is an 
actin filament bundling protein; myosin and tropomyosin, which form part of the 
actomyosin complex that drives actin filament dynamics. In order to further 
understand the localisation of these proteins that interact in a concerted manner 
in remodelling actin and in a bid to identify how other cytoskeletal proteins 
behave in resting platelets, we investigated above mentioned proteins that have 
distinct, yet related roles in numerous aspects of actin dynamics, including 
filament nucleation, branching, elongation, bundling, stabilisation, severing and 
its coordination as an actomyosin complex that provides forces within cells.  
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Figure 5.2 Distribution of proteins within the platelet proteome. Top 100, 
200, 500 most abundant proteins are classified into functional categories. Top-
100 proteins have estimated ˃35,000 copies per platelet, the top-200 have 
estimated ˃16,000 copies per platelet and the top-500 have estimated ˃6,700 
copies per platelet. ER - endoplasmic reticulum. Taken from Burkhart et al. 
(2014). 
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5.1 Aims and objectives 
A number of aspects of the platelet cytoskeleton remain unexplored due to the 
improbability of using recombinant DNA technology. Investigations using the 
platelet proteome have enabled identification of critical cytoskeletal components 
(Gevaert et al., 2000). Further, the importance of cytoskeleton dynamics in the 
functional capability of platelets along with the complexity and cross-interactions 
in platelet cytoskeletal proteins make it extremely interesting to understand 
these proteins. Investigations carried out in the current chapter aim to gather 
preliminary information about actin associated proteins in platelets.  
The main aims are: 
- Perform a proteomics meta-analysis to emphasize the role of the platelet 
cytoskeleton 
 
- Investigate a possible interaction between IQGAP proteins and CAP1 
 
- Preliminary investigation of possible interaction between Arp2/3 and 
CAP1 
 
- Investigate the localisation of cytoskeletal proteins (coronin1a, villin, l-
plastin, myosin IIa, and tropomyosin) involved in the remodelling of actin 
based on their interactions with CAP1 and cross-interactions with each 
other.   
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5.2 Results 
5.2.1 Proteomics meta-analysis of platelet cytoskeletal proteins 
The cytoskeleton determines the shape of the platelet: discoid in resting 
platelets in circulation and more dynamic with flattened shape with presence of 
filopodia and lamellipodia during platelet adhesion and activation (Cerecedo, 
2013). The cytoskeletal changes in platelets encourage thrombus formation and 
subsequently provide stability to sustain the thrombus under high shear forces 
within the arterial vessel wall (Versteeg et al., 2013). Cytoskeletal changes also 
mediate microparticle release from the platelet secretome (Jurk et al., 2005).  
Platelet proteomics and transcriptomics related literature including over 87 
papers and reviews, that included research in human platelet proteomics and 
transcriptomics in subproteomes of platelets, in proteomes of agonist-induced 
platelets, organelle specific proteomes and specific-protein deficient platelets or 
platelet proteomes of patients with platelet-related diseases were screened and 
further restrictions were applied to acquire information specific to thrombin 
induced phospho-proteome related variations in the whole platelet proteome. It 
was further narrowed down to include only the platelet cytoskeletal proteome 
which comprises around 40% of the platelet proteome (Figure 5.2). A meta-
analysis of proteomics publications that review and investigate variation in the 
cytoskeletal proteins (based only on the functional aspect and not localisation of 
the respective proteins), by comparing resting platelet proteome and thrombin-
induced proteome was undertaken (Gevaert et al., 2000; Marcus, Moebius and 
Meyer, 2003; Moebius et al., 2005; Macaulay et al., 2005; Gnatenko and Bahou, 
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2006; Gnatenko, Perrotta and Bahou, 2006; Senis et al., 2007; Esteso et al., 
2008; Zahedi et al., 2008; Qureshi et al., 2009; Senzel, Gnatenko and Bahou, 
2009; Yu et al., 2010; Májek et al., 2010; Rowley et al., 2011; Burkhart et al., 
2012, 2014; Randriamboavonjy et al., 2012; Senis and García, 2012; Zufferey et 
al., 2013; Londin et al., 2014; Osman et al., 2015; Vélez and García, 2015). 
In this chapter we restricted the meta-analysis to the publications assessing 
whole platelet proteomics including thrombin induced variations in whole platelet 
proteomes and excluded several publications. The literature that was excluded 
from the analysis included proteomic variations induced by other (non-thrombin) 
platelet agonists, disease-state platelet proteomics or literature which 
investigated only a specific proteome subset; only exception to the rule was the 
inclusion of Gevaert et al. (2000), where they specifically investigate proteins 
translocating to the cytoskeleton. A list of publications analysed with a brief 
overview and methodology they used can be found in Table 5.1. 
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Table 5.1: Publications included in the proteomics meta-analysis detailing 
the methodology used and a brief overview of the investigations.  
Publication Type of study Overview of 
publication 
Methodology 
(Gnatenko et 
al. 2006) 
Transcriptomics Human platelet 
mRNA transcriptome 
analysis 
RNA-seq, Microarray, SAGE 
(Rowley et 
al. 2011) 
Transcriptomics Comparison of 
transcriptomes of rat 
versus human 
platelets 
RNA-seq, Microarray, SAGE 
(Londin et al. 
2014) 
Transcriptomics Correlation between 
transcriptomics 
versus proteomics in 
human platelets 
RNA-seq, Microarray, SAGE 
(Osman et 
al. 2015) 
Transcriptomics Correlation between 
transcriptomics 
versus proteomics in 
pathogen-reduced 
versus platelet 
concentrates 
(human platelets) 
RNA-seq, Microarray, SAGE 
(Marcus et 
al. 2003) 
Proteomics Phosphorylated 
proteins in resting 
versus thrombin 
stimulation in human 
platelets 
2D-PAGE, MALDI-TOF MS, 
Nano LC-MS/MS 
(Moebius et 
al. 2005) 
Proteomics Membrane proteome 
of human platelets in 
resting versus 
thrombin stimulation 
2D-PAGE, LC-MS/MS 
(Zahedi et al. 
2008) 
Proteomics Phosphoproteome of 
human platelets in 
resting versus 
thrombin stimulation 
IMAC-beads, SCX - protein 
enrichment, LC-MS 
(Randriambo
avonjy et al. 
2012) 
Proteomics Comparison of 
proteomes human 
platelets of control 
versus diabetic 
patients 
2D-PAGE, LC-MS/MS, 
Western blotting 
(Gevaert et 
al. 2000) 
Proteomics Comparison of 
human platelet 
proteins that 
translocate to the 
TX-100 insoluble pellet, 2D-
PAGE, MALDI-TOF MS 
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cytoskeleton upon 
thrombin stimulation 
(Esteso et al. 
2008) 
Proteomics Porcine platelet 
proteome and 
alterations induced by 
thrombin 
2D-PAGE, MALDI-TOF MS, 
Nano LC-ESI/MS 
(Yu et al. 
2010) 
Proteomics Global analysis of rat 
and human platelet 
proteome in thrombin 
induced platelets 
2D-PAGE, IEF, LC-MS/MS, 
iTraq labelling, 2DLC 
(Burkhart et 
al., 2012) 
Proteomics Comprehensive 
proteomics analysis 
of human platelets 
RNA-seq, IEF,  iTraq 
labelling, TiO2 enrichment, 
SCX-protein enrichment, LC-
MS/MS 
(Qureshi et 
al., 2009) 
Proteomics Proteome of human 
platelets in resting 
versus thrombin 
stimulation 
2D-PAGE, MALDI-TOF MS, 
Nano LC-ESI/MS 
 
Table 5.1: (Continued from previous page) Publications included in the 
proteomics meta-analysis detailing the methodology used and a brief 
overview of the investigations.  
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Transcriptomics studies included non-coding RNA in addition to ribosomal and 
messenger RNA from megakaryocytes, which would have skewed our analysis 
and clear functional relevance of cytoskeletal protein transcripts could not be 
derived from the available information, and were therefore omitted. Analysis was 
further narrowed to include only proteomics publications that investigated the 
whole platelet proteome and assessed thrombin induced phosphorylation 
changes (Marcus, Moebius and Meyer, 2003; Zahedi et al., 2008; Qureshi et al., 
2009; Burkhart et al., 2012), as they presented the most comprehensive outlook 
towards changes in the cytoskeletal proteins.  
A key theme that we validated in our analysis was that the cytoskeletal 
machinery is the most abundant protein category and also the most variable in 
platelet proteome when undergoing thrombin-mediated activation in vitro. This 
machinery included cytoskeletal proteins mainly associated with actin and 
tubulin along with signalling proteins that modulated the cytoskeletal proteins 
(Figure 5.1 and 5.2). 
A list of cytoskeletal proteins and the changes in their phosphorylation status 
within the proteome of platelets, or lack thereof, upon thrombin stimulation has 
been compiled using UniProt accession number of the proteins in the Appendix 
1. Tables were retrieved and compiled from proteomics publications (Marcus, 
Moebius and Meyer, 2003; Zahedi et al., 2008; Qureshi et al., 2009; Burkhart et 
al., 2012) and proteins were manually segregated into several groups - actin 
and associated proteins, tubulin and associated proteins, intermediate filament 
proteins, myosins and other motor proteins. The classification of proteins was 
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based on their cytoskeletal function previously assigned in other publications 
(Janmey, 1995; Bearer, Prakash and Li, 2002; Bearer, 2005; Uribe and Jay, 
2009; Blanchoin et al., 2012, 2014; Xue and Robinson, 2013; Bezanilla et al., 
2015). Additionally, only heavy chains of motor proteins were included as they 
associate with actin or tubulin and light chains were omitted from the Appendix. 
 
A mathematical model was generated in IBM SPSS Statistics 23, where each 
protein category was coded and the number of proteins under each 
classification was tallied. These were then converted to percentages based on 
total number of cytoskeletal proteins analysed and shown as a doughnut in 
Figure 5.3 using MS Excel.  
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Figure 5.3: Proportions of number of cytoskeletal proteins in resting 
platelets. Number of cytoskeletal proteins and their distribution within the 
platelet proteome (from Appendix 1) is shown in the central doughnut. The key 
to the distribution charts is shown next to the doughnut.  
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Figure 5.3 shows the proportions of cytoskeletal proteins within the platelet 
proteome based on the total number of proteins. The distribution based on copy 
numbers (Figure 5.4) of the distinct types of cytoskeletal proteins was carried 
out next, providing a more global outlook based on the abundance of proteins. 
Similar to analysis described in reference to figure 5.3, a mathematical model in 
IBM SPSS Statistics 23 was generated which tallied copy numbers under a 
given category of cytoskeletal proteins (actin and associated proteins, tubulin 
and associated proteins, intermediate filament proteins, myosins and other 
motor proteins) and represented as a percentage of total copy number of 
cytoskeletal proteins within the platelet proteome as a mean of copy numbers 
from Burkhart et al. (2012); Marcus et al. (2003); Zahedi et al. (2008); Qureshi et 
al. (2009) and shown as a doughnut using MS Excel. A change in 
phosphorylation status upon thrombin stimulation – increase, decrease or no 
change in dot intensity on 2D-PAGE and auto-radiography was used for further 
classification of the cytoskeletal protein categories. An additional category 
included proteins where no information was available within the publications we 
scrutinised (Marcus, Moebius and Meyer, 2003; Zahedi et al., 2008; Qureshi et 
al., 2009; Burkhart et al., 2012). These 4 sub-categories were coded accordingly 
in IBM SPSS Statistics 23 to generate numerical data showing variations in 
copy numbers. The results were converted into percentage of total copy 
numbers of proteins within each category and depicted as pie charts in figure 
5.4 using MS Excel. 
 
265 
 
 
Figure 5.4 Copy numbers (abundance of protein) of cytoskeletal proteins 
within the resting state and those undergo change in phosphorylation 
status in thrombin-stimulated platelet proteome.  Abundance of cytoskeletal 
proteins and their distribution based on copy numbers within the platelet 
proteome (from Appendix 1) is shown in the central doughnut. The surrounding 
pie-charts represent the different cytoskeletal protein groups that undergo 
change in their phosphorylation status upon thrombin stimulation. The key to the 
distribution charts is shown in the top left corner of the figure. 
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It is evident from both the figures 5.3 and 5.4 that the actin and actin associated 
proteins form the largest group of proteins forming 71% of all the platelet 
cytoskeletal proteins, with regards the copy numbers, and 46% of the total 
number of cytoskeletal proteins. Actin and associated proteins also form a 
significant proportion of the proteins undergoing an increase in phosphorylation 
upon thrombin stimulation of 79% of total actin and associated proteins, based 
on the abundance in copy numbers. This helps emphasize the significant role 
the actin cytoskeleton plays during platelet stimulation by thrombin. Tubulin and 
associated proteins form the second largest group comprising about 19%, in 
terms of the platelet cytoskeletal proteome, of which, 64% undergoes an 
increase in protein phosphorylation upon thrombin stimulation. The abundance 
of intermediate filaments, motor proteins and myosins is less compared to the 
tubulin and actin associated proteins, with a cumulative proportion of around 
10% of total cytoskeletal proteins (Figure 5.4). 
Since actin and associated proteins were the largest proportion of cytoskeletal 
proteins that were undergoing phosphorylation upon thrombin stimulation, we 
sought to identify antibodies that were well-characterised and available in our 
laboratory. A preliminary assessment of actin associated proteins that included, 
Arp2/3, IQGAP1, coronin1a, villin, l-plastin, myosin IIa and tropomyosin with 
respect to their localisation within platelets was carried out and detailed in the 
rest of the chapter, but investigation into the changes in phosphorylation and 
subsequent translocations, as observed in chapter 4, was not possible due to 
time constraints.  
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5.2.2 Is IQGAP an interaction partner of CAP1? 
CAP1, as described in (section 1.6), is an actin-associated protein responsible 
in mediating actin turnover. When assessing the protein architecture, the central 
region of CAP1, more specifically the proline-rich region (Figure 1.8), is well 
conserved across species and therefore interesting for investigation in its role as 
a potential signalling hub. Six well defined proline recognition domains have 
been described (Li, 2005), namely the SH3 (Src-homology domain 3), WW, 
EVH1, GYF, UEV domains. CAP1 is also known to interact with small protein 
like profilin, which also contains the SH3 domain. Amongst these potential 
CAP1 partners, , only the interaction of CAP with profilin is well established 
(Goldschmidt-Clermont and Janmey, 1991). In order to generate a more 
comprehensive list of SH3 domain containing proteins that might potentially 
interact with CAP1, a process of elimination based on presence or absence of 
motifs was used. Interaction of CAP1 with EVH1 domain-containing proteins like 
Ena, VASP, WASP, N-WASP and Homer was deemed unlikely, as these 
require PPxxF (Homer) or FPPPP (Ena/VASP) motifs that are not present in any 
of the human CAPs. A similar argument was applied to UEV (PTAP motif) and 
GYF [(R/K/G)XXPPGX(R/K) motif].  The focus was then shifted to the SH3 
domain containing a minimal PXXP consensus recognition sequence present in 
both CAP1 and CAP2 (although non-canonical motifs exist) (Peche et al., 2007). 
Various SH3 proteins bind to the yeast CAP homolog, including Abp1, Sla3 and 
Rvs167 (Drees et al., 2001), Abl in vitro (Freeman et al., 1996). There are over 
500 SH3-domains in proteins encoded in the human genome, very often 
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signalling proteins (Mayer, 2001). A screening of a library containing 296 human 
SH3 domains in M13-derived phagemid vectors with CAP1 as bait, but 
thatyielded no candidates (Kärkkäinen et al., 2006).  
The WW domain was therefore investigated. It is a 35-40 residues stretch with 
two conserved tryptophan residues approximately 20 residues apart that bind a 
variety of P-rich peptide motifs and are found in less than 100 domains in 
proteins encoded in the human genome (Kay, Williamson and Sudol, 2000; 
Ingham et al., 2005). Hu et al, (2004) carried out the first comprehensive 
protein-peptide interaction map for a human modular domain using individually 
expressed WW domains and genome predicted PPxY-containing synthetic 
peptides. Their study revealed four candidate proteins that may bind to the P-
rich region of CAP (the first three also investigated by Ingham et al 
(2005)): GAS7 (Growth arrest-specific 7 isoform b), a protein involved in 
neuronal development; Formin-binding protein 21 / WBP-4, involved in pre-
mRNA splicing; FE65-like 2, an amyloid betaA4 precursor protein-binding 
protein; and IQGAP2. The IQGAP family of scaffold proteins that play important 
roles in actin remodeling was chosen for further investigation (Brandt and 
Grosse, 2007). The family consists of three members with the same 
architecture, of which IQGAP1 (1000 copies per platelet) and IQGAP2 (81,000 
copies per platelet) are present in platelets (Burkhart et al., 2012) (Appendix 1).  
 IQGAPs are known to scaffold multiple MAPK proteins and regulate focal 
adhesion formation and MAPK signaling from endosomes. IQGAP1 is also 
known to localize at the leading edge of migrating cells (Rac1, Cdc42-
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dependent manner) (Smith, Hedman and Sacks, 2015), a pattern of localisation 
similar to CAP1 (Bertling et al., 2004; Ono, 2013). In platelets, IQGAP2 
associates with cdc42-F-actin cytoskeletal complex and rac1-complex that 
scaffolds Arp2/3 in a cytoplasmic complex in a GTP-dependent manner, thus 
functioning as a distinctive thrombin-regulated scaffolding protein in platelet 
activation. Further, studies in IQGAP1 null platelets implicated it in a shear-
restricted procoagulant pathway modulating α-granule secretion (Schmidt et al., 
2003; Bahou et al., 2004) making it an exciting protein to investigate within the 
platelet cytoskeleton. 
. 
5.2.2.1 Co-immunoprecipitation of CAP1 and IQGAP proteins 
In order to investigate a potential interaction of CAP1 with the WW domain of 
IQGAP a co-immunoprecipitation approach was used. 293FT human embryonic 
kidney (HEK) cells were transfected with Myc-tagged CAP1and GFP-tagged 
WW domains of IQGAP1 or IQGAP2. CAP1 was immunoprecipitated and the 
immune complexes were analysed by Western blotting for the presence of 
IQGAP-WW. Under these conditions, CAP1 is apparently able to co-
immunoprecipitate IQGAP1-WW rather than IQGAP2-WW (Figure 5.5 B). Next, 
an attempt was made to verify that this interaction requires the proline-rich 
region of CAP1. Two truncated overlapping CAP1 constructs were already 
available in the lab. CAP1-N spans residues 1-324 and contains the proline-rich 
region. CAP1-C spans residues 242-475. 293FT HEK cells were transfected 
with Myc-tagged CAP1 constructs and GFP-tagged IQGAP1-WW. IQGAP1-WW 
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was immunoprecipitated and the immune complexes were analysed by Western 
blotting for the presence of CAP1 fragments. As shown in Figure 5.5 C, no clear 
co-immunoprecipitation of IQGAP1-WW with any of the CAP1 fragments was 
apparent. Furthermore, an attempt by Dr Wei Ji in our lab at co-
immunoprecipitating endogenous CAP1 and IQGAP1 from human platelet 
lysates was also negative (Figure 5.5 D). 
IQGAP1 and IQGAP2 play a role in integrating calcium signaling and cAMP 
mediated signaling, where modulation of calcium ions was found to affect 
IQGAP-related cell motility (Smith, Hedman and Sacks, 2015). We therefore 
performed this experiment in the presence or absence of calcium ions but did 
not observe variations in the outcome (Figure 5.5 D).  
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Figure 5.5 No apparent interaction of CAP1 with IQGAP1. (A) Proline rich 
regions of human CAP1 and CAP2. (B) CAP1 apparently co-
immunoprecipitates the WW region of IQGAP1. HEK293T cells were 
transfected with the indicated Myc or GFP-tagged constructs. Protein 
complexes were immunoprecipitated with anti-Myc antibody coupled to 
magnetic beads and along with the lysates (Lys) examined by Western blot for 
the presence of tagged proteins. (C) No apparent interaction of IQGAP1-WW 
with truncated CAP1. HEK293T cells were transfected with the indicated Myc 
or GFP-tagged constructs and processed as in B but using anti-GFP antibody 
coupled to magnetic beads. CAP-N encompasses a. a. 1-324 and includes the 
proline-rich region; CAP-C encompasses a. a. 242-475. The IP blot probed with 
anti-Myc antibody shows a longer exposure than the lysates blot. (D) 
Immunoprecipitation of endogenous CAP1 and IQGAP1 in human 
platelets. Platelet lysates were incubated with anti-IQGAP1 antibody or rabbit 
immunoglobulin (IgG) in the presence 1 mM EGTA (-Ca2+) or 5 mM calcium 
(+Ca2+). Immunocomplexes with protein A Sepharose and examined by 
Western blot along with the lysates (Lys). No apparent co-immunoprecipitation 
of CAP1 and IQGAP1 above unspecific binding. Data in panel C and D is 
generated with the kind help of Dr Wei Ji. 
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5.2.2.2 Immuno-localisation of CAP1 and IQGAP proteins 
As a preliminary, visual indicator of interaction between IQGAP proteins and 
CAP1, immunofluorescence based co-localisation was assessed in platelets 
spread on fibrinogen. Platelets were allowed to spread on fibrinogen matrix for 
30 minutes, fixed, permeabilised and immunostained for IQGAP1 and CAP1. 
Figure 5.6 A indicates that there is little co-localisation of the proteins in the 
cortical regions of platelets and is predominantly in different planes of analysis.  
In order to further clarify if the observed co-immunoprecipitation was due to the 
interaction between WW domain of IQGAP1 and CAP1, HeLa cells were 
transfected with GFP-tagged IQGAP1 and IQGAP1-WW constructs (Images 
captured by Dr Wei Ji). If WW domain had a conspicuous localisation near 
CAP1-rich zones, that would support the probability of protein interaction. 
Although overlayed images show that there is some co-localisation of IQGAP1 
and CAP1, there was no apparent interaction between the WW-domain of 
IQGAP1 and CAP1 as only GFP transfection alone has a similar distribution 
pattern. Although confocal microscopy is insufficient to identify interactions, 
proximity ligation assay would improve visualisation of the interaction between 
the two proteins, if any. 
On the basis of observations made using immunoprecipitation and 
immunostaining techniques, we could not find robust interaction between CAP1 
and WW domain of IQGAP1 (and probably also IQGAP2) and assume it to be 
unlikely under the current experimental conditions. 
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Figure 5.6 (A) Co-immunostaining of CAP1 (red) and IQGAP1 (green) in 
spread platelets. Platelets were allowed to spread on fibrinogen, fixed and 
immunostained with mouse anti-CAP1 and rabbit anti-IQGAP antibodies 
followed by Alexa568-labeled anti-mouse and Alexa488-labeled anti-rabbit 
antibodies. Optical sections were acquired with a fluorescence microscope 
equipped with a structured illumination attachment. Sections were 230 nm apart. 
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Shown is a maximum projection image in 3 planes after deconvolution and 
single planes of the region indicated with a square. CAP1 is shown in red, 
IGGAP1 in green. Scale bar-5µm. (B) Co-staining of CAP1 (red) and IQGAP1 
(green) in HeLa cells. Cells were transfected with GFP-tagged IQGAP1 
constructs fixed and immunostained with anti-CAP1 antibody. Nuclei were 
visualized with DAPI (blue). Images were acquired as in (A) and deconvolved 
single planes overlaid. Scale bar-10 µm. Images were captured in collaboration 
with Dr Wei Ji. 
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5.2.3 A possible interaction between Arp2/3 and CAP1: preliminary 
approach 
The Arp2/3 complex is known to nucleate elongating actin filaments and is well 
characterised for its role in actin dynamics in platelets (Bearer, Prakash and Li, 
2002; Li et al., 2002). Arp2 and Arp 3 proteins with 5 additional associated 
proteins (p16, p20, p21, p34 and p40) form the Arp2/3 complex. When 
assessing their crystal structures, Arp2 and Arp3 resemble actin monomers. In 
vitro nucleation models of actin filaments have shown that “daughter” actin 
filaments start elongating at a 70˚ angle from the “mother” filament (Dyche 
Mullins, Heuser and Pollard, 1998). Further, it has been shown that different 
activators of the Arp2/3 complex, like Neuronal-Wiskott-Aldrich Syndrome 
Protein (N-WASP) and Scar-1 (suppressor of cAMP receptor 1) spatially 
regulate nucleation and branching of actin filaments in 3D (Remedios et al., 
2003).  
Li et al. (2002) have shown that the Arp2/3 complex localises at the platelet 
cortex in response to agonist stimulation in the early stages of filopodia 
formation. They show that actin polymerisation rather than actin reorganisation 
activates Arp2/3 complex as it binds to the sides of existing filaments. N-WASP 
is a more potent activator of Arp2/3 compared to WASP (which is more 
abundantly present in platelets).  
CAP1 and Arp2/3 have been shown to be active at similar times during actin 
filament elongation in actin turnover models (Bugyi and Carlier, 2010). Profilin, 
which is a known interacting partner of CAP1 (Goldschmidt-Clermont and 
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Janmey, 1991) is also known to bind Arp2 of the Arp2/3 complex (Remedios et 
al., 2003). In Arabidopsis, CAP1-null in addition to mutation in Arp2/3 complex 
synergistically enhanced morphological defects, which suggested that CAP1 
and Arp2/3 either regulates actin in co-ordination or that they perform related 
functions in similar actin regulatory pathway (Deeks et al., 2007). In order to 
investigate the distribution of Arp2/3 in resting platelets and to evaluate its 
localisation in spread platelets with respect to CAP1, we used anti-Arp2/3 
(Millipore p34-Arc/ARPC2) to immunostain platelets and in Western blot of 
fractionated resting platelet samples.  
Localisation of Arp2/3 towards the cortical regions of platelets when spread on 
fibrinogen and collagen is consistent with observations made by Li et al. (2002) 
where they first described it in platelets spread on glass. Although, in our 
observations (Figure 5.7 A), CAP1 and Arp2/3 were both present in the platelet 
cortical regions, the punctate staining did not show any co-localisation in the 
fibrinogen-spread platelets and irregular co-localisation patterns were observed 
in collagen-spread platelets, which made it difficult to ascertain co-localisation, if 
any. 
The distribution of Arp2/3 in resting platelets was assessed by fractionation into 
membrane and cytosol as described in (section 2.7) and samples that 
previously characterised (Figure 4.3) as devoid of contamination from either 
membrane or cytosolic fractions were used. Latrunculin B was used to 
depolymerise F-actin to assess actin-dependence of Arp2/3 to the membrane or 
cytosolic fractions. It was observed that 26% of Arp2/3 was found in membrane 
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and 74% was present in the cytosol. This did not vary significantly when F-actin 
was depolymerised – 28% was found to be membrane associated compared to 
72% present in the cytosol (Figure 5.7 B).  
The association of Arp2/3 to the detergent insoluble pellet was carried out in 
samples generated and characterised previously (Figure 4.4). The presence of 
Arp2/3 pellets and supernatants isolated at low and high speeds suggests that 
not all Arp2/3 is associated to the detergent insoluble pellet when platelets are 
in their quiescent state. When actin filaments are depolymerised using LatB 
prior to lysis of resting platelets, it becomes clear that the association of Arp2/3 
to the detergent insoluble pellet depends entirely on binding actin, evident from 
its absence in LatB treated pellet samples, at both low and high speeds (Figure 
5.7 C). 
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Figure 5.7 Subcellular localisation and distribution of Arp2/3. (A) Arp2/3 
localisation with respect to CAP1: Human blood platelets (2 x 107 platelets) 
were allowed to spread on fibrinogen coated coverslips or collagen coated 
coverslips. Platelets were fixed, immunostained for Arp2/3 (Alexa 568, 
secondary antibody, red) and co-stained for CAP1 (Alexa 488, secondary 
antibody, green) for visualisation using a fluorescent microscope. Scale bar = 
10µm. (B) Subcellular distribution of Arp2/3 by fractionation: Human blood 
platelets (8 x 108/mL platelets) were lysed by freeze-thaw in liquid nitrogen. 
Samples were then spun at 100,000xg for 1 hour to separate membrane and 
cytosolic fractions. The cytosolic (C) and membrane (M) fractions were 
normalised by volume and analysed using Western blotting. CD36 was used as 
a membrane marker, whereas as Syk was used as a cytosolic marker in resting 
platelets. (C) Association of Arp2/3 to the detergent insoluble pellet: Human 
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blood platelets (8 x 108/mL platelets) were lysed in the presence of 1% TX-100 
and lysates spun at low speed (15,600xg) for 20 min and high speed 
(100,000xg) for 1 hour. The supernatant (SN) and pellet (P) were normalised by 
volume for Western blotting. CD36 was used as a pellet marker, whereas 
GAPDH was used as a marker for the supernatant.  
All samples were resolved on 12% SDS-PAGE gel, blotted onto PVDF 
membrane and probed with anti-Arp2/3 (anti-p34). Latrunculin B (LatB; 20µM; 
20 min) was used to depolymerise F-actin prior to lysis.  
281 
 
5.2.4 Distribution of coronin 1a in resting and spread platelets 
Coronins are F-actin binding proteins that play a role in remodelling the actin 
cytoskeleton. Coronin 1a is mainly expressed in hematopoietic tissues and cells 
and to a lesser extent in neuronal tissues. Structurally, it has 7-bladed β-
propellers which contain WD-40 repeats. Interestingly, coronins also contain an 
acidic domain towards the C-terminal, which resembles Scar proteins, which are 
known to activate actin nucleating proteins like Arp2/3 (Uetrecht and Bear, 
2006). Research evidence confirms a role for coronin in recruiting Arp2/3 to 
create nucleation sites on growing actin filaments. Additionally, coronin seems 
to modulate cofilin interaction with F-actin – at the barbed end, it protects the 
filament from cofilin-mediated disassembly whereas at the pointed end, it 
enhances the function of cofilin causing an increase in F-actin disassembly. 
Overall, coronins increase the plasticity of the actin cytoskeleton by differential 
modulation of other actin binding proteins (Gandhi and Goode, 2013). 
Coronin 1a is required for phagocytosis, cell adhesion and spreading as shown 
in neutrophils and it is known to localise at the F-actin rich membrane 
protrusions in T-lymphocytes. In macrophages, it is proposed that coronin 1a 
function is mediated by phosphorylation by PI3K and is responsible for binding 
Arp2/3 (Gandhi and Goode, 2013; Jayachandran and Pieters, 2015). Coronin 1a 
depletion has also been show to protect endothelial cells from TNF-α-induced 
apoptosis via the modulation of p38β expression and signalling (Kim et al., 
2015). 
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In Figure 5.8 A and B, it can be seen that coronin co-localises with F-actin on 
fibrinogen and collagen matrices, an observation similar to those made in other 
haematopoietic cells (Jayachandran and Pieters, 2015). When assessing the 
subcellular distribution, it was observed that most coronin 1a was cytosolic 
(66%) and 34% was membrane associated. When F-actin was depolymerised 
prior to fractionation using LatB, coronin 1a association to the membrane was 
reduced to 24%, indicating that coronin 1a at the membrane is not entirely F-
actin associated and that it may be responsible for binding other platelet 
membrane proteins. 
When assessing its association to the detergent insoluble platelet fraction, as 
described previously in (Figure 4.4), it was observed that almost all coronin 1a 
was recovered in the F-actin rich detergent insoluble pellet at low speed of 
isolation and that this was reversed when F-actin was depolymerised. These 
observations further reinforce the strong interaction between F-actin and coronin 
1a that is observed in other mammalian cell types (Uetrecht and Bear, 2006). 
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Figure 5.8 Subcellular localisation and distribution of coronin 1A. (A) 
Coronin1A localisation on different matrices: Human blood platelets (2 x 107 
platelets) were allowed to spread on fibrinogen coated coverslips or collagen 
coated coverslips. Platelets were fixed, immunostained for coronin 1A (Alexa 
568, secondary antibody, red) and counterstained with FITC-phalloidin (green) 
for visualisation using a fluorescent microscope. Scale bar = 10µm. (B) 
Subcellular distribution of coronin 1A by fractionation: Human blood 
platelets (8 x 108/mL platelets) were lysed by freeze-thaw in liquid nitrogen. 
Samples were then spun at 100,000xg for 1 hour to separate membrane and 
cytosolic fractions. The cytosolic (C) and membrane (M) fractions were 
normalised by volume for Western blotting. CD36 was used as a membrane 
marker, whereas Syk was used as a cytosolic marker for resting platelets. All 
samples were resolved on 12% SDS-PAGE gel, blotted onto PVDF membrane 
and probed with anti-coronin1A. Latrunculin B (LatB; 20µM; 20 min) was used to 
depolymerise F-actin prior to lysis. 
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5.2.5 Distribution of villin in resting and spread platelets 
Villin is 92.5 kDa that belongs to the gelsolin superfamily of actin binding 
proteins and is predominantly found in microvilli of epithelial cells. Villin contains 
six gelsolin repeats which form the core of the protein and a headpiece that 
contains the carboxyl-terminal domain which is similar to that of actin cross-
linking proteins like dematin, supervillin and advillin. Villin has been described 
as actin-severing, -capping, -nucleating, and –bundling protein (Remedios et al., 
2003). 
 Actin binding functions of villin have been shown to vary according to the 
calcium concentrations – capping actin filaments at 10-30 nM and severing at 
100-200 µM. Another regulation of villin occurs by tyrosine phosphorylation 
which reduces its affinity for F-actin. Tyrosine phosphorylated villin can sever 
actin at nanomolar concentration of calcium. Actin-nucleating is inhibited by 
tyrosine phosphorylation and high concentration of calcium is required. Actin-
bundling function of villin is enhanced by its interaction with PIP2 and inhibited 
by tyrosine phosphorylation. Actin-capping function on the other hand, is 
reduced as a result of PIP2 interaction and is enhanced by calcium (Khurana 
and George, 2008). Other actin binding proteins like tropomyosin (discussed in 
section 5.2.8) can inhibit villin-actin interaction. The function of villin described in 
epithelial cells suggests a role in communicating between cytoskeleton and 
signal transduction pathways owing to its interaction with secondary 
messengers like calcium and PIP2. 
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Interestingly, a recent study of the platelet proteome of resting platelets shows 
that 1,600 copies of villin (P09327) and 620 copies of supervillin (O95425) are 
present per platelet making it a novel target of investigation in platelets.  
Anti-villin antibody generated in mouse host (102C3) was used for the 
investigations. Antibody was previously characterised and used in our laboratory 
(Grimm-Gunter et al., 2009). Platelets were spread on fibrinogen to allow 
visualisation of villin in platelets. Figure 5.9 A shows that villin is distributed 
across the platelet and seems concentrated towards the central region of the 
spread platelet. Interestingly, actin and villin co-localisation was observed in 
central region, site of granule release, but no co-localisation with F-actin-rich 
stress fibres was evident.  
When resting platelets were fractionated into membrane and cytosol, as 
previously described (Figure 4.3), villin was found to be predominantly cytosolic 
and minimal presence was observed in the membrane fraction (Figure 5.9 B). 
LatB treatment to depolymerise F-actin in resting platelets did not alter the 
distribution of villin, as expected. 
The presence of villin in the pellet and supernatant at both low and high speeds 
is indicative that all villin is bound to the detergent insoluble fraction (Figure 5.9 
C; for controls see Figure 4.4). Further, depolymerisation of actin in resting 
platelets using LatB shows a lack of villin in the detergent insoluble pellets at 
both isolation speeds. This proves that the association of villin to the detergent 
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insoluble pellet in resting platelets is entirely dependent on its association with 
F-actin. 
 
 
Figure 5.9 Subcellular localisation and distribution of villin. (A) Subcellular 
localisation of villin: Human blood platelets (2 x 107 platelets) were allowed to 
spread on fibrinogen coated coverslips. Platelets were fixed, immunostained for 
villin (Alexa 568, secondary antibody, red) and counterstained for actin filaments 
(FITC-phalloidin, green) for visualisation using a fluorescent microscope. Scale 
bar = 10µm. (B) Subcellular distribution of villin: Human blood platelets (8 x 
108/mL platelets) were lysed by freeze-thaw in liquid nitrogen. Samples were 
then spun at 100,000xg for 1 hour to separate membrane and cytosolic 
fractions. The cytosolic (C) and membrane (M) fractions were normalised by 
volume for Western blotting. CD36 was used as a membrane marker, whereas 
as Syk was used as a cytosolic marker in resting platelets (C) Association of 
villin in detergent insoluble pellet. Human blood platelets (8 x 108/mL 
platelets) were lysed in the presence of 1% TX-100 and lysates spun at low 
speed (15,600xg) for 20 min and high speed (100,000xg) for 1 hour. (A) The 
supernatant (SN) and pellet (P) were normalised by volume for Western blotting. 
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CD36 was used as a pellet marker, whereas GAPDH was used as a marker for 
the supernatant.  
All samples from (B and C) were resolved on 12% SDS-PAGE gel, blotted onto 
PVDF membrane and probed with anti-villin. Latrunculin B (LatB; 20µM, 20 min) 
was used to depolymerise F-actin prior to lysis.  
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5.2.6 Distribution of L-plastin in resting and spread platelets 
Plastins are actin-bundling proteins which belong to the α-actinin superfamily. 
There are three isoforms of plastin in mammals – L-plastin, T-plastin and I-
plastin, all of which are structurally similar and differ only in their terminal 
sequences (Shinomiya, 2012). L-plastin is characteristically found in 
haematopoietic cells, T-plastin has a more diverse expression profile including 
immune cells, fibroblasts, endothelial cells, and epithelial cells and I-plastin is 
found in the small intestine, colon, and kidney and stereocilia of inner ear (Chen 
et al., 2003; Grimm-Gunter et al., 2009; Morley, 2012; Shinomiya, 2012).  
The key features of plastin structure that differentiates it from other proteins in 
the α-actinin superfamily are the two tandem actin binding domains which allow 
simultaneous binding of two actin filaments via the calponin-homology domains 
(CH-domain) thus cross-linking and bundling the filaments (Shinomiya, 2012).  
The actin-bundling function is initiated in response to adhesion signals 
generated in the immune cells - L-plastin-rich podosomal structures have been 
identified in migrating macrophages and osteoclasts (Morley, 2012; Shinomiya, 
2012). L-plastin binds cytoplasmic domains of β1 and β2 integrins and it has 
been suggested that it might regulate inside-out signalling in leukocytes (Chen 
et al., 2003; Le Goff et al., 2010). Interestingly though, LPL deficient mice do not 
show any alteration in integrin-linked adhesion of neutrophils but they were 
found deficient in Syk activation as the function of LPL has been characterised 
to be downstream of FcγR activation (Morley, 2012).  
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L-plastin is regulated by serine phosphorylation and secondary messengers like 
calcium. Phosphorylation of L-plastin increased its affinity to binding F-actin and 
caused a consequential increase in its presence in the focal adhesions sites. In 
the investigations carried out in neutrophils, the phosphorylation of LPL 
occurred independently of its translocation to podosomes or calcium flux and 
actin polymerisation and a clear understanding of how it affects F-actin bundling 
is yet unclear (Morley, 2012). Proteomics studies in resting platelets have 
identified three isoforms – 1,600 copies of I-plastin (Plastin1 -P14651), 2,000 
copies of L-plastin (Plastin2 -P13796), and 4,500 copies of T-plastin (Plastin3 -
P13797) per platelet (Burkhart et al., 2012).  
In this section we characterise L-plastin in platelets using anti-L-plastin. 
Antibody was previously characterised and used in our laboratory (Grimm-
Gunter et al., 2009). In order to visualise the localisation of L-plastin in platelets, 
they were allowed to spread on fibrinogen for 30 minutes and immunostained 
for L-plastin and counterstained for actin using phalloidin. Consistent with the 
observations in neutrophils, L-plastin in platelets was predominantly found to be 
cytosolic and it co-localised with F-actin in the central region of the spread 
platelets (Figure 5.10 A). 
When resting platelets were fractionated as previously described (section 2.7), it 
was confirmed that L-plastin was only present in the cytosol and this did not 
alter when F-actin was depolymerised using LatB (Figure 5.10 B). Although the 
blots presented in Figure 5.10 B and C do not give a clear picture for 
quantitation owing to technical issues in the blotting process, protein bands are 
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evident and thus we only make preliminary inferences regarding protein 
localisation. 
The association of L-plastin to the detergent insoluble pellet in both low and high 
speed isolations suggests that L-plastin is not only bound to the detergent 
insoluble fraction but also present in the soluble fraction (Figure 5.10 C). When 
F-actin in platelets was depolymerised before isolation of detergent insoluble 
pellet, there were no differences when compared to untreated controls, which 
suggested that although L-plastin is associated with the detergent insoluble 
fraction, it is independent of its association to actin and that other it might be 
bound to other detergent insoluble proteins or protein complexes in the platelet 
cytosol. 
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Figure 5.10 Subcellular localisation and distribution of L-plastin. (A) 
Subcellular visualisation of L-plastin: Human blood platelets (2 x 107 
platelets) were allowed to spread on fibrinogen coated coverslips. Platelets were 
fixed, immunostained for villin (Alexa 568, secondary antibody, red) and 
counterstained for actin filaments (FITC-phalloidin, green) for visualisation using 
a fluorescent microscope. Scale bar = 10µm. (B) Subcellular distribution of L-
plastin: Human blood platelets (8 x 108/mL platelets) were lysed by freeze-thaw 
in liquid nitrogen. Samples were then spun at 100,000xg for 1 hour to separate 
membrane and cytosolic fractions. The cytosolic (C) and membrane (M) 
fractions were normalised by volume for CD36 was used as a membrane 
marker, whereas Syk was used as a cytosolic marker for resting platelets  (C) 
Association of L-plastin in detergent insoluble pellet. Human blood platelets 
(8 x 108/mL platelets) were lysed in the presence of 1% TX-100 and lysates 
spun at low speed (15,600xg) for 20 min and high speed (100,000xg) for 1 hour. 
(A) The supernatant (SN) and pellet (P) were normalised by volume for Western 
blotting. CD36 was used as marker for pellet fraction, whereas, GAPDH was 
used as marker for the supernatant fraction.  
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All samples from (B and C) were resolved on 12% SDS-PAGE gel, blotted onto 
PVDF membrane and probed with anti-L-plastin. Latrunculin B (LatB; 20µM, 20 
min) was used to depolymerise F-actin prior to lysis.  
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5.2.7 Distribution of myosin IIA in resting and spread platelets 
The regulation of the cytoskeleton requires ATP-driven motor proteins like 
myosin IIA that regulate cell motility, cell division, migration, adhesion and 
polarity. In embryonic stem cell fibroblasts, myosin IIA has been shown to 
restrain random migration of cells and promote microtubule dynamics – thereby 
mediating cell contractility/motility and providing coupling between microtubules 
and actomyosin systems (Even-Ram et al., 2007). All three isoforms of class II 
myosins are present in platelets –myosin IIA (P35579- 96,900 copies per 
platelet), myosin IIB (P35580 – 13,900 copies per platelet) and myosin IIC 
(Q7Z406 – 11,400 copies per platelet) (Burkhart et al., 2012). Non muscle 
myosin isoforms studied in 3T3 fibroblast cells suggest that all isoforms have 
distinct subcellular localisation – myosin IIA was found enriched in the Golgi 
apparatus whereas myosin IIB was more peripherally located (Togo and 
Steinhardt, 2003), evidence for which is not available in platelets.  
Myosin IIA is 230 kDa protein and the holoenzyme consists of two identical 
heavy chains and two light chains, which regulate the activity and stability of the 
protein. In platelets, myosin IIA has been shown to generate the force required 
for clot retraction. After stimulation of platelets, integrins get tethered to the 
underlying actin filaments by binding several adhesion site proteins, like talin, 
tensin, filamin, zyxin, paxillin, vinculin, α-actinin and moesin. Once tethered to 
actin, myosin is the motor that applies the contractile forces on actin filaments to 
cause clot retraction (Michelson, 2012).  
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Myosin IIA self-aggregates into smaller bipolar filaments, each containing 28 
molecules. Activity of myosin IIA is regulated by 20 kDa light chain which 
promotes conformational changes in the protein that favours filament assembly. 
Phosphorylation of myosin light chain kinases by calcium ions (Ca2+) generates 
the contractile forces applied on actin molecules (Michelson, 2012).  Myosin IIA 
contains two different light chains (called essential and regulatory light chains); 
both are Ca2+-binding proteins but differ from calmodulin, a Ca2+-binding 
regulatory subunit found in many enzymes, in their Ca2+-binding properties 
(Lodish 2000).  
Magnesium ion (Mg2+) driven concerted ATP hydrolysis and movement of the 
myosin heads along adjacent actin filaments generates a sliding motion that 
results in contraction of the interlinked actin filaments (Betapudi, 2014).  
Myosin IIA was predominantly found to be present in the cytosol of resting 
platelets and in spread platelets some myosin IIA appears to be present 
peripherally (Figure 5.11 A). Myosin IIA association with the membrane fraction 
was not affected by depolymerisation of F-actin, which suggests that the 
membrane association of myosin IIA is actin independent (Figure 5.11 B). 
Antibody was previously characterised and used in our laboratory (Grimm-
Gunter et al., 2009).  
When its association with detergent insoluble fraction of resting platelets was 
analysed (Figure 5.11 C) it was interesting to observe that myosin IIA was found 
only in the high speed isolation and under conditions of F-actin depolymerisation 
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was completely absent from the pellet. This meant that the minimal association 
of myosin IIA to the detergent insoluble high speed pellet was entirely 
dependent on its association with F-actin. 
 
 
 
Figure 5.11 Subcellular localisation and distribution of myosin IIA. (A) 
Subcellular visualisation of mysosin IIA: Human blood platelets (2 x 107 
platelets) were allowed to spread on fibrinogen coated coverslips. Platelets were 
fixed, immunostained for myosin IIa (Alexa 568, secondary antibody, red) and 
counterstained for actin filaments (FITC-phalloidin, green) for visualisation using 
a fluorescent microscope. Scale bar = 10µm. (B) Subcellular distribution of 
myosin IIA: Human blood platelets (8 x 108/mL platelets) were lysed by freeze-
thaw in liquid nitrogen. Samples were then spun at 100,000xg for 1 hour to 
separate membrane and cytosolic fractions. The cytosolic (C) and membrane 
(M) fractions were normalised by volume for Western blotting. CD36 was used 
as a membrane marker, whereas Syk was used as a cytosolic marker for resting 
platelets. (C) Association of myosin IIA to actin in detergent insoluble 
pellet. Human blood platelets (8 x 108/mL platelets) were lysed in the presence 
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of 1% TX-100 and lysates spun at low speed (15,600xg) for 20 min and high 
speed (100,000xg) for 1 hour. (A) The supernatant (SN) and pellet (P) were 
normalised by volume for Western blotting. CD36 was used as marker for the 
pellet fraction, whereas GAPDH was used as a marker for the supernatant 
fraction.  
All samples from (B and C) were resolved on 12% SDS-PAGE gel, blotted onto 
PVDF membrane and probed with anti-myosin IIA. Latrunculin B (LatB; 20µM, 
20 min) was used to depolymerise F-actin prior to lysis.  
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5.2.8 Association of tropomyosin to the detergent insoluble pellet in 
resting platelets 
Tropomyosins make up 1.6% of total platelet proteins and are composed of two 
similar, non-identical dimeric subunits – αα and ββ. Non-muscle tropomyosin 
found in platelets lacks 37 amino acids in the amino terminal region compared 
to their muscle protein counterparts and the carboxyl-terminal is markedly 
different (Gerhards, DiGirolamo and Hitchcock-DeGregorij, 1985). Although 
sequence similarities exist in the other amino residues, the terminal-end 
differences lead to different properties and consequently differences in function 
of the tropomyosins. While muscle tropomyosin polymerizes head-to-tail to form 
long filaments that lie along actin grooves, platelet tropomyosin polymerises 
poorly owing to the difference in the carboxyl-terminal (Michelson, 2013). 
Additionally, platelet tropomyosin binds weakly to actin filaments and shows low 
affinity for skeletal muscle troponin (troponin is absent in platelets) (Gerhards, 
DiGirolamo and Hitchcock-DeGregorij, 1985; Crabos et al., 1991). Taken 
together, this leads to the conclusion that it is unlikely for platelet tropomyosin to 
regulate the actin-myosin interactions and probably have a novel role in 
platelets (Michelson, 2013). 
Tropomyosin in fibroblasts is only associated to actin filaments that are 
organised into stable bundles and absent from the filaments that in a dynamic 
state of flux and is thought to confer rigidity and stability to actin filaments in 
non-muscle cells (Bryce et al., 2003; Khaitlina and Hinssen, 2014). A similar 
function in platelets can be hypothesised owing to the lack of troponin. 
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A preliminary assessment of tropomyosin association with detergent insoluble 
fraction of resting platelets provides information that tropomyosin is present in 
soluble and insoluble fractions at both speeds of isolation (Figure 5.12). A 
number of bands appear on the blot when probed with the anti-tropomyosin 
antibody. The bands represent multiple tropomyosin isoforms, as the antibody 
from Chemicon, identifies tropomyosin isforms 1, 2, 3, 5a, 5b, and 6 and it was 
previously characterised and used in our lab (Grimm-Gunter et al., 2009).  
An interesting observation was that in the low speed isolation, tropomyosins 
appeared predominantly in the soluble fraction in control samples, but 
remarkably absent in the detergent insoluble fraction when F-actin is 
depolymerised. Furthermore, tropomyosins appear predominantly in the high 
speed detergent pellet fraction, whereas the amounts in the pellet reduce when 
F-actin is depolymerised using Lat B. Observations from detergent insoluble 
pellets from both isolations suggest a strong interaction between tropomyosins 
and detergent insoluble pellet in resting platelets, although the interaction is not 
entirely dependent on actin binding. We performed immunostaining using anti-
tropomyosin as we did for other cytoskeletal proteins, but due to time 
constraints, it was not possible to optimise the antibody for use in visualising in 
platelets and reproduce them successfully. 
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Figure 5.12 Association of tropomyosins to actin in detergent insoluble 
pellet. Human blood platelets (8 x 108/mL platelets) were lysed in the presence 
of 1% TX-100 and lysates spun at low speed (15,600xg) for 20 min and high 
speed (100,000xg) for 1 hour. (A) The supernatant (SN) and pellet (P) were 
normalised by volume for Western blotting. CD36 was used as a marker for the 
pellet fraction, whereas GAPDH was used as a marker for the cytosolic fraction. 
All samples were resolved on 12% SDS-PAGE gel, blotted onto PVDF 
membrane and probed with anti-tropomyosin. Latrunculin B (LatB; 20µM, 20 
min) was used to depolymerise F-actin prior to lysis. 
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5.3 Discussion 
5.3.1 Proteomics of the platelet cytoskeleton: Limitations  
Our proteomics meta-analysis revealed that actin binding proteins within the 
cytoskeleton form the biggest proportion of total cytoskeleton proteins and it has 
previously been shown that cytoskeleton-related proteins are the most abundant 
proteins in platelets (Burkhart et al., 2014). We investigated phosphorylation of 
platelet cytoskeletal proteins upon thrombin stimulation in a meta-analysis which 
covered research articles that used various methodologies and platelet 
proteome enrichment protocols like use of phospho-protein enrichment beads 
(IMAC beads) (Zahedi et al., 2008; Qureshi et al., 2009), stable isotope labelling 
(SIL) and specific ion-exchange columns in the LC/MS (Marcus, Moebius and 
Meyer, 2003; Qureshi et al., 2009). The methods used in the papers we 
assessed, included assessment of dot intensities of proteins on 2D-PAGE that 
are prone to errors – especially since complex spots can contain more than one 
protein and subject to false-positive protein identifications (Senis and García, 
2012; Burkhart et al., 2014). Moreover, the use of LC/MS techniques has 
overcome some of these limitations and increased the speed of analysis. It is 
possible to identify and quantify thousands of proteins within hours to a pre-set 
false discovery rate, where the unwanted identifications of random proteins are 
controlled. The main drawback of this approach though, is that quantitation of 
individual protein isoforms, which is done at the peptide level, is skewed and 
may not be a true representation of the protein abundance. A key example of 
this limitation was that CAP1 was identified in platelet proteomics studies but 
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CAP2 was not, although investigations from our lab and our collaborator, Dr 
Peche, suggest that CAP2 is present in platelets (unpublished). We identified a 
similar trend in our meta-analysis where, L-plastin isoform, which is the most 
abundant isoform of plastin in haematopoietic cells, is not represented in the 
copy numbers obtained from the proteomics studies, where T-plastin is the most 
abundant (Grimm-Gunter et al., 2009; Burkhart et al., 2012). Since, the three 
isoforms of plastins are similar, differing only in their N-terminus (Shinomiya, 
2012), it may be presumed that software randomly recognises one isoform over 
another as a hit when assessing the MS data. Thus, it might misrepresent the 
true abundance of a protein isoform during protein identification.  
In addition to these limitations, a key to understanding platelet proteome would 
lie in standardisation of platelet preparation, activation and subsequent protein 
purification protocols when studying platelets to give an accurate and consistent 
platelet proteomic profile (Harrison et al., 2011) which would further enable true 
quantitation of the platelet proteome. Although, recent evidence from Burkhart et 
al. (2014) suggests that platelet proteome is stable across healthy donors and 
reproducible over multiple blood donations using LC/MS, an observation which 
reinforces the observations by Winkler et al. (2008), where they assessed 500 
protein dots using 2D-PAGE. 
An understanding of the phospho-proteome and the quantitative changes 
occurring therein would provide important clues in evaluating platelet signalling 
pathways and in identification of novel drug targets based on the patient’s 
platelet proteome, a step towards the personalising of treatments in platelet 
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disorders or disease pathogenesis (Burkhart et al., 2014; Vélez and García, 
2015). 
 
5.3.2 Actin-binding protein in platelets 
Proteins that interact with actin to regulate the polymerization or 
depolymerization of individual filaments, or the organisation of groups of 
filaments into higher order structures may play several roles during different 
stages of platelet shape change. Although most proteins have only one specific 
type of interaction with actin, the state of the actin-molecule (whether globular, 
or filamentous and whether bound to ADP or ATP) and the presence of other 
associated proteins can influence how this specific activity affects the 
cytoskeleton of the cell as a whole. Thus a single activity can produce many 
different outcomes when viewed from the perspective of the whole platelet 
during its many morphological changes (Hartwig, Steffen and Cell, 1992; 
Bearer, Prakash and Li, 2002). An overview of localisation of a few actin binding 
proteins in resting platelets is presented in this chapter.  
 
5.3.2.1 Arp2/3 and CAP1 have distinct distribution patterns 
Arp2/3 complex in platelets has been characterised to be present in the platelet 
cortical regions in spread, activated platelets (Calaminus et al., 2008). Arp2/3 in 
resting platelets is thought to be dormant and its activation is considered as the 
promoting step in platelet shape change upon stimulation (Li, Kim and Bearer, 
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2002). The observations in resting platelets indicated that most Arp2/3 is 
cytosolic and the association to the membrane is partially dependent on its 
association to actin. Further, Arp2/3 association to the detergent insoluble pellet 
was entirely dependent on its association to actin, confirming the evidence 
shown by (Fox et al., 1988).   
CAP1 and Arp2/3 are postulated to play a role in plant development either in a 
common regulatory pathway or in co-ordination as a complex regulating actin 
dynamics (Deeks et al., 2007). Further, owing to commonality that CAP1 and 
Arp2/3 have a role in co-ordinating actin dynamics and have a common 
interacting partner in profilin (Bearer, Prakash and Li, 2002; Balcer et al., 2003), 
we investigated if there was any underlying interaction between the two 
proteins. It was observed in the preliminary assessment in spread platelets that 
although both proteins localise cortically, there was no evidence of the two 
proteins interacting, or co-localising in the platelet cortex when spread on both, 
collagen and fibrinogen matrices. This evidence ruled out obvious possibilities 
that Arp2/3 and CAP1 potentially interact, but a lack co-immunoprecipitation of 
the two proteins would have provided more conviction to the conclusion. 
 
5.3.2.2 Complex interactions and associations exist between actin binding 
proteins 
Arp2/3 and coronin 1a have been established to have influence on actin 
nucleation. Phosphorylation of coronin 1a mediated by PI3K in macrophages is 
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known to affect its Arp2/3 binding (Gandhi and Goode, 2013). Coronin 1a was 
found to have membrane associations independent of its association to actin. 
Research in coronin 1a deficient mice has shown that coronin 1a influences 
cAMP and PKA regulation via Gαs in neuronal cells (Jayachandran et al., 2014), 
which might explain its tethering to the G-protein coupled receptors at the 
platelet membrane under resting or activation inhibitory conditions. Research in 
our lab using PGI2 -related PKA activation to understand the role of coronin 1a 
in platelet function is currently underway.  
Presence of short actin filaments are known to activate Arp2/3-related 
nucleation along the sides of actin filaments. Tropomyosins inhibit this 
nucleation by Arp2/3 (Blanchoin, Pollard and Hitchcock-DeGregori, 2001). The 
lack of Arp2/3 in the high speed detergent insoluble pellet upon actin 
depolymerisation and a corresponding increase in tropomyosins may be 
indicative of this inverse relation between the two proteins. Since a precise 
mechanism of action of tropomyosins in platelets is to yet be defined, owing to 
the lack of troponins in platelets (Michelson, 2012), speculative investigations 
may reveal a unique function for tropomyosins in regulation of Arp2/3 activity 
and a role in a broader regulation of actin turnover. 
Tropomyosins inhibit association of F-actin to its binding protein, villin, a protein 
commonly known to have a critical role in the microvilli of epithelial cells 
(Khurana and George, 2008). The presence of villin in platelets is unexpected 
as it is normally only found in epithelial cells but its presence may provide 
additional reinforcement to the cytoskeletal machinery that requires rapid 
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transformation upon activation due to the multiple actin dynamic functions that 
are attributed to the protein (in epithelial cells).  
All villin that was found to associate with the detergent insoluble pellet of resting 
platelets was dependent on its association with actin. This emphasises a 
potential role for villin in platelet actin cytoskeleton. A role for villin in platelets 
can be further investigated by using Ca2+ and its chelators, as villin exists in an 
autoinhibited conformation and its association to calcium releases it, like a hinge 
mechanism, which makes it available for interaction with F-actin (Hesterberg 
and Weber, 1986). Actin capping function of villin increases in presence of Ca2+ 
and decreases with PIP2 (Khurana and George, 2008). Additional regulation of 
villin activity occurs via tyrosine phosphorylation (Tomar, 2004) and preliminary 
investigations in platelets can be carried out in signalling pathways initiated by 
Src-family kinases to identify if villin truly has a role to play in actin dynamics in 
platelets. 
Association of actin binding proteins to PIP2 is an important regulator of actin 
dynamics and selectively promotes or inhibits these proteins. An important actin 
binding protein, profilin, when associated to PIP2 cannot bind actin monomers, 
whereas hydrolysis of PIP2 allows profilin to bind actin monomers (Lambrechts 
et al., 1997). CAP1 associates with this free profilin in the cytoplasm and co-
ordinates assembly of actin filament at the barbed end. Additionally, Arp2/3 
associates with profilin as it nucleates filaments at 70˚ angle to the existing, 
growing actin filament generating branched, three dimensional actin networks. 
As seen, in Figure 4.4 all profilin was found to be present in the detergent 
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soluble fraction of resting platelets, a testament to its specificity for binding actin 
monomers. 
L-plastin is thought to be sufficient to promote changes in integrin-mediated 
adhesion in lymphocytes. L-plastin depleted cells showed reduction in talin 
recruitment and actin polymerisation (Morley, 2012). Talin is an important 
component of focal adhesions and has been shown to localise at the actin 
nodules, which are podosome-like structures mediating platelet-substrate and 
platelet-platelet interactions (Calaminus et al., 2008; Poulter et al., 2015). 
Another important feature of talin is its ability to activate integrin-mediated 
inside-out signalling. Additionally, L-plastin, when phosphorylated localises to 
focal adhesion sites and increases attachment to F-actin, but it is still unclear if 
L-plastin performs this function as a part of a complex or as an adapter protein 
linking integrins to the actin cytoskeleton (Morley, 2012).Together with 
observations that talin interacts with CAP1 in HeLa cells (Haitao Zhang et al., 
2013), and with L-plastin in lymphocytes (Morley, 2012), it can be postulated 
that L-plastin, talin and CAP1 are most likely responsible for influencing the 
adhesive capacity of a cell and would be an interesting observation to make in 
platelets. Experimental set-up that investigated co-immunoprecipitation in 
platelet lysates and co-immunostaining in spread platelets displaying actin 
nodules and probed for proteins including talin, CAP1 and L-plastin would reveal 
interesting preliminary insights into the feasibility of the adhesion hypothesis. 
The key to critically investigating any protein in platelets is by use of deficient or 
knockout mouse models, some of which are already available and described in 
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literature – of the proteins investigated in the current chapter, mouse models are 
available for coronin1a (Föger et al., 2006), IQGAP2 (Chiariello et al., 2012), 
CAP2 (Peche et al., 2007), villin (Pinson et al., 1998), and L-plastin (Grimm-
Gunter et al., 2009) deficiency, but there are some others that cannot be 
generated owing to their critical role in cell regulation and KO strategies are 
lethal in cofilin1 (Bamburg and Bernstein, 2010), profilin 1 (Witke et al., 2001), 
ARPC (Suraneni et al., 2012) and myosin IIa deficient mice (Even-Ram et al., 
2007) and yet others like CAP1 and tropomyosins have not yet been created. 
Based on the preliminary observations made in the current chapter, we 
hypothesise that there are several actin associated protein candidates that can 
be investigated further and their interactions can reveal how the platelet 
cytoskeleton undergoes dynamic changes in an efficient manner.  
 
5.3.3 IQGAP1 does not appear to interact with CAP1 
An interaction between CAP1 and IQGAP1 was considered probable owing to 
presence of suitable known interacting domains on the two proteins – interaction 
between proline-rich domains in CAP1 with WW domain of IQGAP proteins. 
This probability was validated when some CAP1 was co-immunoprecipitated 
with IQGAP1 WW domain, in transfected cells, which was hypothesised to 
interact with proline-rich region in CAP1, but the IQGAP protein itself did not 
show any interaction.  
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Since there was no solid evidence of direct interaction between the likely 
candidates for domain interaction, a lack of overall interaction between the two 
proteins was assumed. Two conditions arise from this assumption – there is no 
interaction between the proteins or that the method has limitations which fail to 
recognise the interactions as the conditions under which this is studied may 
present ionic strengths that predispose proteins to different protein folding 
patterns and therefore failing to interact. 
The proline-rich region of CAP1 is conserved across evolution and is thought to 
be vital for the role of CAP1 in its intracellular cytoskeletal remodelling. IQGAPs, 
have been characterised as scaffolding proteins that affect cytoskeletal 
reorganisation in a Rac1 and Cdc42-dependent manner via secondary signals 
like Ca2+/calmodulin release (Smith, Hedman and Sacks, 2015). Since there 
was a lack of change in CAP1 and IQGAP1 interaction in presence or absence 
of Ca2+, it was clear that any potential interaction did not occur in the 
calmodulin-dependent signalling pathways.  
Phosphorylation of CAP1 has been shown to be an important event in regulating 
the function of CAP1 (Zhou et al., 2014), and a speculation that conformational 
changes in the proline-rich region of CAP1 ensuing from phosphorylation may 
promote interaction between IQGAP1 and CAP1. As seen in figure 5.13, there 
are several putative sites of phosphorylation present within the proline-rich 
domain of CAP1 protein, of which Y164, T307, S308 and S310, have been 
confirmed in site-specific mutational analysis (http://www.phosphosite.org/). 
Phosphorylation of CAP1 at any of the sites within the proline-rich domains 
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could lead to conformational change in the protein structure, affecting the 
activation status of the protein and its interaction with presumed binding 
partners such as IQGAP1. 
 
 
 
Figure 5.13 Phosphorylation sites on the human CAP1. Sites identified as 
phosphorylatable, based on having site-specific methods for identification 
include Y164, T307, S308 and S310, and most other sites identified lie within 
the proline-rich central region of the protein, as indicated by the outlines. 
(Source: http://www.phosphosite.org/) 
 
 
Calcium chelating agents that bind intracellular calcium like BAPTA/AM (1,2-bis-
(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester) 
can provide interesting insights into the mechanism of IQGAP1 and CAP1 
interaction under stimulatory conditions (where CAP1 phosphorylation state is 
altered) to completely rule out any potential for interaction between the domains 
of the two proteins. 
An independent study with site-specific mutations at the phosphorylation sites 
on CAP1, co-transfected in cell lines as in the present investigation, could 
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present a profile of interactions between the two proteins, thus providing more 
insights into any underlying mechanisms of action. Additionally, producing 
recombinant proteins and testing them using surface plasmon resonance (SPR) 
strategies would enable assessing any possible direct interaction between the 
two proteins. If a confirmation of interaction is observed, proximity ligation 
assays could help visual assessment of the interaction within platelets. 
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CHAPTER 6 
GENERAL DISCUSSION AND FUTURE OUTLOOK 
 
The research surrounding MetS and its associated co-morbidities like CVD have 
highlighted the role of adipokines in the disease progression. Novel 
observations are reported in this thesis regarding the potential role of resistin in 
platelet activation, thus contributing towards the building of a preliminary 
disease model in vitro. This study enhances the knowledge in the field by 
showing that resistin blunts thrombin mediated platelet aggregation and dense 
granule secretion, and that it affects the cytoskeleton in addition to activating 
downstream effectors of PI3K and MAPK pathways. Interestingly, these 
investigations into the proposed resistin receptor, CAP1, have brought to the 
forefront the phenomenon of CAP1 translocation upon agonist stimulation. 
Explorations in the platelet model have revealed that CAP1 translocates to the 
cytosol when stimulated with thrombin, while it translocates towards the 
membrane when inhibited with PGI2. Additionally, this study also found that 
resistin caused a translocation of CAP1 away from the membrane, albeit this 
observation was only preliminary. Furthermore, the subcellular localisation of 
several actin cytoskeletal proteins was assessed, where the limitations of 
working with platelets became more apparent in elucidating the precise role of 
cytoskeletal proteins. 
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Platelets are known to be inherently difficult cells to manipulate as they are not 
amenable to microinjection due to their small size. Also, their lack of a nucleus 
precludes genetic manipulation, and slight changes in their environment can 
result in activation (Patel-Hett et al., 2008). These limitations have prevented 
direct visualization of cellular dynamics in resting and activated platelets. 
Insights into cytoskeletal structures have come primarily from microscopic 
analyses and assessments of the detergent insoluble fractions of resting and 
activated platelets (Hartwig et al., 1999; Fox, 2001; Patel-Hett et al., 2008; Senis 
and García, 2012). The solution to overcoming these limitations comes with 
proteomic analyses and protein assessments in gene knockdown models to 
gain further insight into the regulation of the platelet cytoskeleton (Patel-Hett et 
al., 2008; Senis and García, 2012). 
The results achieved here have presented with possibilities of further discussion 
where CAP1 and resistin might have relative roles that are in tandem rather 
than ones previously suggested in a ligand-receptor relation. It has therefore 
opened up avenues for additional exploration in the field, which follows in the 
sections ahead. 
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6.1 Does resistin affect platelet receptors? 
G-protein coupled receptors are regulated by two main families of protein 
kinases – GRK (G-protein coupled receptor kinases), which phosphorylate 
agonist-occupied GPCRs to mediate homologous receptor desensitisation 
(Figure 6.1 A) and secondary messenger (Ca2+) activated kinases, such as 
PKC, which phosphorylate ligand-bound and inactive GPCRs in a heterologous 
manner (Figure 6.1 B) (Hardy et al., 2005). PAR1 signalling was desensitised 
using its receptor agonist peptide at subthreshold levels, where PAR1 was not 
internalised but the signalling cascade including Ca2+ mobilisation, PKC 
signalling and α and dense-granule secretion were downregulated. This 
desensitisation of the signalling pathway was resensitised by subthreshold level 
doses of PAR4 peptide (Ubl, Sergeeva and Reiser, 2000; Fälker et al., 2011). 
PKC-mediated desensitisation of purinergic GPCRs like P2Y1 and P2Y12 on 
platelets, when exposed to ADP in a concentration and time dependent manner 
is previously reported by (Hardy et al., 2005).  
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Figure 6.1 Model mechanisms of G-protein coupled receptor 
desensitisationin platelets. (A) Classical model. Upon stimulation of platelets 
by an agonist (a) The GPCR is activated by agonist leading to (b) G protein 
coupling and effector modulation, where the α and βγ subunits dissociate, 
allowing phosphorylation by GRK. (c) The agonist-occupied GPCR is 
subsequently phosphorylated by GRK, and (d) arrestin binds to the 
phosphorylated GPCR, leading to receptor desensitisation, thus preventing 
additional GPCR mediated signalling and (e) is followed by internalisation of the 
receptor. (B) Secondary messenger dependent-kinase model. The first 
events in classical model after agonist stimulation are similar and involve GPCR 
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coupling and subsequent dissociation of the α and βγ subunits. The difference is 
that arrestins do not play a role in GPCR desensitisation, instead alternative 
events may follow which are dependent on secondary messenger proteins that 
are also activated during agonist stimulation: (a) Activated protein kinase C 
(PKC) can directly phosphorylate and desensitise the GPCR, or  (b) PKC can 
phosphorylate and activate GRK2, which consequently has an enhanced ability 
to phosphorylate the GPCR, or (c) PKC can phosphorylate other, as yet 
unidentified, regulatory proteins, which then effect GPCR desensitisation. 
Desensitisation of GPCR render them unavailable for triggering their respective 
downstream signalling pathways (Adapted from (Kelly, Bailey and Henderson, 
2008) 
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The hypothesis that is presented here is one of resistin-mediated pre-activation 
of platelets. A variation on the hypothesis that has not been explored as a part 
of this study is receptor desensitisation. The identity of the precise thrombin 
receptor which is activated in response to resistin treatment is still unknown, an 
assessment of effect of resistin on platelet aggregation responses upon 
stimulation with receptor agonist peptides would provide preliminary clues about 
the receptor involved. PAR1 and PAR4 receptor agonist peptides (SFLLRN and 
AYPGKF, respectively) can be used to determine if there is any dose dependent 
desensitisation of receptors (Kim et al., 2002). Additionally, flow cytometric 
experimental evidence to determine the change in surface expression of PAR1 
or PAR4 can be assessed to rule out the possibility of receptor internalisation 
owing to exposure of platelets to resistin. Since PKC activation occurs upon 
activation of PARs,  a fura-2 fluorescence-based assay using pan-PKC 
inhibitors [Ro31-8425 and Ro31-8220 (Fälker et al., 2011)]  as controls when 
characterising intracellular Ca2+ mobilisation (Kong and Lee, 1995) would help 
outline if signalling downstream of PAR was affected by resistin. Together these 
experiments would clarify which PAR is activated in response to resistin and if 
the blunting of platelet aggregation that was noted was a result of receptor 
internalisation or receptor desensitisation. Above experimental set-up with 
additional control by using PPARγ-inhibitors, which are described as resistin 
inhibitors (Steppan and Lazar, 2004), can help account for resistin-mediated 
activity of receptors and reveal the existence of additional mechanisms of 
resistin action on platelet function. 
317 
 
This data suggests that dense granule release is inhibited by resistin treatment 
of platelets, whereas an evaluation of α- granules is pending. The report by Qiu 
et al. (2014) suggesting an increase in P-selectin expression upon resistin 
treatment lacks key controls that enable assessment of α- granule release and a 
repetition including the controls will clarify if there is any differential regulation of 
granule release upon exposure of platelets to resistin. 
 
6.2 CAP1 in actin nodule-mediated platelet adhesion 
Actin nodules are podosome-like structures that develop in spreading platelets 
and form a network of actin structures that are thought to play a key role in 
platelet-substrate and platelet-platelet interactions (Calaminus et al., 2008; 
Schachtner et al., 2013; Poulter et al., 2015). It has been reported that actin 
nodules are enriched in cytoskeletal proteins like talin, cortactin, Arp2/3 and 
vinculin (Calaminus et al., 2008), whereas the centre of the actin nodules 
appears devoid of integrin β3, only appearing as clusters on the periphery of the 
nodules (Poulter et al., 2015).  Interestingly, CAP1 localising at the actin 
nodules in spread platelets was observed. In its role in cell motility and cell 
adhesion, CAP1 was shown to co-IP with FAK and talin in HeLa cells (Haitao 
Zhang et al., 2013). Talin, which is a key component of focal adhesions, 
regulates integrin-mediated inside-out signalling (Nieswandt, Varga-Szabo and 
Elvers, 2009; Ciobanasu, Faivre and Le Clainche, 2013) along with several 
other cytoskeletal proteins like zyxin, vinculin, VASP, α-actinin, skelemin, L-
plastin, and others (Calderwood, Shattil and Ginsberg, 2000). CAP1 association 
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with talin and the observations that CAP1 localises at actin nodules, together is 
suggestive of the role CAP1 might play in signal transduction from integrins, 
during activation, to the actin cytoskeleton, or from the cytoskeleton enabling 
integrin activation, a role similar to that of talin and L-plastin (Morley, 2012; 
Ciobanasu, Faivre and Le Clainche, 2013; Haitao Zhang et al., 2013).  
In order to assess if CAP1 played a role in adhesion in platelets, a preliminary 
step would be performing co-immunoprecipitation in platelet lysates and 
assessing association of CAP1 with proteins like integrinβ3, talin, and FAK. 
Simultaneously, observations in spread platelets can be sought by co-
immunostaining for CAP1 along with integrinβ3, talin, and FAK to replicate and 
identify any co-localisation of CAP1 with talin and other indicated proteins. 
CAP1-talin association would suggest that CAP1 was involved in regulating 
integrin inside-out signalling, and CAP1-integrinβ3 association would further 
help corroborate the possibility that CAP1 plays a role in platelet adhesion by 
means of actin nodules. 
Actin nodules are also sites of phosphorylation of tyrosine residues (Poulter et 
al., 2015). Phosphorylation of Tyr397 on FAK is critical for FAK activity and 
promotes its association to Src (Schlaepfer, Mitra and Ilic, 2004). It would be 
interesting to find if FAK phosphorylation affected CAP1 localisation to actin 
nodules, but unfortunately it would be difficult to perform experiments in 
platelets to elucidate it, owing to the lack of phospho-CAP1 antibodies, lack of 
CAP1 KO mice and the impracticality of silencing protein expression in platelets.  
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6.3 CAP1 and resistin in apoptosis  
Elevated levels of CAP1 and resistin have both been correlated with multiple 
cancer pathologies as described in sections 1.3.3 and 1.6.2. Additionally, 
matrix-metalloproteinase-9 (MMP-9) elevation in response to resistin-mediated 
PKCε activation (Ding et al., 2011) and MMP-9 specific degradation of CAP1 as 
a substrate (Cauwe et al., 2008), juxtaposes MMP-9 as a factor that might 
potentially regulate the interaction of the two proteins in vivo.  
 
6.3.1 Novel role for resistin in clearing extracellular CAP1 
The main criticism of Lee et al. (2014), where they first presented evidence of 
CAP1 and resistin interaction is the demonstration of protein-protein interaction 
using recombinant proteins, without sufficient evidence in vivo. The critique also 
includes the lack of extracellular CAP1 domain required for binding extracellular 
resistin, in addition to the absence of resistin internalisation. Interestingly, CAP1 
was found in the urine samples of patients with systemic lupus erythromatosus 
and associated as an endothelial cell related autoantigen, suggestive of the 
importance of clearing all extracellular CAP1 (Frampton et al., 2000; Cauwe et 
al., 2008). Extracellular CAP1 may be required to prevent actin polymerisation 
or block free ADP sites on F-actin. One study notes that mice that were given 
intravenous G-actin showed pulmonary venous obstruction by actin filaments in 
addition to pulmonary microthrombi. ADP bound to F-actin (in 1:1 ratio) acts as 
a more potent platelet agonist compared to free ADP alone owing to its 
multivalency and can lead to wanton thrombus formation when F-actin is found 
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in circulation (Scarborough, Bradford and Ganguly, 1981; Lee and Galbraith, 
1992) thus highlighting the need to block ADP sites or be degraded effectively in 
circulation.  
The fact that CAP1 is present in the extracellular milieu owing to cytolysis 
(Cauwe et al., 2008) presents an alternative, where CAP1 and resistin might 
potentially interact with each other in the extracellular domain without the need 
for resistin internalisation. The circulating levels of CAP1 and resistin might 
determine the efficiency of the interaction, if any. Since resistin causes an 
elevation in MMP-9 expression in vascular smooth muscle cells (Ding et al., 
2011), it might suggest a novel role for resistin in healthy subjects, in clearing 
extracellular CAP1, removing its actin regulatory effects, thus preventing actin 
toxicity resulting from cytolysis and protecting against systemic autoimmune 
diseases (Lee and Galbraith, 1992; Cauwe et al., 2008).  
 
6.3.2 A pro-inflammatory complex of CAP1-resistin in promoting apoptosis 
Another avenue of investigation could be along the lines of CAP1-mediated 
apoptosis in platelets (Leytin et al., 2006; Gyulkhandanyan et al., 2012, 2013; 
Leytin, 2012; Posch et al., 2013; Zharikov and Shiva, 2013). CAP1 has been 
established as a pro-apoptotic protein that shuttles actin to mitochondria in 
response to endogenous apoptosis inducers in mammalian cells. CAP1 
provides a direct link from the actin cytoskeleton to the mitochondria (site of 
apoptosis) by functioning as an actin shuttle in response to signals that cause 
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apoptosis (Wang et al., 2008). Resistin on the other hand, has been 
demonstrated to be a survival factor in mammalian cells, responding to ER 
stress (Gao et al., 2009; Suragani et al., 2013; Rak et al., 2015). Contrasting to 
this, elevated levels of resistin are also confirmed to increase the production of 
MMP-9. MMP-9 when overexpressed, is pro-apoptotic (Bergers et al., 2000; 
Mannello et al., 2005; Ding et al., 2011). MMP-9 also helps decrease CAP1 
levels in vivo (Xie et al., 2014) which is anti-apoptotic. Owing to such contrasting 
observations in relation to these three proteins in vitro and in vivo, a hypothesis 
emerges where these proteins have distinct roles under varying physiological 
conditions. Extrapolating the evidence, it can be speculated that intracellular 
CAP1 is pro-apoptotic, but when released extracellularly after cytolysis, it forms 
a complex with resistin forming a pro-inflammatory complex that promotes cell-
death or carcinogenesis. Further adding to the speculations, MMP-9-mediated 
degradation of CAP1 may be prevented if it forms a complex with resistin and 
can help explain the distinct observations in relation to resistin and MMP-9, with 
respect to CAP1, where free resistin is anti-apoptotic, and supposedly, CAP1-
resistin complex increases MMP-9 expression leading to tumourigenesis.  
Validation of this speculative hypothesis of CAP1-resistin-MMP-9 complex 
formation would be extremely difficult using only platelets as the key cell model 
of investigation. As such, MMP-9 is known to have inhibitory role in platelets 
(Wrzyszcz and Wozniak, 2015). The use of endothelial cell-lines, 
megakaryocytic cell lines, since these closely affect platelet behaviour, would 
enable the convenience of various knockdown tools in resolving potential 
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protein-protein interactions. An ideal candidate for this investigation would be 
endothelial cells, owing to CAP1-related auto-immune pathology (Cauwe et al., 
2008) and resistin-mediated effects on endothelial cell signalling (Dandona et 
al., 2006; Manduteanu et al., 2009). Additional tools that could be used would 
include anti-CAP1 antibody to clear extracellular CAP1, kinase-inhibitors to 
prevent downstream effectors of apoptosis, TZDs to dampen resistin-related 
outcomes and Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) which prevents 
MMP-9 expression would be deemed as effective controls during in vivo 
investigations. In order to delineate the role of CAP1 in regulating the actin 
cytoskeleton (Hubberstey and Mottillo, 2002; Ono, 2013; Zhou, Zhang and 
Field, 2014) and its role in apoptosis, which is shown to be actin-independent 
(Wang et al., 2008), the use of actin depolymerising agents or inhibitors of actin 
polymerisation like latrunculins and cytochalasins would aid in distinguishing the 
two roles and in firmly assessing how CAP1 interacts with other proteins, like 
resistin, independently. Positive tests of apoptosis would include mitochondrial 
toxins and potent agonists like thrombin, which are known to induce apoptosis in 
platelets (Lopez et al., 2008; Gyulkhandanyan et al., 2013), as well as 
endothelial cells (Bae et al., 2009). These tests would reveal changes in CAP1 
and MMP-9 expression, upon apoptosis induction in the presence or absence of 
resistin. Since the dose of thrombin (high/low) determines which of the distinct 
PAR1 and PAR4-mediated downstream activatory pathways are triggered 
(Kahn et al., 1999; Holinstat, 2006; Duvernay et al., 2013), it would be 
interesting to assess if there are concentration dependent effects on the 
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expression and interaction amongst the proteins based on varying degrees of 
thrombin-induced inflammation or apoptosis. In addition to using thrombin for 
promoting apoptosis, PAR1 and PAR4 peptides could be used to further resolve 
the activation pathway involved and further aid in elucidating the  CAP1, MMP-9 
and/or resistin-related paradigm. 
This preliminary understanding of how CAP1, resistin and MMP-9 interact, 
would form the basis of a bigger investigation that would firmly establish the role 
of these proteins in disease states that they are correlated and enhance our 
understanding if they form inflammatory complexes which influence their 
behaviour in vitro and in vivo, thus improving the understanding of inflammation 
and disease progression. 
 
6.4 The role of CAPs and resistin in cardiac myopathy 
Resistin has been correlated withIR, obesity and T2DM and consequently, also 
with CVD (Jung, Park, et al., 2006; Meshkani and Adeli, 2009; Jamaluddin et al., 
2012; Huang and Yang, 2015). It has been established that increased levels of 
resistin in diabetic patients lead to increase of sarcomere contraction in the 
cardiac tissue affecting its contractility in addition to promoting  cardiac 
hypertrophy by stimulation of AMP-activated kinases in response to IRS-
1/MAPK phosphorylation (See Figure 1.2) (Kim et al., 2008; Kang et al., 2011). 
Interestingly, CAP2 is known to localise near the M-band of the sarcomere and 
its deficiency also leads to a disarray of sarcomeric actin filaments initiating 
324 
 
cardiac hypertrophy (Peche et al., 2013; Kosmas et al., 2015). Also of interest is 
that cardiac myopathy related mortality in CAP2 KO mice, where female mice 
presented better outcomes compared to their male counterparts, highlighting the 
male versus female differences (Peche et al., 2013) . When this is noted in the 
light of the observation that circulating levels of resistin have also been shown to 
differ between males and females (Steppan and Lazar, 2004; Chen et al., 
2009), taken together, this is suggestive of a link between CAP1 and resistin 
could have implications in cardiac myopathies too, but prior to that any 
interactions between CAP2 and resistin remains to be established. 
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6.5 Potential for a relation between IQGAP and CAP via resistin? 
IQGAPs are multidomain cytoplasmic scaffolding proteins that juxtapose Rho 
GTPases Rac1 and Cdc42, Ca2+/calmodulin signals and cytoskeletal 
reorganization events. In platelets, functionally distinct roles for IQGAP1 and 
IQGAP2 have been suggested. IQGAP1 was proposed to modulate the 
procoagulant function of platelets by regulating the secretory pathway of α-
granule exocytosis (Schmidt, 2012b), whereas IQGAP2 has been shown to act 
as a scaffolding protein linking thrombin activation to platelet cytoskeleton 
(Schmidt et al., 2003). Ablation of IQGAP2 (Iqgap2 -/-) in a mouse model has 
shown the mice to be hypoglycaemic and protected from hepatic steatosis 
andIR, supporting the notion that IQGAP2 may be involved in causing IRin liver 
cells (Chiariello et al., 2012). 
Although the investigations stated in (Chapter 5) show no interaction of CAP1 
with IQGAP1 it may be interesting to study if IQGAP1 expression was altered 
when platelets were pre-treated with resistin, and extending the investigation to 
gauge if CAP1 and IQGAP1 interaction occurred in response to external stimuli 
such as treatment with resistin. The supporting precursors for the above study 
are available in literature which show that IQGAP2 deficiency leads to inhibition 
of GSK3β kinase activity (Schmidt, 2012a), which in turn has been shown to 
affect CAP1 phosphorylation (Zhou et al., 2014) and resistin involvement in Akt 
upregulation, which is regulated by GSK3β (Cho et al., 2001; Woulfe et al., 
2004b). An investigation similar to the one carried out in (chapter 3 and 4) and 
probing for IQGAP1 instead can reveal if resistin affects the localisation profile 
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of the protein, as observed in the case of CAP1. Additional investigations to 
include GSK3 inhibitors will shed more light on the involvement of the kinase in 
resistin-related changes in IQGAP1, if any. Since Iqgap1 -/- mice are available 
(Li et al., 2000), they can be used as a model to understand  IRowing to resistin 
and the role of IQGAP1 therein. Public availability of phospho-CAP1 (Zhou et 
al., 2014) antibody would improve the study significantly in the data produced to 
assess mechanisms of IR. 
 
6.6 Bioenergetics influencing platelet cytoskeletal reorganisation 
Actin polymerisation and depolymerisation are governed strictly by nucleotide 
exchange that provide the energy required for cell movements (Bugyi and 
Carlier, 2010). The energy requirements are thought to be higher in platelets 
undergoing cytoskeletal reorganisation and granule secretion, evidence of which 
was first described in 1985 by Verhoeven et al. It was noted that metabolic 
stress regulates cytoskeletal reorganisation in cancer cells and it raises the 
probability that similarly -oxidation also regulates actin dynamics in spreading 
platelets (Caino et al., 2013). Mitochondrial function assessment as an indicator 
of energetics within platelets was carried out recently, providing an insight that 
cytoskeletal reorganisation upon activation may indeed be governed by the 
metabolic stress experienced by platelets (Chacko et al., 2013; Kramer et al., 
2014). In MetS, blood cells experience metabolic stress owing to the presence 
of adipokines and impaired glucose metabolism and it may affect the platelet 
cytoskeleton, a trend we observed when platelets were exposed to elevated 
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levels of resistin. An investigation of the effect of resistin on metabolic behaviour 
of platelets using an extracellular flux analyser which measures oxygen 
consumption rate and extracellular acidification rate and records mitochondrial 
respiration and glycolysis as a function of metabolic vigour, will enable the 
understanding if resistin affects platelet metabolism. Additional controls using 
insulin and insulin sensitizers would clarify potential mechanisms underlying the 
effect of resistin on platelet function, if any. A correlation can then be sought 
between metabolism of resistin-treated and untreated platelets to assess how 
resistin pre-treatment affects shape change upon treatment with platelet 
agonists in a time course, as we have preliminary evidence from aggregation 
data to support the metabolic observations. This experiment would also require 
the incorporation of controls where resistin itself is inhibited (TZDs – insulin 
sensitizers), the platelet actin cytoskeleton is depolymerised (latrunculins, 
cytochalasins), thus inhibiting shape change, in addition to respiratory complex 
inhibitors (rotenone, antimycin, oligomycin, cyanides.), alongside simultaneous 
aggregation and spreading experiments to gain a clearer mechanistic overview 
of effect of resistin on platelet metabolism during cytoskeletal reorganisation. 
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6.7 Ethnic and racial variation in circulating resistin is yet to be 
established 
Variation in the concentration of circulating resistin in male and female 
population and its correlation to risk of diabetes is well documented in clinical 
studies (Steppan and Lazar, 2004; Chen et al., 2009). The key disease states 
that are predicted by elevated resistin are IR, atherosclerosis, and diabetes 
(Lehrke et al., 2004; Reilly et al., 2005). There is clear evidence of certain racial 
groups being predisposed to IR and diabetes established since 1990’s 
(Suchindran et al., 2009; Tuchman, 2011; Spanakis and Golden, 2013). 
Resistin, as predictor of atherosclerosis in males was established by Reilly et al. 
(2005). A recent clinical study examined if plasma resistin levels were an 
effective predictor of atherosclerosis and CVDs, and they reported that the 
association of resistin to CVD risk was greatest in the Hispanic ethnic group 
(Muse et al., 2015). A study carried out in normal, pregnant females based on 
ethnic differences and distinct patterns were observed in the circulating levels of 
adipokines (Chen and Scholl, 2015). Clinical data is not available for plasma 
resistin concentrations within specific ethnic communities related to IR but it can 
be presumed that such variations potentially exist affecting their predisposition 
to IR and diabetes, as it did for CVD. A clinical study is required where multi-
ethnic population which is age and gender matched, are measured for multiple 
indicators of IR like HOMA index, QUICKI, and McAuley index (to avoid bias 
towards IR measurement) can then be associated with plasma resistin levels to 
accurately identify any racial/ethnic correlations and associations between IR 
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and plasma resistin concentrations. Platelet response to agonists along with IR 
predictors will add to the observations of the clinical study and help reveal 
association of plasma resistin to thrombosis states. 
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APPENDIX 1 
Classification of cytoskeletal proteins: Classification and their abundance 
(copy numbers) in platelets identified from proteomics studies including the 
changes in phosphorylation of proteins upon thrombin stimulation (Average ratio 
of activated/resting phosphorylation of protein). Information charts from (Marcus, 
Moebius and Meyer, 2003; Zahedi et al., 2008; Qureshi et al., 2009; Burkhart et 
al., 2012) is used to compile the table. 
Actin and actin associated proteins 
Protein 
accession 
number 
Estimated 
copy 
number 
Cytoskeletal protein 
MW 
[kDa] 
Average 
ratio 
(Activated/ 
Resting) 
P60709 795,000 
ACTB_HUMAN Actin, cytoplasmic 
1  
41.7 1.06 
P63261 791,000 
ACTG_HUMAN Actin, 
cytoplasmic 2  
41.8 1.63 
P62736 600,000 
ACTA_HUMAN Actin, aortic 
smooth muscle  
42 1.03 
P07737 503,000 PROF1_HUMAN Profilin  15 0.99 
A8MW06 320,000 
TMSL3_HUMAN Thymosin beta-
4-like protein 3  
5.1 0.15 
P23528 244,000 COF1_HUMAN Cofilin  18.5 1 
Q562R1 220,000 
ACTBL_HUMAN Beta-actin-like 
protein 2  
42 1.18 
A9Z1Y9 159,000 
TMSL6_HUMAN Putative 
thymosin beta-4-like protein 6  
5.1  - 
P37802 130,000 TAGL2_HUMAN Transgelin-2  22.4 0.99 
Q9Y490 116,000 TLN1_HUMAN Talin  269.6 1.03 
P67936 107,000 
TPM4_HUMAN Tropomyosin 
alpha-4 chain  
28.5 0.95 
Q9Y281 93,200 COF2_HUMAN Cofilin-2  18.7  - 
P12814 92,100 ACTN1_HUMAN Alpha-actinin  103 1.04 
P21333 87,700 FLNA_HUMAN Filamin-A  280.6 1 
Q01518 41,700 
CAP1_HUMAN Adenylyl cyclase-
associated protein 1  
51.9 1.01 
P61158 30,600 ARP3_HUMAN Actin-related 47.3 1.05 
370 
 
protein 3  
P61160 30,300 
ARP2_HUMAN Actin-related 
protein 2  
47.3   
Q99439 29,500 CNN2_HUMAN Calponin-2  33.7 0.94 
O15145 27,500 
ARPC3_HUMAN Actin-related 
protein 2/3 complex subunit 3  
20.5 1.13 
P47756 26,400 
CAPZB_HUMAN F-actin-capping 
protein subunit beta 
31.3 1.02 
P59998 26,000 
ARPC4_HUMAN Actin-related 
protein 2/3 complex subunit 4  
19.7 1.02 
P09493 26,000 
TPM1_HUMAN Tropomyosin 
alpha chain  
32.7 0.93 
P35609 25,800 ACTN2_HUMAN Alpha-actinin-2  103  - 
P31146 23,400 COR1A_HUMAN CoroninA  51 0.98 
Q9ULV4 23,300 COR1C_HUMAN CoroninC  53.2 1 
P06753 23,100 
TPM3_HUMAN Tropomyosin 
alpha-3 chain  
32.8 0.98 
O15511 22,900 
ARPC5_HUMAN Actin-related 
protein 2/3 complex subunit 5  
16.3 1.01 
P52907 20,900 
CAZA1_HUMAN F-actin-capping 
protein subunit alpha  
32.9 0.98 
O15143 19,100 
ARC1B_HUMAN Actin-related 
protein 2/3 complex subunit 1B  
40.9 1.03 
O15144 17,400 
ARPC2_HUMAN Actin-related 
protein 2/3 complex subunit 2  
34.3 1.07 
P47755 16,400 
CAZA2_HUMAN F-actin-capping 
protein subunit alpha-2  
32.9 0.98 
P35241 15,500 RADI_HUMAN Radixin  68.5 0.9 
Q14315 15,500 FLNC_HUMAN Filamin-C  290.8 0.26 
Q08495 14,500 DEMA_HUMAN Dematin  45.5 0.98 
P60981 14,400 DEST_HUMAN Destrin  18.5 1.04 
Q9Y4G6 13,700 TLN2_HUMAN Talin-2  271.4 1.1 
P15311 13,300 EZRI_HUMAN Ezrin  69.4 1.15 
Q27J81  7,500 INF2_HUMAN Inverted formin-2  137.5  - 
P63313 5,500 TYB10_HUMAN Thymosin beta0  50  - 
Q01082 4,600 
SPTB2_HUMAN Spectrin beta 
chain, brain 1  
274.4 1 
P13797 4,500 PLST_HUMAN Plastin-3  70.8 1.18 
O94929 2,100 
ABLM3_HUMAN Actin-binding 
LIM protein 3  
77.8 1.05 
P13796 2,000 PLSL_HUMAN Plastin-2  70.2 0.84 
Q9NZ32 2,000 ARP10_HUMAN Actin-related 46.3 1.01 
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protein 10  
Q9UHB6 1,900 
LIMA1_HUMAN LIM domain and 
actin-binding protein 1  
85.2 1.07 
O00399 1,900 
DCTN6_HUMAN Dynactin 
subunit 6  
20.7 1.94 
P09327 1,600 VILI_HUMAN Villin  92.6 0.98 
P53814 1,600 SMTN_HUMAN Smoothelin  99.4 1.21 
Q14651 1,600 PLSI_HUMAN Plastin  70.2   
Q8N556 1,400 
AFAP1_HUMAN Actin filament-
associated protein 1  
110  - 
O14639 1,100 
ABLM1_HUMAN Actin-binding 
LIM protein 1  
87.6 0.86 
Q12792 1,000 TWF1_HUMAN Twinfilin  40.3 1.15 
P46940  1,000 
 IQGA1_HUMAN Ras GTPase-
activating-like protein IQGAP1  
189.1 0.94 
P57737 760 CORO7_HUMAN Coronin-7  100.5 0.95 
P02549 650 
SPTA1_HUMAN Spectrin alpha 
chain, erythrocyte  
279.8 0.69 
O95425 620 SVIL_HUMAN Supervillin  247.6 0.96 
P35221 Low CTNA1_HUMAN Catenin alpha-1  100 1.35 
O75369 Low FLNB_HUMAN Filamin-B  278 0.99 
Q27J81 Low INF2_HUMAN Inverted formin-2  135.5 0.97 
P62328 Low TYB4_HUMAN Thymosin beta-4  5.1  - 
A4UGR9 Low 
XIRP2_HUMAN Xin actin-binding 
repeat-containing protein 2  
198.5  - 
Tubulin and microtubule associated proteins 
Protein 
accession 
number 
Estimated 
copy 
number 
Cytoskeletal protein 
MW 
[kDa] 
Average ratio 
(Activated/ 
Resting) 
P68366 185,000 
TBA4A_HUMAN Tubulin alpha-
4A chain  
49.9 1.14 
Q9BQE3 174,000 
TBA1C_HUMAN Tubulin alphaC 
chain  
49.9 1.09 
Q9H4B7 144,000 TBB1_HUMAN Tubulin beta chain  50.3 1.06 
Q9NY65 128,000 
TBA8_HUMAN Tubulin alpha-8 
chain  
50.1 1.05 
Q9H853 125,000 
TBA4B_HUMAN Putative tubulin-
like protein alpha-4B  
50  - 
P07437 115,000 TBB5_HUMAN Tubulin beta chain  49.6 0.98 
Q13748 110,000 
TBA3C_HUMAN Tubulin alpha-
3C/D chain  
49.9 0.85 
P68371 106,000 TBB2C_HUMAN Tubulin beta-2C 49.8 1.04 
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chain  
P04350 96,000 
TBB4_HUMAN Tubulin beta-4 
chain  
49.6  - 
P68371 94,700 
TBB2C_HUMAN Tubulin beta-2C 
chain  
49.8 1.04 
Q15555 7,600 
MARE2_HUMAN Microtubule-
associated protein RP/EB family 
member 2  
37 0.96 
P23258 2,300 
TBG1_HUMAN Tubulin gamma 
chain  
51.1 1.05 
P23258 2,000 
TBG1_HUMAN Tubulin gamma 
chain  
51.1 1.05 
Q86UP2 1,800 KTN1_HUMAN Kinectin  156.2 1.07 
P27816 1,700 
MAP4_HUMAN Microtubule-
associated protein 4  
120.9 0.54 
Q96PK2 1,500 
MACF4_HUMAN Microtubule-
actin cross-linking factor 1, 
isoform 4  
670.1  - 
Q66K74 1,400 
MAP1S_HUMAN Microtubule-
associated protein 1S  
112.1 0.95 
Q9UPN3 1,300 
MACF1_HUMAN Microtubule-
actin cross-linking factor 1, 
isoforms 1/2/3/5  
620 0.98 
Q96PK2 1,100 
MACF4_HUMAN Microtubule-
actin cross-linking factor 1, 
isoform 4  
670.1  - 
Q9BSJ2 1,000 
GCP2_HUMAN Gamma-tubulin 
complex component 2  
102.5 1.01 
Q96CW5 850 
GCP3_HUMAN Gamma-tubulin 
complex component 3  
103.5 0.97 
P78559 750 
MAP1A_HUMAN Microtubule-
associated protein 1A  
305.3 0.87 
Q99867 <500 
TBB4Q_HUMAN Putative tubulin 
beta-4q chain  
51  - 
Q9BVA1 <500 
TBB2B_HUMAN Tubulin beta-2B 
chain  
48.7  - 
Q3ZCM7 <500 
TBB8_HUMAN Tubulin beta-8 
chain  
49.9  - 
Q71U36 <500 
TBA1A_HUMAN Tubulin alphaA 
chain  
49.9   
P46821 Low 
MAP1B_HUMAN Microtubule-
associated protein 1B  
270.5  - 
A6NHL2 Low 
TBAL3_HUMAN Tubulin alpha 
chain-like 3  
49.9  - 
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Q13885 Low 
TBB2A_HUMAN Tubulin beta-2A 
chain  
49.9 1.06 
Intermediate filament proteins 
Protein 
accession 
number 
Estimated 
copy 
number 
Cytoskeletal protein 
MW 
[kDa] 
Average ratio 
(Activated/ 
Resting) 
Q13884 5,700 SNTB1_HUMAN Beta-syntrophin  58 1.1 
P13645 3,700 
K1C10_HUMAN Keratin, type I 
cytoskeletal 10  
66  - 
P08670 2,400 VIME_HUMAN Vimentin  53.6 0.95 
P35527 1,800 
K1C9_HUMAN Keratin, type I 
cytoskeletal 9  
66  - 
P35908 1,600 
K22E_HUMAN Keratin, type II 
cytoskeletal 2 epidermal  
66  - 
P02545 1,200 LMNA_HUMAN Prelamin-A/C  74.1 0.83 
P02533 780 
K1C14_HUMAN Keratin, type I 
cytoskeletal 14  
66.5  - 
P13647 Low 
K2C5_HUMAN Keratin, type II 
cytoskeletal 5  
47  - 
P13646 Low 
K1C13_HUMAN Keratin, type I 
cytoskeletal 13  
66  - 
P08779 Low 
K1C16_HUMAN Keratin, type I 
cytoskeletal 16  
66  - 
Q86Y46 Low 
K2C73_HUMAN Keratin, type II 
cytoskeletal 73  
66  - 
P78386 Low 
KRT85_HUMAN Keratin, type II 
cuticular Hb5  
66  - 
Myosins 
Protein 
accession 
number 
Estimated 
copy 
number 
Cytoskeletal protein 
MW 
[kDa] 
Average ratio 
(Activated/ 
Resting) 
P60660 229,000 
MYL6_HUMAN Myosin light 
polypeptide 6  
16.9 0.9 
P35579 96,900 MYH9_HUMAN Myosin-9  226.4 0.97 
P19105 88,100 
ML12A_HUMAN Myosin 
regulatory light chain 12A  
19.8 0.96 
P24844 88,000 
MYL9_HUMAN Myosin regulatory 
light polypeptide 9  
19.8 0.95 
O14950 86,900 
ML12B_HUMAN Myosin 
regulatory light chain 12B  
19.8  - 
P14649 20,900 
MYL6B_HUMAN Myosin light 
chain 6B  
22.7 1 
P35749 15,300 MYH11_HUMAN Myosin1  227.2 0.92 
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P35580 13,900 MYH10_HUMAN Myosin0  228.9 0.88 
Q7Z406 11,400 MYH14_HUMAN Myosin4  200  -  
P05976 10,900 
MYL1_HUMAN Myosin light chain 
1/3, skeletal muscle isoform  
16.7  - 
Q15746 4,200 
MYLK_HUMAN Myosin light chain 
kinase, smooth muscle  
210.6 1.01 
O00159 2,700 MYO1C_HUMAN Myosin-Ic  121.6 0.97 
Q86YV6 2,400 
MYLK4_HUMAN Myosin light 
chain kinase family member 4  
211  - 
Q9Y4I1 1,800 MYO5A_HUMAN Myosin-Va  215.3 1 
Q92614 1,700 MY18A_HUMAN Myosin-XVIIIa  233 0.93 
Q13459 1,400 MYO9B_HUMAN Myosin-IXb  243.4 0.95 
P12829 1,300 
MYL4_HUMAN Myosin light chain 
4  
21.6  - 
B0I1T2 1,000 MYO1G_HUMAN Myosin-Ig  116.4 1.23 
Q9UM54 690 MYO6_HUMAN Myosin-VI  149.6 1.04 
O00160 640 MYO1F_HUMAN Myosin-If  124.8 1.06 
O00160 590 MYO1F_HUMAN Myosin-If  124.8 1.06 
Q9Y4I1 <500 MYO5A_HUMAN Myosin-Va  215.3 1 
Q9UKX3 <500 MYH13_HUMAN Myosin3  200  - 
Q9ULV0 Low 
MYO5B_HUMAN Unconventional 
myosin-Vb  
210  - 
P13533 Low MYH6_HUMAN Myosin-6  150  - 
Q13402 Low MYO7A_HUMAN Myosin-VIIa  150  - 
Other motor proteins 
Protein 
accession 
number 
Estimated 
copy 
number 
Cytoskeletal protein 
MW 
[kDa] 
Average ratio 
(Activated/ 
Resting) 
Q14203 3,600 
DCTN1_HUMAN Dynactin 
subunit 1  
141.6 1 
Q9UJW0 3,000 
DCTN4_HUMAN Dynactin 
subunit 4  
52,3 1.01 
O75935 3,000 
DCTN3_HUMAN Dynactin 
subunit 3  
21.1 1.07 
Q9NQT8 1,700 
KI13B_HUMAN Kinesin-like 
protein KIF13B  
202.5 1 
Q9H1H9 1,000 
KI13A_HUMAN Kinesin-like 
protein KIF13A  
195.8  - 
Q9BVG8 820 
KIFC3_HUMAN Kinesin-like 
protein KIFC3  
92.7 1.06 
Q13409 640 
DC1I2_HUMAN Cytoplasmic 
dynein 1 intermediate chain 2  
71.4 1.09 
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O43896 550 
KIF1C_HUMAN Kinesin-like 
protein KIF1C  
195.8  - 
Q9UFH2 <500 
DYH17_HUMAN Dynein heavy 
chain 17, axonemal  
515  - 
Q9P225 Low 
DYH2_HUMAN Dynein heavy 
chain 2, axonemal  
507.4 0.85 
Q8TE73 Low 
DYH5_HUMAN Dynein heavy 
chain 5, axonemal  
528.7  - 
Q96JB1 Low 
DYH8_HUMAN Dynein heavy 
chain 8, axonemal  
514.3  - 
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APPENDIX 2 
Complete details of antibodies including their usage. 
Antibody 
Supplier (Details) 
Western blotting 
(Dilution in TBS-T) 
Immunostaining 
(Dilution in PBS) 
CAP1 Abcam (ab133655) 1:8000 1:300 
β-actin Abcam (ab20272) 1: 500 - 
GAPDH Calbiochem (6C5-CB1001) 1:6000 - 
CD36 Santa Cruz (H-300 - SC-9154) 1:1000 - 
Cofilin 
Received as a gift from 
Cologne 
1:500 - 
Profilin 
Received as a gift from 
Cologne 
1:500 - 
Coronin 
1a 
Abcam (ab72212) 1:1000 1:100 
pAKT Cell Signalling (9271) 1:1000 - 
p38 Abcam (ab7952) 1:1000 - 
pERK1/2 Cell Signalling (4370) 1:1000 - 
pVASP 
Ser 157  
Cell Signalling (3111) 1:1000 - 
pVASP 
Ser 239 
Cell Signalling (3114) 1:1000 - 
Syk Santa Cruz (4D10-SC1240) 1:1000 - 
IQGAP1 
Santa Cruz (H-109- SC-
10792) 
1:1000 - 
Arp2/3 
complex 
Millipore (ARPC2/p34-Arc) 1:200 1:20 
myc 
Generated in lab previously 
(Grimm-Gunter, 2009) 
Non-diluted - 
GFP 
Generated in lab previously 
(Grimm-Gunter, 2009) 
Non-diluted - 
p(Ser) 
PKC 
substrate 
Cell Signalling (2261) 1:1000 - 
Villin 
Generated in lab previously 
(102C3) (Grimm-Gunter, 2009) 
1:1000 1:300 
L-plastin 
Generated in lab previously 
(Grimm-Gunter, 2009) 
1:1000 1:300 
Myosin 
IIa 
Novus Biologicals (NBP1-
31733) 
1:1000 1:300 
Tropo-
myosin 
Chemicon (AB5441 - 
1,2,3,5a,5b,6) 
1:1000 1:100 
